

INNOVATIONS
FOR
HEALTH

CLUSTER
BIOTECHNOLOGY
BAVARIA



25



BIOTECH IN BAVARIA

A QUARTER CENTURY OF SUCCESS

managed by



REPORT 2021 | 22
including more than 300 company profiles



At the service
of patients

We at Roche in Penzberg have been researching, developing and producing innovative ingredients for drugs and diagnostic tests for 50 years.

More at roche.de.

CONTENT

Greeting	
Bavarian Ministry of Economic Affairs, Regional Development, and Energy	5
Preface of the managing director	
Prof. Dr. Horst Domdey, CEO and Spokesman Bavarian Biotechnology Cluster	7
Company development	
Bavarian biotech in numbers	8
25 years Bio^M & Munich Biotech Cluster	
The “Bio ^M Cluster” celebrates its anniversary	18
Prof. Dr. Horst Domdey – “Mr. Cluster”	
Portrait: the man with the biotech gene	28
25 years and still going strong	
Guest contribution from Dr. Viola Bronsema	30
I wanted to build a local biotech industry on the European level	
Interview with Prof. Dr. Horst Domdey	32
We are in the century of biology	
Interview with Prof. Dr. Ernst-Ludwig Winnacker	36
We need a new corporate culture – this is the only way to attract and retain the best people	
Interview with Dr. Simon Moroney	40
Is antibiotic resistance the next insidious pandemic?	
Interview with Dr. Hannelore Meyer	44
Recognition for Bavarian research against COVID-19	
Bavaria’s highest award for three Munich scientists	48
I expect the beginning of a golden age of biotechnology	
Interview with Dr. Philipp Baaske	50
Fostering spin-offs in Bavaria	
m ⁴ Award winners on track for success	54
DigiMed Bayern	
Medicine of the future – promising developments	58
International affairs	
It takes time to do business with Japan right!	60
Bio ^M forging the CE4BIG alliance with four other European health clusters	61
Life science centers in Bavaria	
Regional networks	62
Development in Regensburg	
Guest contribution from Dr. Thomas Diefenthal	64
Cutting-edge research	
Munich’s IZB attracts great interest from investors	66
Company profiles	68

GREETING

Bavarian Ministry of Economic Affairs, Regional Development, and Energy

HUBERT AIWANGER

Member of the Bavarian State Parliament, Bavarian State Minister of Economic Affairs, Regional Development, and Energy, Deputy Minister President of Bavaria



Munich's biotech cluster is celebrating its 25th birthday. We offer our heartfelt congratulations on this special anniversary to its cluster management, Bio^M. Over the years, its innovation hub has turned into a biotechnology hotspot. Thus, it comes as no surprise that so many spin-offs, start-ups, and biotech as well as pharma companies have made Munich an incubator for medical innovations "Made in Bavaria".

In the past two years, the biotech industry has attained a new level of significance and recognition on a global scale. COVID-19 has illuminated biotechnology's relevance to the future of medical innovation. Yet as this pandemic subsides, albeit gradually, other equally important aspects are also coming back into light.

The Munich Biotech Cluster stands ready as an accelerator for further groundbreaking trends. One example here is how the centralization of Big Data will enable the digital processing of patient data in order to facilitate prevention, diagnosis, and treatment. The lighthouse project DigiMed Bayern is driving these developments forward. New ideas from research are entering the translational process and paving the way for swift response to future challenges, such as antibiotic resistance.

That is why the Bavarian State Government constantly strives to improve the environment for innovation. Companies here benefit from an excellent ecosystem featuring close proximity to academia and science, partnerships, easily accessible financing options, and full support for approval and test procedures. Moreover, there are a great number of start-ups, a partnership network of cluster companies to leverage local synergies, and an excellent infrastructure for bringing scientific discoveries to the market.

The Bavarian Ministry of Economic Affairs is looking forward to continuing its impactful support for biotech companies. New inspiration from science and research, digital solutions, and emerging A.I. fields of application promise an exciting future. We are glad to have Bio^M as a strong partner. Let us continue our fruitful cooperation in order to maintain Bavaria's position as a dynamic think tank as well as its leading role when it comes to medical trends and innovation.

ROLAND WEIGERT

Member of the Bavarian State Parliament, State Secretary at the Bavarian Ministry of Economic Affairs, Regional Development, and Energy



Hubert Aiwanger *Roland Weigert*

Hubert Aiwanger

Roland Weigert

Bio^M - central point of contact for pharma and biotechnology in Munich and Bavaria

- consulting for founders-to-be, start-ups & SMEs
- grant & seed financing support
- pre-seed incubation & m⁴ award
- networking & partnering, matchmaking
- events, conferences & training
- representing Bavarian biotechnology world-wide
- investment opportunities
- online platform with industry news, press releases, job exchange, company database and much more



PREFACE OF THE MANAGING DIRECTOR



PROF. DR. HORST DOMDEY

CEO and Spokesman
Bavarian Biotechnology Cluster

After the “BioTech Region München” had been selected as one of three winning regions in the BioRegio Competition in 1996, and the Federal Ministry of Research (BMFT) had committed DM 50 million for the co-financing of innovative research projects, setting up an organization to distribute the promised funds – after prioritizing the research projects through a rigorous, neutral review process – was deemed essential. This organization was also expected to tackle and implement what was a truly novel project at the time, namely the establishment and management of a biotech seed fund.

For this reason, Bio^M Munich Biotech Development GmbH was founded on June 18, 1997, and shortly thereafter became a small “Aktiengesellschaft”. When I eventually signed my employment contract with Bio^M AG in December 1997, I had no idea where this journey would take me in the coming years, and I could never have envisaged that it would become a real “Jungle River Cruise”.

As with all adventure travel, it is of utmost importance to have an excellent and reliable crew on board. This is exactly what I have always had over the years, and I would therefore like to take this opportunity to sincerely thank all past and present crew members. Of course, several of my crewmates decided to disembark from this voyage and, much to my delight, embarked on their own careers – some of which have been quite extraordinary.

At the beginning of my scientific career in the late 1970s, I would never have thought it possible that there could be anything more exciting than to live the life of a scientist. However, as I then experienced, innovation is the real icing on the cake of science. And so, it was my privilege to witness

the creation and the establishment of the Munich Biotechnology Innovation Cluster, and, in countless cases, I was able to observe how research results gave rise to innovations that were not only financially attractive, but also extremely important to the welfare of our society. The Bio^M Cluster, as this innovation-driven Munich life science cluster is now very often called, only managed to develop so successfully because the greater Munich area has such an immense, almost explosive innovation potential which is fed by its many excellent scientific institutions and which we, at Bio^M, have very often been able to uncover, support and drive toward success.

Does a 25th anniversary also imply that the “Jungle River Cruise”, which began in 1997, has already reached its destination? I don’t think so, because even a high-tech cluster like the Bio^M Cluster, which is certainly no longer in its infancy, must adapt to known and unknown challenges and be prepared for them. Growth, which might be the focus over the next few years, brings with it extraordinary tasks, such as providing space, manpower and endless financing. To ensure that we remain competitive, moreover, new discoveries must be constantly evaluated and, if possible, incorporated into the innovation process. After 25 years, the cruise may be interrupted briefly to bring fresh supplies and perhaps even a new captain on board. But then it will continue – to ever new adventures.

 A handwritten signature in black ink, appearing to read 'Horst Domdey'. The signature is stylized and fluid.

Prof. Dr. Horst Domdey

BAVARIAN BIOTECH IN NUMBERS

Bavaria has now been a leading hub for life science companies for 25 years. In 2021, the Free State was home to a total of 509 companies. The slow but steady increase in this figure year by year is primarily an indicator of a very future-proof and stable industry even in economically difficult times.

289 of these (+5%) are biotech companies forming the backbone of the industry within the region. It is mainly small and medium-sized (SME) companies within biotech that have contributed to this growth (+8%). Encouragingly, this large proportion (a total of 226) originates directly from Bavaria or has relocated their headquarters here. However, 63 internationally operating biotech companies also have subsidiaries, offices or sites in Bavaria, thus enriching the location and the industry. Many have proven to be agile think tanks that deliver innovative ideas and attract highly qualified employees.

The 226 Bavarian biotechnology companies operate in the following areas: therapeutics with the highest increase to 65 companies, diagnostics (25), technology platforms, devices and reagents (64), bioinformatics and digital health (26), industrial biotechnology (17), agriculture, food and environment (11). Another 18 companies are regarded as players in the industry but are not involved in any of the above activities.

Bavaria is home to about 64 large pharmaceutical companies, many of which have their European or German headquarters in the Free State. Among them are various global players such as Roche, GlaxoSmithKline (GSK), Novartis, Daiichi Sankyo, and Merck, Sharp & Dome (MSD). The latest addition to this collection is Moderna, who opened their first German site in Munich last year.

In addition, there are 60 contract research and clinical research organizations (CROs), as well as 96 service providers, contract manufacturers, suppliers and distributors, all of which focus on supporting biotechnology companies.

Another noteworthy development is the new establishment of industry-relevant companies, e.g. the following:

Having been active in the region for many years, the major life science investor **Andera Partners** has opened an office in Munich. The company has thus made its intentions clear concerning its increased ambitions not only in Germany, but also in the entire DACH region.


Also new in Munich is the office of **Pharmaplan**, a company belonging to the TTP Group that specializes in planning and realizing pharmaceutical and biotech plants. The office is one

NEW COMPANIES

COMPANY	CATEGORY	LOCATION
Lumatix Biotech GmbH	Therapeutics	Munich
Eximmium Biotechnologies GmbH	Therapeutics	Munich
SmartBax GmbH	Therapeutics	Munich
Curevision GmbH	Digital Health	Munich
DEOXY GmbH	Diagnostics	Munich
Densilia GmbH	Diagnostics	Deggendorf
Nanostruct GmbH	Biotech Devices & Reagents	Würzburg
Neurevo GmbH	Therapeutics	Munich
FluiMed GmbH	Biotech Devices & Reagents	Grünwald
Avelios Medical GmbH	Bioinformatics/Digital Health	Munich
Athos Biopharma GmbH	Therapeutics	Holzkirchen
Moderna Germany GmbH	Therapeutics	Munich
hema.to GmbH	Bioinformatics/Digital Health	Munich
rnatics GmbH	Therapeutics	Martinsried

THE BAVARIAN BIOPHARMA SECTOR

Number of companies



DR. PATRICK GROSSMANN
Co-founder Invitris



2021 was a very exciting year for Invitris, because our team was recognized with the renowned m⁴ Award. This award really helps us to leverage our universal phage technology platform to develop competitive products. We were also fortunate to be accepted to the first batch of INCATE, a world-class incubator for biotech products solving antimicrobial resistance. This puts us in the perfect position to prepare our next fundraising activities that we anticipate to start by the fall of this year. We hope to find a great wet laboratory in close proximity to Bio^M and other biotech startups.

of 26 subsidiaries in Europe and India, delivering support with close customer proximity in southern Germany.

Another newcomer is **Innovative Molecules**. With a focus on developing next-generation treatments for herpes simplex-induced diseases, the company has relocated its headquarters to the Bavarian capital.

The pharmaceutical company **Novartis** also announced the opening of a new site in central Munich – the second site in Bavaria after Nuremberg. The Basel-based company is thus greatly expanding its presence in the region and, above all, moving closer to the biotech cluster in Munich.

Newly founded companies

One of Bavaria's greatest strengths continues to be its many excellent academic institutions and research centers. The Bavarian biotech industry receives considerable support from several world-renowned universities, university hospitals and research institutes. The sheer density of research activities, active drug development and production, and the broad range of analytical services, make the Free State a globally recognized hotspot for life science developments.

These institutions are an enormous source of innovation and generate a plethora of spin-offs and start-ups every year. In addition, there is a firmly established network of supporting organizations and wide-ranging assistance for young entrepreneurs. In the last two years, biotechnology has celebrated a certain upswing which, unlike in many other industries, can also be attributed in part to the pandemic. After 20 new companies were founded in 2020, the pace slowed

somewhat in 2021. However, with 13 promising, newly founded companies and 1 new settlement, the figures remain at a consistently high level.

Employment

From small start-ups to global biotechnology and pharmaceutical groups with thousands of employees, Bavaria is home to life science companies of all shapes and sizes.

The leaders in this field are the pharmaceutical companies **Hexal/Sandoz** with more than 1,300 employees at its Holzkirchen site and **Roche Diagnostics**, the Swiss multinational that employs around 7,200 people in Penzberg. A "real Bavarian" flagship is the listed former start-up **MorphoSys**, which currently has about 730 employees.

Small (< 49 employees) and medium-sized (< 249 employees) companies account for the largest share in the region. The rising number of biotech companies (currently about 40) with more than 100 employees is a very satisfying development. This is a good indicator that more and more enterprises are also able to grow organically and are becoming important local employers.

In total, about 44,000 people work in the pharma and biotech related sector in Bavaria. As of 2021, approximately 11,000 people were employed by the pharmaceutical companies,




MATTHIAS WEBER
CFO Sandoz Germany

Sandoz is the biggest pharmaceutical producer in Germany and well established with its local brands Hexal AG and 1A Pharma GmbH. It develops, manufactures and distributes generics for off-patent prescription pharmaceuticals as well as OTC brands like ACC or Gingium. The company is based in Holzkirchen where it employs 1,300 people supporting its sales and marketing operations and also developing highly complex biosimilars as well as manufacturing innovative patch solutions. Holzkirchen is located in the immediate vicinity of some of Bavaria's most beautiful lakes and mountains but is also suitable for commuters from Munich thanks to its excellent public transport connections. This creates ideal working conditions for our employees.

THE BAVARIAN BIOPHARMA SECTOR

Employment



while Biotech (SMEs and international) has become an incredibly important employer within the sector with a combined workforce of around 22,000. International companies employ an average of about 245 people at their local sites (15,000 in total), while Bavarian biotech companies have shown strength during pandemic and offer secure jobs to highly qualified employees, with an average of 32 each (7,000 in total).

Financing / Company news / IPOs

In economic terms, 2021 was still impacted by the global pandemic. The approval of various vaccines and the resulting tailwind for the industry, however, certainly had a positive impact. The success stories of German researchers and developers have caused a sensation worldwide and brought the entire economic sector into focus. In addition, it has become clear that an enormous economic potential lies dormant within the dynamic biotechnology sector. Bavarian companies posted highly satisfactory financial figures last year and, once again, many financing rounds were successfully completed. In particular, several follow-up pledges of considerable volume clearly indicate that many of the companies are on a promising path toward commercially viable products.



DR. DOMINIK SCHUMACHER
CEO and founder Tubulis (left)

DR. JONAS HELMA-SMETS
CSO and founder Tubulis

“We founded Tubulis to develop next-generation antibody-drug conjugates (ADCs), innovating on all fronts: target molecules, linker technologies and payloads. Over the last two years, we have made significant advancements toward this goal, growing the company and expanding the team with critical hires to establish ourselves as leaders in the ADC field. A recent highlight, our USD 60 million Series B, will enable us to bring a first product candidate into the clinic. Delivering clinical validation for our technologies and pipeline is a key focus going forward. We are excited to work with our pioneering team to achieve this important next step.

Public funding

The Bavarian funding measure, **BayTherapie2020** – initiated by Bio^M –, was another success that hopefully has also highlighted the enormous future potential of Bavarian companies, and merely requires the appropriate support. During this process, 22 outstanding Bavarian therapy concepts were submitted in a quest for some of the EUR 50 million funding available. A total of five companies received a grant. **Pieris Pharmaceuticals** from Hallbergmoos near Munich was awarded EUR 14.2 million with a view to accelerating the clinical development of its product candidate, an inhalable therapeutic agent for the treatment of SARS-CoV-2-induced lung damage. **Formycon** will receive funding of EUR 12.7 million for the further development of the COVID-19 drug Fyb207, a promising antiviral drug candidate for the treatment of infections from current and future coronaviruses. **Origenis** and **Ethris** also received funding within the scope of BayTherapie2020. Ethris is developing ETH47, an inhaled mRNA therapeutic with a mode of action that is independent of virus mutations. Origenis is working on the development of a drug designed to suppress virus replication in the body. **Eisbach Bio** is developing a new class of drugs that inhibit viral replication or interfere with the cells' own mechanisms that can trigger other serious diseases.

At the Technical University of Munich, start-up **rnatics** has developed an RNA-based compound against inflammatory lung damage resulting from severe cases of COVID-19. The German Federal Ministry of Education and Research (BMBF) is now supporting the further development of the drug with EUR 7 million. In parallel, the BMBF is supporting research into drugs against SARS-CoV-2 at **Eisbach Bio** and **Explicat Pharma** from Hohenbrunn with funding of almost EUR 8 million and EUR 4.2 million, respectively.

Financing deals 2021

In 2021 Bavarian companies negotiated a total of at least 9 financing deals amounting to a volume in the double-digit millions.

ITM Isotope Technologies Munich, a radiopharmaceutical biotech company based in Garching near Munich, closed a financing round worth a total of EUR 90 million in convertible bonds. ITM intends to use the proceeds to expand its precision oncology pipeline and support the late-stage development and market approval of its lead product candidate.

MorphoSys AG increased the share capital by issuing 1,337,552 new ordinary shares from authorized capital excluding the subscription rights of existing shareholders, which were purchased by Royalty Pharma Investments 2019 ICAV, a subsidiary of Royalty Pharma plc. for EUR 85 million as part of a strategic partnership.

Munich-based start-up **Kaia Health**, which is developing digital therapies for back pain, osteoarthritis, and chronic obstructive pulmonary disease (COPD), closed a EUR 65 million Series C financing round. The funds will be used to improve the treatment of musculoskeletal conditions (MSK) and COPD with digital products and provide broader access to effective therapies.

Martinsried-based **iOmx Therapeutics** closed a EUR 65 million Series B financing round.

Immunic announced the completion of a EUR 42 million public offering. The company has succeeded in listing on the Nasdaq stock exchange in New York after its merger with the US company Vital Therapies, including a share swap.

AMSilk, one of the world's leading suppliers of innovative high-performance bio-based silk materials, raised a EUR 29 million Series C funding. This will be used to accelerate the ongoing scale-up of AMSilk's industrial projects.

Having relocated its headquarters to Munich, **Innovative Molecules** also announced the completion of its EUR 20 million Series A equity financing round. With a focus on developing next-generation treatments for herpes simplex-induced diseases, the company plans to use the funds to further develop its preclinical product candidate.

Leukocare, a biotechnology company focused on the development of biopharmaceutical formulations, announced the completion of a EUR 14.6 million financing round.

The recently founded start-up **Origin.Bio** from Pullach near Munich hopes to conquer the world of synthetic biology with specially produced microorganisms and thus produce sustainable raw materials. To this end, it has raised USD 15 million. Using microorganisms, Origin.Bio aims to produce the same ingredients as are achieved with traditional chemical industry processes – but with 10 times less energy and virtually no waste.

Many other companies received grants and financing in the single-digit millions. These include **Kranus Health**, **deepc**, **Dermagnostix**, **mk2 Biotechnologies**, **HMNC Brain Health**, **SciRhom**, **Smart4Diagnostics**, **Medigene**, **Avelios Medical**, **Orbit Health** and **Vision Health**.

There was also very encouraging news for the research sector: **The Max Planck Society** plans to further develop the Martinsried campus to become a flagship for life sciences beyond Germany and Europe. The Free State of Bavaria will support the project with up to EUR 500 million over the next ten years. A corresponding letter of intent has been signed by all parties involved.

2021 also brought great news for the Munich start-up scene: **UnternehmerTUM** and the **TUM Venture Labs** will receive support from entrepreneur brothers Andreas and Thomas

DR. NADJA FENN
CEO OPSYON



“Winning the Munich business plan competition 2021 was an amazing success that was only achieved by the efforts of the complete OPSYON team. We cherish excellent scientists, willing to go the extra mile to successfully translate our university spin-off project into the recently launched OPSYON Therapeutics GmbH, despite the difficult times during the Corona pandemic. The support by experienced advisors from the Munich area further allows to accelerate and de-risk the development of OPSYON's multi-functional antibodies, providing cancer patients an effective treatment with low side effects.”

Strüngmann with the sum of EUR 25 million over the next ten years. The international standing of Europe's largest start-up and innovation center at the Technical University of Munich and the new TUM Venture Labs will benefit hugely from this funding.

The **Werk1** business incubator has also been promised considerable funding: the Bavarian State Ministry of Economic Affairs, Regional Development and Energy will provide Werk1 with a total of EUR 22.4 million over the next six years.

Financing deals 2022

ITM received a EUR 25 million capital increase from strategic partner Grand Pharma. A EUR 33 million equity investment from Indigenous Critical Infrastructure Fund Canada (ICIF) and a private equity fund managed by Portland Investment Counsel Inc. increased the cash raised in 2022 to EUR 58 million.

In January, Planegg-based biotechnology company **Ethris** raised USD 26.3 million in a Series B funding round led by Laureus Capital. Ethris plans to use the money to further develop its mRNA therapeutics and proprietary platform, and to expand the company's production capacity.

Martinsried-based **PreOmics** also secured Series B financing in January from Bruker Corporation totaling EUR 13.5 million. As a spin-off from the Max Planck Institute of Biochemistry in Martinsried, PreOmics won the m⁴ Award pre-seed competition in 2013 and develops innovative automation and sample preparation tools and consumables for proteomics analysis using mass spectrometry.

Tubulis, the 2017 m⁴ Award winner, recently secured Series B financing of EUR 60 million. The Munich-based biotech start-up intends to use this funding to accelerate its antibody-drug

conjugates (ADCs) pipeline toward clinical evaluation and expand its range of platform technologies for the treatment of cancer.

Pipeline

Traditionally, the Bavarian biotech landscape has been strongly geared towards the development of pharmaceuticals. This entails long-term research and development projects, which add up to a lengthy process – from the identification of a drug candidate through preclinical and clinical studies to approval. On average, it takes ten to twelve years before a product is ready for market. In addition, only one in ten clinical projects entering phase I clinical development is ultimately approved. Over the years, the Bavarian biotechnology industry has built up an impressive pipeline of compounds which, by May 2022, had reached the preclinical (41) or even clinical (118) phase. As recently as 2013, for example, only 49 candidates were in clinical development. A total of 37 products are currently in clinical phase I, 53 in phase II and 28 in phase III. In the context of the coronavirus pandemic, fast approval procedures for vaccines have shown that there is still enormous potential for improvement, especially in terms of steps that can be completed in parallel. In this respect, the accelerated approval procedures have raised the hope for many developers that a lot of processes can also be accelerated in future studies. As in previous years, cancer therapy accounts for the largest share of compounds in clinical development with a total of 56 projects. Nearly 50% of all ongoing clinical studies by Bavarian companies are in the field of oncology, accordingly. This is followed by autoimmune therapeutics with 14 projects. At present, there are eight studies into diseases affecting the central nervous system, six in infectious diseases and three involving cardiovascular diseases.

MONIKA STEGER
Managing Director
Bayern Kapital



Bayern Kapital has been a strong venture capital and growth investor for Bavarian biotech start-ups for over 25 years. With the Wachstumsfonds Bayern and, since last year, also with the Scale-Up Fund Bavaria, we manage two funds with which we as Bayern Kapital can invest double-digit million amounts. Although Corona caused a lot of turbulence in 2021, it also showed the strengths of our region. Only recently have biotech-companies from our portfolio made a name for themselves again, for example Tubulis and SIRION. This shows our successful investment strategy: as flexible as it is needed for the individual company.

Approvals and highlights

Bavarian efforts in the fight against the coronavirus have resulted in many promising developments and drug candidates. **Formycon**, **Bavarian Nordic**, **Eisbach Bio** and **Immunic** proved to be pioneers in this respect, but university research groups from Würzburg and Munich have also made important contributions. While not all candidates will reach the market, the researchers have provided very valuable groundwork for future developments and have contributed to a better understanding of the coronavirus and its properties.

Besides the pandemic, research has of course continued in many other indications. Thus, some companies have reached important milestones on the road toward approval of their new drugs.

The Regensburg-based NMR diagnostics company **numares** has filed an application for approval with the US Food and Drug Administration (FDA). If granted, the NMR (Nuclear Magnetic Resonance) platform for AI-driven, metabolomics-based diagnostics will be the first NMR-based clinical laboratory system to analyze and evaluate metabolic data using AI. The goal is to better diagnose, prevent, and treat diseases.

MorphoSys announced that the European Commission has approved its humanized monoclonal antibody Minjuvi® (tafasitamab) in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.

The pharmaceutical group **Roche** and its partner **MorphoSys** may have delivered hope for timely approval of an Alzheimer's drug candidate in the US. According to Roche, gantenerumab has been granted breakthrough therapy status. Gantenerumab is an IgG1 antibody in the MorphoSys development pipeline. It is designed to remove certain brain deposits that are a hallmark of Alzheimer's disease.

Formycon and its licensing partner Bioeq recently received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for FYB201, a biosimilar to Lucentis®. Formycon and Bioeq also announced that an application for approval has been filed with the European Medicines Agency (EMA) for their biosimilar candidate, which is intended as a treatment for severe eye disease.



Deals and collaborations

In 2021, there was again a strong desire for collaboration between biotechnology companies. The extent of these collaborations varied greatly: from exchanging technologies, licensing, providing research and production capacities to acquisitions.

Planegg-based **ViGeneron** has announced a research collaboration with Daiichi Sankyo Company, Limited in Tokyo.

DRUG PIPELINE OF BAVARIAN BIOTECH SMEs

Number of projects by phase and indication



As of May 2022. Not included are the non-clinical projects of morphosys. Included are subsequent clinical trials with partners.

STEFFEN TROPITZSCH

CEO Iris Biotech



“Business as usual? Not in current times. Flexibility, innovative ideas and a good team help us to overcome the current times!”

The two companies will evaluate ViGeneron's proprietary intravitreally injected vgAAV vectors for delivery of a novel therapeutic protein. Together, they aim to develop a gene therapy treatment for a common eye disease. ViGeneron had already signed a global collaboration agreement with Biogen in early January 2021.

SIRION Biotech entered into a licensing and collaboration agreement with Sanofi. The two companies aim to develop improved AAV capsids as gene therapies for life-threatening diseases.

ChromoTek, a specialist in nanobody-based reagents, and **Absolute Antibody**, a leading provider of recombinant antibody technologies, have announced their collaboration to produce recombinant antibodies for research applications.

Leukocare and **Malvern Panalytical Ltd** have agreed to pool their expertise in vaccine formulation and stabilization in the interests of improving the availability of vaccines against COVID-19.

Another partnership between local companies is also particularly satisfying: The two Martinsried-based players **Leukocare** and **Formycon** are cooperating in the field of high-quality biopharmaceuticals. In addition, Leukocare is expanding its range of services with **Rentschler Biopharma** by opening a joint site in the U.S.A.

NanoTemper Technologies and **PharmAI** are collaborating to find suitable drug candidates by screening vast amounts of data.

Immunic and **4SC** have signed an agreement under which Immunic will settle its remaining royalty obligation on net sales of IMU-838, for USD 17.25 million. The transaction will be payable 50% in cash and 50% in shares of Immunic's common stock.

Pieris entered into a research collaboration with Roche subsidiary **Genentech** to develop therapies for respiratory diseases and ophthalmology. Pieris will receive USD 20 million upfront from the deal and is eligible for more than USD 1.4 billion in additional potential milestone payments plus royalties on commercialized programs.

Dermapharm, a manufacturer of branded pharmaceuticals, is expanding its group of companies through **Dermapharm** to include a stake in the field of immunotherapy against COVID-19. To this end, the company has completed the acquisition of new shares in **CORAT Therapeutics GmbH**, based in Braunschweig, Germany.

Eisbach Bio and the team of Prof. Dr. Naim Bajcinca from the Technische Universität Kaiserslautern announced a collaboration in which they will use deep learning to track and trace emerging mutations in the genome of SARS-CoV-2 and develop sustainable small molecule inhibitors that will target the virus long-term.

Immunic has announced an in-licensing deal with the University Medical Center Goettingen, Germany, designed to accelerate the development of treatments for viral infections, including COVID-19 and influenza.

Formycon and **SCG Cell Therapy Pte Ltd** announced that they have entered into a licensing agreement to develop and commercialize **FYB207**, **Formycon's** COVID-19 drug. Under the agreement, **SCG** has access to **Formycon's** ACE2 fusion protein technology and acquires an exclusive license to develop, manufacture and commercialize the drug in the Asia Pacific region, excluding Japan.

Medigene, an immuno-oncology company with clinical projects focused on the development of T-cell-targeted cancer therapies, has announced the expansion of the joint analyses of potentially novel cancer antigens with **IRICoR** and the University of Montréal.

The biotech company **ITM**, based in Garching near Munich, has found a new partner in China for its targeted radionuclide cancer therapy. The deal with the listed pharmaceutical company **Grand Pharma** could bring **ITM** revenues of up to EUR 520 million plus royalties. Under the deal, **Grand Pharma** will be granted the development, manufacturing and marketing rights for two drug candidates and a diagnostic from **ITM**.

The diagnostics company **Mikrogen** from Neuried has acquired **Lophius Biosciences** from **BioPark Regensburg**, in a bid to enter the future market of T-cell-based tests. Immuno-diagnostics play a major role in transplantation and infectious and autoimmune diseases.

Planegg-based biotech company **MorphoSys** has acquired the US biopharmaceutical company **Constellation Pharmaceuticals** for a total equity value of USD 1.4 billion and has thus entered into a strategic financing partnership with **Royalty Pharma**.

American powerhouse **PerkinElmer** has entered into an agreement to acquire **SIRION Biotech** from Munich, a leading global provider of viral vector-based technologies that drive improved delivery performance for cell and gene therapies.

The sell-off came as a surprise given that SIRION was reportedly on the verge of its own IPO.

By incorporating Gruppo Tronchet's integrated medical offering, Nuremberg-based laboratory services provider **SYNLAB** has expanded its expertise and its patient-oriented portfolio. The integration of Gruppo Tronchet's health centers into SYNLAB's international laboratory network ensures mutual knowledge transfer and will thus improve patient care in Italy.

Company highlights

Together with Bio^M, the Bavarian State Ministry of Economic Affairs, Regional Development and Energy selected the five winners of the m⁴ Award pre-seed competition, with each team receiving up to EUR 500,000 from the Bavarian Ministry for a period of two years. The winners of 2021 were **BetaRegeneration**, **Invitris**, **Mallia Biotech**, **SELECKREM** and **SugarSwitch**.

Munich-based **GeneSurge** reached the finals of the international XPRIZE Rapid Covid Testing competition. Though the victory ultimately did not go to Bavaria, participation in the final was a great achievement for GeneSurge.

In the 2021 Businessplan Wettbewerb Nordbayern, Bay-StartUP selected its winning startups: first place in the final of the competition went to the Würzburg-based biotech startup NanoStruct. Second and third place also went to the life sciences: to medtech start-ups BD-4 from Erlangen and inContAlert from Bayreuth, respectively. In Southern Bavaria, biotech start-up Opsyon came first with innovative antibodies for cancer therapies.

The 2021 winners of the "Most Innovative Product" award in the category Leap Innovations were again announced at the "Pharma Trend – Image & Innovation Award". **Formycon** came out on top ahead of **Ethris**, with third place going to **Pieris**. The three Munich-based companies were each honored for their development of therapeutics against COVID-19.

The winners of this year's "BioRegions Innovation Award" were announced at the start of the German Biotechnology Days 2021 in Stuttgart. The jury was impressed by three projects from the fields of medical technology and vaccine and active ingredient research. In addition to winning the Innovation Award, the project of the Munich-based company **Dymium** won the Audience Award.

Special honors for **ibidi**: The Pharma Tech Outlook magazine named ibidi as one of its top 10 leading virology tech solution providers in Europe. The company from Gräfelfing also won an "Export Award Bavaria" in the category of "Successful order processing in Corona times". As a supplier in the laboratory sector, ibidi has adapted its approach to interacting with customers considerably since the beginning of the pandemic and thus impressed the jury.

Great achievement for start-up **inContAlert**: After a successful application, EUR 712,000 in EXIST funding for research transfer went for the first time to the University of Bayreuth.

In the "TOP 100 Innovation Competition", Munich-based protein analytics company **NanoTemper Technologies** was named "Innovator of the Year" for the third time in the category for companies with up to 200 employees.

The pharmaceutical giant **Roche**, which has a large site in Bavaria, celebrated its 125th anniversary in 2021. The motto of the celebrations was simple: Celebrate Life. In 2022, moreover, Roche in Penzberg will celebrate its 50th anniversary at the Nonnenwald site.

Iris Biotech celebrated its 20th anniversary last year. Since its foundation in 2001, Iris Biotech in Marktredwitz in Upper Franconia has been supplying products for peptide synthesis, drug delivery and life sciences from research scale to commercial production, both for academia and industry.

The academic scene has also lived up to its excellent reputation. In the current QS World University Ranking 2021, Bavarian universities confirmed their standing in the international scientific community. In the European Union, the Technische Universität München (TUM) ranked highest, in 50th place, while the **Ludwig-Maximilians-Universität München** (LMU) made it to 63rd place in an international comparison. Würzburg and Erlangen-Nuremberg came in the TOP 250, and the University of Regensburg the TOP 400.



DR. MAX PÖHLMANN
Project- & Clustermanager Bio^M

Bavaria is and remains a great biotech location. However, we must by no means rely on our mountains and the Oktoberfest as drawing horses, but must make it as comfortable as possible for companies here. Bavaria's popularity is not just a blessing, but also comes with challenges such as the shortage of suitable laboratory space. We also have some room for improvement when it comes to bio production. We are trying to remove as many obstacles as possible for small and large companies in the sector so that Bavaria can really develop its true potential as a location for the future.



25 YEARS BIO^M & MUNICH BIOTECH CLUSTER

The "Bio^M Cluster" celebrates its anniversary

A large, metallic, 3D-style number '25' is centered in the upper half of the page. It is surrounded by a radial pattern of bright blue starburst light effects. Below the number, the dark blue silhouette of a city skyline is visible, including a tall tower on the left and a church with two domes on the right.

25

To make biotechnology more economically viable and to keep pace with progress made in the USA, the former Ministry of Research and Technology launches the BioRegio Competition in 1996.

Head of the Gene Center, Prof. Dr. Ernst-Ludwig Winnacker, and his team apply for recognition as a model region for biotechnology with the vision of advancing innovation and establishing a Munich biotech cluster. As one of the competition winners, Munich receives funding of DM 50 million (equivalent to roughly EUR 25 million) and can thus support companies in the biotechnological sector by covering 50% of their project costs. By the turn of the millennium, more than 20 companies in the Munich area benefit from such funding.

Localization

Relocation of the Faculty of Chemistry and Pharmacy (LMU) from downtown Munich to Martinsried-Großhadern.

IPO

MorphoSys is the first Munich biotechnology company to go public.

BIOPARK Regensburg

Establishment of the Innovation and Start-up Center of the University of Regensburg.

1997


1998

1999

BIOPARK
REGENSBURG GMBH

Anniversary:

Bio^M is established in 1997 as the cluster management organization for coordinating the rollout of the BioRegio concept in Munich. Prof. Horst Domdey is appointed as chief executive of Bio^M AG.





© Ernst A. Graf

Technical University of Munich (TUM)

Foundation of the TUM School of Life Sciences in Weihenstephan (Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt)

Ups and downs

External financing hits the record sum of EUR 500 million in 2000. Almost simultaneously, however, the research-intensive, high-risk biotechnology sector must learn its lesson after the "New Market" at Frankfurt Stock Exchange collapses. Investment drops sharply, with significant knock-on effects over the next few years such as a decrease in the number of biotech funds and IPOs. However, VC companies increase in number and become more active as of 2014.



IGZ Würzburg

is founded and assumes operations in northern Bavaria.

2003

2002

2001

2000

Cluster expansion

The Innovation and Start-Up Center for Biotechnology is launched in Weihenstephan to the north of Munich.



© IZB Freising_Weihenstephan



Biocenter
The Faculty of Biology (LMU) opens its Biocenter at the Campus Martinsried-Großhadern.

New challenges for Bio^M

The Bavarian Biotechnology Cluster is founded in 2006 by the Bavarian government and Bio^M GmbH is engaged in connecting all biotechnology regions in Bavaria.



2005

Acquisition

Novartis acquires Hexal and relocates the headquarters of its international generics division to Holzkirchen near Munich. The former Hexal owners (Strüngmann Brothers) start investing in German biotechnology.

2006

2007

2008



© Shutterstock, Alexander Zamaraev

Elite universities

The two Munich universities (LMU and TUM) achieve success in the German Universities Excellence Initiative.

2004

On the market

The first German biotechnology company to launch a drug is Martinsried-based Medigene.



© medigene



© Heddergott, Andreas TUM

Innovation

Removab (Trion Pharma/ Fresenius Biotech) is the world's first multi-specific antibody, developed in Munich and brought to market.

2009

2010

Personalized medicine

As a future strategy, "m⁴ Personalized Medicine and Targeted Therapies" is among the winners of the BMBF Leading-Edge Cluster Competition. Managed by Bio^M, the Leading-Edge Cluster has more than 100 partners from industry and science and funds more than 60 collaborative projects between academic institutions, clinical research, and industry partners from 2010 – 2015.



Annette Schavan, then Federal Minister for Education and Research and Prof. Dr. Horst Domdey

m⁴

Partnership

With a view to their future partnership, Bio^M and the Life Science Cluster of Osaka/Japan sign a collaboration agreement in 2011.

m⁴ Award

The pre-seed competition m⁴ Award, aimed at academic research projects in the field of biomedicine with spin-off potential, is presented for the first time in 2011 by the Bavarian State Ministry of Economic Affairs, State Development and Energy.

A total of 30 research projects with spin-off potential have since received the award in six calls. So far, nine spin-offs have been successfully established.



2011

The first Munich Biomarker Conference

is launched by Bio^M – the European networking event for personalized medicine.





Award

Bio^M is awarded the European Gold Label for Cluster Excellence.

2013

Hotel

Opening of the IZB Residence at the Campus Martinsried-Großhadern. After several extensions, the Innovation and Start-Up Center for Biotechnology (IZB) in Martinsried and Weihenstephan covers a total area of more than 26,000 m².

2014

2012

Major deal

Amgen acquires Munich-based Micromet (Inc.) for USD 1.2 billion, making Munich Amgen's largest research center outside the USA. Blockbuster Blnicyto subsequently reaches market maturity.

EIT Health

The European headquarters of EIT Health is opened in Munich. Bio^M is one of the partners in this healthcare initiative, the largest of its kind in Europe, comprising 140 partners from 16 countries.





© Presse LMU, Christoph Olesinski

BMC

The Biomedical Center dedicated to applied cell research is opened at the Campus Martinsried-Großhadern.

2016

BioSys-M

Opening of the Research Center for Molecular Biosystems at the Campus Martinsried-Großhadern.



© Presse LMU, Christoph Olesinski

2015

Investment

In 2015, Roche invests approx. EUR 600 million in biopharmaceutical production facilities, an education center, diagnostics production facilities and infrastructure in Penzberg. It is one of the largest biotechnology centers in Europe, currently with over 7,200 employees.



© Roche, Klein_Bodenbender

InnoMuNiCH

Support for the establishment of a platform for R&D collaboration between Bavarian companies and Japanese research institutions and pharmaceutical companies comes in the form of the Inno-MuNiCH project. It is developed within the framework of the Bio^M Leading-Edge Cluster Initiative and funded by the BMBF as a means of deepening the partnership with Japan in the field of personalized medicine.



2017

FORUM Science & Health


With current topics in health research as well as high-ranking speakers from science and industry, the first FORUM Science & Health offers a platform to stimulate discussion and prompt interdisciplinary dialogue.



© Bio^M/Andreas Grasser

FORUM
Science & Health

State Secretary Roland Weigert, StMWi (left) with Prof. Dr. Horst Domdey



● DigiMed Bayern

The lighthouse P4-medicine project DigiMed Bayern is launched with over EUR 22 million in funding from the Bavarian State Ministry of Health and Care.

DigiMed Bayern collects and analyzes big data from patients diagnosed with atherosclerotic diseases. Patients and individuals at risk should benefit in the future due to the improved prediction of disease risks, targeted prevention, diagnosis and treatment.

● Coronavirus pandemic

Following identification of the SARS-CoV-2 virus as the trigger for the infectious disease, COVID-19, and its global spread, a pandemic is declared in March 2020. From the outset, numerous Bavarian companies and research teams drive innovative research into the development of testing systems, vaccine candidates and drug treatments in a concerted effort to overcome the pandemic.



© Shutterstock

2018

2019

2020

**Biotech Talk
aus Bayern**



● BayTherapie2020 funding program

Out of a total of 22 submissions, six outstanding Bavarian therapy concepts are awarded funding as part of BayTherapie2020. The Bavarian funding package offers EUR 50 million to support companies in the development of therapeutics against COVID-19.

● Podcast

The Bio^M podcast "Biotech Talk aus Bayern" goes live in 2020, sharing news from innovative scientists and key players in Bavarian biotechnology.



© Shutterstock

Gold Label

Bio^M is awarded the European Gold Label for Cluster Excellence for the second time.



2021

Since 1997, Bio^M has been the central network organization for the biotechnology sector in Munich and Bavaria, commissioned by the Bavarian Ministry of Economic Affairs.

As a non-profit organization, Bio^M offers the biotech community wide-ranging support through its extensive network.

The cluster management acts as a centralized access point, connecting Bavarian life science companies with relevant national and international partners and supporting Bavarian biotech companies throughout the process of setting up their business.

To this end, Bio^M has developed a unique support program aimed specifically at aspiring start-ups and entrepreneurs in the life sciences sector: the Bio^M inQlab virtual incubator.

Bio^M has supported more than 200 start-up companies over the last 25 years.

2022



VISION

Bavaria – the place for the
medicine of the future



PROF. DR. HORST DOMDEY – “MR. CLUSTER”

The man with the biotech gene

In a 3rd floor office of the IZB West II, Horst Domdey can be found in conversation with a group of young people. This is a regular working day for him and a familiar sight to his team, as the door to the office of the managing director of the Bio^M Biotech Cluster organization is always open. Open to founders, company representatives, scientists, investors, and industry stakeholders. Given that Horst Domdey – also known as “Mr. Cluster” – has networking in his veins and knows the industry like no other, there is always a steady stream of visitors.

The man of the first hour

In the mid-1990s, as part of the team of then director of the Gene Center Munich, Prof. Dr. Ernst-Ludwig Winnacker, Horst Domdey worked on a concept for the BioRegio competition, of which Munich was one of the winners in 1996 and which brought biotechnology funding to the region. On establishing the Bio^M cluster management organization in 1997 as a means of implementing the BioRegio concept, Horst Domdey became managing director and thus the man of the first hour of the Munich biotechnology cluster.

Visionary focused on founders

Since then, he has tirelessly pursued his vision of turning Munich into a successful biotechnology hub for the medicine of the future. He gives talks at national and international congresses, travels extensively abroad to promote the location, establishes partnerships with international biotechnology regions, advises and connects representatives from industry, science, politics and finance with the support of his team, and sits on various committees and advisory boards. In doing so, he attaches great importance to bringing people together and to recognizing trends that are decisive to the industry. Thanks to his special focus on founders, Bio^M has



Bavarian State Minister of Science and the Arts Bernd Sibler presents the “Pro meritis scientiae et litterarum” award to Prof. Dr. Horst Domdey (left)

developed a customized portfolio over the years to support budding start-ups in the field of medical biotechnology.

By 2001, the Munich Biotech Cluster had already amassed over 100 companies and has continued to grow to the extent so that by 2022 there will already be more than 200 companies in the sector in the Munich region.

In 2013, Horst Domdey received the state medal for special services to the Bavarian economy.

Significant trends – personalized medicine and digitization

With their concept titled “m⁴ Personalized Medicine and Targeted Therapies”, Horst Domdey and his team landed a major coup in 2010 by winning the top cluster competition of the BMBF. Between 2010 and 2015, more than 70 projects between academic institutions, clinical research teams and industrial partners in Munich benefited from

funding of EUR 100 million. This gave the biotech region a tremendous boost.

The Munich Biomarker Conference was launched by Domdey and his team in 2011, bringing scientists and physicians together with the biotech and pharmaceutical industry every year until 2016 to discuss the latest trends in biomarker research.

In 2017, the FORUM Science & Health emerged: a new event format and national meeting point for all players from the health sector focused on personalized medicine with a view to interdisciplinary exchange. From Nobel Prize winner to founder – every stakeholder in the industry can have their say here.

Horst Domdey recognized the importance of digitization to modern medicine early on and in 2018 launched another project close to his heart: The P4 medical lighthouse project, DigiMed Bayern, was initiated with funding of more than EUR 20 million from the Bavarian State Ministry of Health and Care.

In 2019, Horst Domdey received the “Pro meritis scientiae et litterarum” award from the Bavarian Ministry of Science and the Arts for special services to science and the arts.

Cluster management in times of pandemic

In 2020, the coronavirus pandemic posed major challenges not only to the cluster’s companies but also to Bio^M – networking in times of restricted contact! Horst Domdey’s door remained open – virtually and in real life. During a pandemic, the managing director of a biotech cluster organization still has plenty to do. He was convinced that, in addition to the urgent need for vaccines, drugs for treating COVID-19 were also required. Alongside members of the medical, scientific, and industrial sectors, his voice was heard, and the Bavarian government launched BayTherapie2020, a multi-million Euro funding initiative.

In 2022, the horror of the coronavirus pandemic is slowly waning, not least because of the achievements in biotechnology. But there is no time to rest: the next challenges are just around the corner. Horst Domdey gives warning: Medical biotechnology must not be forgotten once the coronavirus pandemic has been overcome, because the danger of a pandemic caused by bacteria, for example, is quite real. The achievements of biotechnological research in recent years must be driven forward and further developed, something that is only possible under the right conditions and with a good investment climate.

So, what’s next for Horst Domdey? After 25 years as managing director of the Bio^M cluster organization, at the age of 70, he will pass on the baton in 2022. While his grandchildren will enjoy a little more of his time, his ties with the biotechnology industry will not be severed. And those who know him also know that his door will remain open in the future to anyone seeking and welcoming his advice.



Ihr High-Tech-Unternehmen sucht Eigenkapital?

Bayern Kapital bietet:

- Eigenkapital für Start-Up, Expansion, Later-Stage und Growth
- Co-Investments mit Partnern von 0,25 bis 25 Mio. EUR
- Langjährige Finanzierungserfahrung



NEU:
ScaleUp-Fonds Bayern
Tickets
10–25 Mio. EUR

25 YEARS AND STILL GOING STRONG

Guest contribution from Dr. Viola Bronsema

There is one thing that probably everyone in the German biotech community agrees on. An important cornerstone for the blossoming of the German biotechnology industry was the Bioregio Competition of the Federal Ministry of Education and Research in the mid-1990s. Another thing about which there is widespread consensus is that Bio^M and the Bavarian biotech cluster, respectively, is one of the most successful in Germany. This success was made possible in part by public funding from the Federal Ministry of Education and Research to competing bioregions competition, which launched Bio^M 25 years ago.

A lot has happened since those founding years, not only in Bavaria. From a veritable biotech hype, abruptly interrupted by the bursting of the dotcom bubble, renewed growth, again slowed down by the financial crisis, and further continuous growth in the decade up to the Corona pandemic. This global health crisis catapulted the biotech industry to unimagined heights. The development of vaccines and diagnostics has led to a sudden increase in public recognition. Since 2020, politicians have been happy to show their faces with representatives of the industry, which was not a given for many years.

The time has never been better to show what biotechnology can achieve (and provide). For our health, but also in many other areas such as chemical and textile industry, food and feed and more generally speaking for sustainability. Biotechnology has worked wonders in recent decades, largely unnoticed though by the general public. Who doesn't know someone who has to inject themselves with insulin several times a day? Genetically engineered insulin, mind you, which has been produced at large scale since the 1980s. But not in Germany at first, because we didn't want it then.

Rheumatism therapy was revolutionized when the first antibody therapies came onto the market in 2002 and has taken away chronic pain from millions of people. Personalized cancer therapy with antibodies has already saved many lives. And then: our daily life. Wash clothes clean, even at low temperatures with "biological active washing powder"!; we have all heard this advertisement before. But hardly anyone knows that this is only possible due to biotechnological methods that have changed the enzymes in the detergent accordingly. And the list goes on and on. Whether cheese or bread, vitamins or flavours, clothing or animal feed. Nothing works without biotechnology anymore.



But that's not all by a long shot. Technologies such as biotechnology are constantly being developed further. And next to the global health crisis, the world climate is also in crisis. We need to reduce the amount of energy that we use and turn to renewable energy sources that do not emit carbon dioxide and other greenhouse gases. We need to urgently reduce land and water use; we need to preserve the biodiversity and we need to feed the still growing world population. There are many challenges ahead of us and biotechnology offers solutions for most of them. We can convert flue gases into chemicals with the help of microorganisms, we can produce bio-based biodegradable plastics, we can convert residual and waste materials into biofuel, we can remediate soil and water, we can grow mammalian and fish cells for novel future food, and leather from bioreactors, we can design higher-yielding, drought- and salt-tolerant crops and we are developing personalized cell therapies for the seriously ill.

Can we really do all that, or are these just promises again, as some people say? Most of these things are happening already, very often in small scale laboratory set-ups. What is missing is the technology transfer into large scale applications and innovation for our society. There is no shortage of bright minds, creative ideas and opportunities. What is lacking is society's support and enthusiasm for these technological solutions suited to secure our future together with social innovations and integration. What is also missing is support from the political arena. To be sure, there is now recognition, especially for the achievements of vaccine developers. However, there is still a lack of understanding of how technology transfer can succeed on a broad basis. BioNTech is a beacon of the biotech industry and a great example of what it takes for a biotech company to succeed.



© Bio Deutschland

Germany should take its cue from this example. Rhineland-Palatinate is doing that now, with the billions of taxpayers' money that BioNTech has flushed into city and state coffers. We need to strengthen and professionalize technology transfer at universities, we need to set up suitable funding programs for young and growing biotech companies with unbureaucratic and easy access. We need to create incentives for investors and private individuals to invest in promising biotech companies in order to provide large sums of capital for scale-up and growth of promising start-ups. We need to make entrepreneurship desirable, and we need to accept that failing can be a good thing.

The Munich and Bavarian biotech cluster grew from a competition winning bioregion in the nineties to an international recognized high-tech cluster. It is, together with other regional business development organizations and the federal biotech association BIO Deutschland, committed to creating these framework conditions and ensuring that biotech companies can thrive and receive the appreciation they deserve. We are confident that this commitment will pay off and that we will see more success stories like those of BioNTech and many others in Bavaria and Germany in the next 25 years.

About BIO Deutschland:

As the sector association of the biotechnology industry, BIO Deutschland has set itself the objective of supporting and promoting the development of an innovative economic sector based on modern biosciences. The Berlin-based association currently has over 370 members.

BIO DEUTSCHLAND

DR. VIOLA BRONSEMA, CEO OF BIO DEUTSCHLAND

Since 2006, Dr. Viola Bronsema has been the CEO of the biotechnology industry association BIO Deutschland. Prior to that she held management positions in communication and public relations at Roche Diagnostics and Eli Lilly, among others.

I WANTED TO BUILD A LOCAL BIOTECH INDUSTRY ON THE EUROPEAN LEVEL

Bio^M and the Munich Biotech Cluster are turning 25 – and can look back on a great success story. With the support of the Biotech Cluster management organization, the life science region has developed into one of the most successful biotech clusters in Europe. Prof. Dr. Horst Domdey has led Bio^M since its foundation.

PROF. DR. HORST DOMDEY
Managing Director of Bio^M



Bio^M: Bio^M and the Munich Biotech Cluster celebrate their 25th anniversary. You have been successfully leading Bio^M since its foundation as managing director. Can you still remember how it all began? What was your vision back then?

Prof. Dr. Domdey: For me, it still seems to be like yesterday, and I am still able to remember many details which, of course, I will not describe; otherwise, this would be become a huge compilation of mostly nice anecdotes. The whole endeavour started with the preparation of a strategy of the *Initiativkreis Biotechnologie München*, the aim of which was to develop a strong, competitive biotech region in the greater Munich area. This strategic concept was then submitted to *Bundesministerium für Forschung und Technologie (BMFT)* with the goal to become one of the winners in the so called *BioRegio* competition and to get recognized in this way as a German model region for biotechnology. In a jury session a couple of weeks later, the strategy which was backed by several meters of filled folders to prove what we had claimed was defended by Prof. Dr. Ernst-Ludwig Winnacker who presented our plans on the basis of – how he named it – the Munich biotechnology innovation culture. It was indeed me, who eventually volunteered to participate at the award ceremony on November 2, 1996, where only three out of 17 applicants would receive the “*BioRegio Award*”. Since our proposal belonged to the three successful ones I had the honour to receive the *BioRegio Award* from our former *Bundesforschungsminister Rüttgers*. To my and everybody’s big surprise, it was not only the certificate that the *BioRegion Munich* was recognized as a model region for biotechnology, but the certificate was accompanied by the Minister’s promise to primarily fund biotech research activities in the three winning regions *Heidelberg*, *Rheinland* and *Munich* with up to *DM 50 million* (around *EUR 25 million*) each with the condition that the research projects received a 50% co-financing from private sources. This meant that only research projects of the local biotech industry were eligible for getting funded. The local pharma companies immediately abstained from trying to get also a piece of this *DM*

50 million cake. To have a fair distribution of the promised *DM 50 million* funding and to be able to start also the seed funding activities which had been proposed as a major part of *Bio^M’s* biotech development strategy, an organization had to be created. On June 18, 1997, *Bio^M* was founded, originally as a *GmbH* which was one month later converted into an *Aktiengesellschaft*, the *Bio^MAG*. I have to admit that I had no concrete vision but just one goal: to build a local biotech industry that is not only competitive on the national but also on the European level.

Which events would you highlight?

Out of the many many other very interesting developments in *Bio^M’s* 25 years history I would just like to mention a very few other ones:

In 2006, *Bio^M AG* spun out its daughter company *Bio^M Biotech Cluster Development GmbH* which was designed to become the organization to run all activities for the development and the management of the *Munich Biotech Cluster*, which is now very often entitled “*Bio^M Cluster*, and leaving *Bio^M AG* just the seed financing activities.

In the same year, *Bio^M* was granted the management of the *Bavarian Biotech Cluster* – with a strong focus on medical biotechnology – including the three biotech regions of *Würzburg*, *Regensburg* and *Munich*. In 2007, our proposition to the national *BioIndustry 2021 Competition*, organized by the *BMBF*, in which *Bio^M’s* strategic concept for the development of industrial biotechnology in *Bavaria* was selected to become one of the five winning proposals. This led eventually to the formation of *Bio^M’s* sister company *Bio^M WB GmbH* which later renamed itself into *Industrielle Biotechnologie Bayern GmbH*. In 2010, the *Munich Biotech Cluster* became one of the three winners in the *Leading Edge Cluster Competition (Spitzenclusterwettbewerb)* of the *BMBF*. With its strategic concept “*m⁴ – Personalized Medicine and Targeted Therapies*” it was able to raise almost *EUR 100 million* from the *BMBF*, the local biotech industry and the *State of Bavaria*. In more than 60 research projects and

six infrastructural projects it was possible to establish the proposed concept of *personalized medicine / precision medicine* in the *Munich Biotech Cluster*. The strongest effect – at least in my opinion – was the establishment of new co-operations and multilateral networks.

In 2018, after almost three years of detailed planning and structuring, *DigiMed Bayern*, originally conceptualized by *Bio^M* and funded by more than *EUR 22 million* by the *Bavarian Ministry of Health and Care*, was able to start its activities under the scientific leadership of Prof. Dr. Heribert Schunkert of the *German Heart Center, Munich* with *Bio^M* being responsible for the coordination and the controlling of *DigiMed Bayern*.

What were the biggest challenges in the founding phase?

Many of the actors and stakeholders who were involved in the creation of *Bio^M* – including me – tried very hard to identify a person who would not only be able to – but also love to – manage the newly founded *Bio^M AG*. This turned out to be a futile effort for many months. In the end, it was a very persuasive letter of a representative of the *Bavarian Ministry of Economic Affairs* and the very convincing words of the *Chairman of Bio^M’s Supervisory Board* – together with two glasses of a very tasty *Bordeaux wine* – that led to me signing a management contract with *Bio^M*. The next challenge was to find the right people to put together a team. Fortunately, I was able to identify the right people, convince them and finally hire them, so everything was ready to go.

What were important developments, steps, stages in the last 25 years?

One of the first things to get accomplished was to raise the money for the planned seed financing activities. With our cornerstone investor, the *State of Bavaria*, who committed itself to provide 25 percent of the planned *DM 15 million*, we succeeded in convincing banks, pharmaceutical companies, *VCs* and many others to provide the money which we planned to use for seed financing of newly founded biotechnology companies which were almost entirely

spin-offs of the local academic institutions. The great success stories of the initial seed financings created a strong interest of other investors so that we had to do another financing round raising in this way another EUR 4 million. In total, Bio^M AG has seed-financed more than 40 start-up teams, with a final success rate of – unfortunately – less than 50%, however, with some of the successful companies achieving multiples of up to seven.

Which would you consider the biggest success stories in the cluster?

First of all, I want to mention the IPO's of MorphoSys in 1999 and of GPC Biotech and Medigene in 2000. Then also the first drug Catumaxomab of the Munich based biotech SME TRION Pharma reaching the market as well as the first blockbuster Blinitumab or Blincyto developed by Micromet and finally marketed by Amgen. Micromet was acquired by Amgen for about USD 1.12 billion and became Amgen Research Munich, also a big story. Overall, I would like to highlight here companies like ibidi, Nanion or NanoTemper, and many others, which develop the tools for doing research in the life sciences, or a diagnostic company like Mikrogen which was founded 33 years ago, which also means it is the oldest biotech company in our cluster, and which has an excellent business performance. A great achievement was also the successful establishment of a Bavarian R&D funding program with a size of more than EUR 50 million for those biotech companies which have committed themselves to develop highly innovative COVID-19 therapies. A further very positive collateral effect of this Bavarian program was that it additionally triggered several funding programs of the BMBF so that eventually more than EUR 400 million from the State of Bavaria and the BMBF have become available for supporting R&D, marketing and distribution of COVID-19 therapies developed in Germany.

What do you see as the success factors of the cluster and of Bio^M?

The most important prerequisite for the successful development of the cluster is certainly the high concentration of excellent science and scientists in the Greater Munich area. The majority of local biotech

companies are spin-offs from the two universities and their hospitals, the biology-oriented Max Planck Institutes and the Helmholtz Center Munich. In addition, there has been a strong entrepreneurial spirit in the scientific community for many years, which has made this abundance of start-ups possible. I would also like to mention the strong support from the Free State of Bavaria that has reached the cluster, mainly through its Ministry of Economic Affairs. And finally, there is the great openness of the vast majority of cluster partners, both from industry and academia, to cooperate and contribute, even if they don't make a direct profit.

It is more difficult to describe Bio^M's success factors. I would say it is its strong commitment to facilitating or improving technology transfer, its ability to identify topics from which the cluster actors can benefit, its ability to raise money to fund research and development projects of the cluster partners, and, last but not least, the fact that Bio^M is not profit-oriented, but only wants to increase the success of the companies. As long as the local biotech industry is successful, Bio^M can also claim to be successful.

What does the 25th anniversary mean to you personally? What balance do you draw?

The 25th anniversary clearly shows me that it's high time for me to leave – although my engagement as CEO or managing director is currently "only" 24 years; in the first year of Bio^M's existence, I worked just as a consultant for Bio^M. I would never have imagined that I would stay with Bio^M for so long.

My balance sheet: It was a huge amount of fun what I had in these past years, however, sometimes the situation has also been critical. The best description is probably the one that I used in my editorial. These 25 years where a most adventurous jungle river cruise, and that is a way of life that I love. I can by no means claim that my work – it was never really work – played an important role in the fantastic development of the cluster, but on a few specific occasions I, together with my team, was able to contribute a little to the cluster's success story.

What do you wish for the biotechnology industry in Germany and Bavaria in the future?

The success it deserves! For the companies that rely on venture capital financing, I would like to see a well-funded venture capital companies that compete with each other for the best deals. I hope to see a change in our tax law system that would make financing in high-tech areas like biotech less risky and thus more attractive. And I wish the companies growth opportunities that they recognise and know how to use them. Unfortunately, one could get the impression that a biotech company categorically needs a billionaire up its sleeve to be successful: I'm afraid we don't have enough of those billionaires, at least not those who might be interested in investing in one or more biotech companies.

Which trends are emerging, and which future topics will occupy the industry in the long term?

A major trend I perceive at the moment is the strong interest of investors in CDMOs. This reflects the strong demand for production facilities which were completely booked out during the pandemic. A further trend is the possible use of nucleic acids, mainly RNAs, to develop them as drug candidates especially for those diseases which could be treated until to date neither with small molecules nor with specifically engineered proteins. The perhaps strongest trend in my perception is the keen interest to get access to real world data and use them for a better design of the development of therapies, including the use of artificial intelligence.

What do you wish for yourself and the Bio^M team in the future?

A dream would come true if a successor is found and hired for me who is an excellent expert in the field – as I was – and who is nice – as I was, I hope – but who in addition has even better innovative ideas than I had on how to not only increase the strength and power of Bio^M, but to take the status of the entire Bio^M Cluster to the next level through stronger growth and even more success stories.

MUNICH'S MAGICAL NUMBER 4

4 Biotech pioneers – m⁴ Personalized Medicine – m⁴ Award – P4 Medicine

There are **4 companies** that can be described as biotech pioneers in the Greater Munich Area: Mikrogen, Mikromet, MorphoSys, and Medigene, all founded between 1989 and 1994.

In 2012 Amgen acquired Micromet for USD 1.2 billion, making Munich Amgen's largest research center outside the USA. The blockbuster Blincyto subsequently reached market maturity.

The other companies from the early days are also still an important part of the Munich Biotech Cluster today and are successful in the fields of personalized T cell-based therapies (Medigene), discovery, development, and delivery of innovative cancer medicines (MorphoSys) and as

provider of system solutions for medical laboratory diagnostics (Mikrogen).

In 2010 the future strategy, "**m⁴ Personalized Medicine and Targeted Therapies**" was among the winners of the BMBF Leading-Edge Cluster Competition. With its focus on personalized medicine, Munich has succeeded in further raising its profile as a leading location for drug development. Lighthouse projects and a total of more than 60 cooperation projects between academic institutions, clinical research and industrial partners have been carried out with great success.

Following the Leading Edge Cluster project, the **m⁴ Award** was launched in 2011

by the Bavarian Ministry of Economic Affairs and is aimed at academic research projects with spin-off potential in the field of biomedicine. A total of 28 research projects with spin-off potential have been awarded in six rounds of competition to date. Nine spin-offs have been realized since then.

In 2018, the project DigiMed Bayern was funded with EUR 22.5 million by the Bavarian Ministry of Health. Its focus is on **P4 Medicine** (Predictive, Preventive, Personalized, Participatory) in the field of Atherosclerosis. DigiMed Bayern collects and analyzes big data from patients diagnosed with atherosclerotic diseases.



YOUR DIAGNOSTICS STUDIES IN GOOD HANDS.

TRIGA-S is a preferred CRO partner for the planning and conduction of analytical and clinical performance studies of in vitro diagnostics according to international regulations (e.g. EU-IVDR, US-CFR).

Since 1998, our name stands for excellency and trustful collaboration.

TRIGA-S SCIENTIFIC SOLUTIONS

Mühlal 5 • D-82392 Habach
Tel. +49 (0) 88 47 - 695 78 0

info@triga-s.de
www.triga-s.de

CONTRACT LABORATORY (BSL2)
STUDY MANAGEMENT · CLINICAL MONITORING
DATA MANAGEMENT · BIOSTATISTICS

COMPLETE SAMPLE MANAGEMENT:
COLLECTION · LOGISTICS · PROCESSING · STORAGE

WE ARE IN THE CENTURY OF BIOLOGY

He is considered the father of German biotechnology: Ernst-Ludwig Winnacker is a professor of biochemistry and has been instrumental in countless discoveries in genetic research. He has left his mark on German genetic research like no other. On establishing the Gene Center Munich, he laid the foundation for the "Biotech Valley" in Martinsried and thus for the most successful German biotech cluster.



© Gene Center Munich

PROF. DR. ERNST-LUDWIG WINNACKER
Professor-Emeritus at the
Ludwig-Maximilians-Universität München (LMU)

Bio^M: In 1984, you founded the Gene Center in Munich, a leading interdisciplinary and internationally visible institute. You are thus considered a pioneer of the successful Munich biotech scene with its university facilities, research institutes and biotech companies. What feeling do you get seeing this center for life sciences, which in a way is also part of your life's work?

Prof. Dr. Winnacker: It's a good feeling of course when I drive here and look around. At the time, in 1984, this was not expected at all. The hospital and the Max Planck Institute were here. Nothing else existed at that point. Even the Gene Center, the building that was being planned and built at that time, was initially supposed to be located in the city center, where the Pinakothek der Moderne is now. Then the state government suddenly decided, especially the then Minister Zehetmair, that it made no sense to place such a tall building in the middle of the city, even if it were close to the LMU and the old chemistry buildings. However, he then promised me that it would be built quickly out here. The fact that so much else has been added here was not apparent at the time. You couldn't really imagine it. We then inaugurated the building in 1994 with a party in a large marquee where the chemical buildings now stand but did not exist back then. It is wonderful of course that it has all turned out so well. Overall, it also fits in with the concept that you need a critical mass in science and interdisciplinarity. That's all here now. It's wonderful.

You have attracted excellent researchers from all over the world to settle near the Isar river. How did you manage to create this unique atmosphere and gather so many top international researchers here at the site?

I was in fact very fortunate to have worked at Berkeley between 1968 and 1970 with Professor Baker as a tutor. He had discovered and worked on vitamin B12 but was also responsible for many appointments in the area, including at Stanford. Every other Saturday we would drive to Stanford to visit his acquaintances: Professor Kornberg or Paul Berg, both of whom subsequently received the Nobel Prize, also for the development of genetic engineering. That's where you were taught what scientific excellence means and, above all, where you

can find it. I kind of internalized that. Then there was the matter of the junior research groups: that was part of the concept, to look for young scientists who could work here independently. I called that early independence – I always went to wherever the people were, including Stanford, and watched how they worked, where they worked, and what the setting was like. Was this really an environment that creates quality and allows scientific independence? Because that was the idea behind this. I tried that and indeed found the first generation of eight scientists in this way.

You were President of the German Research Foundation (DFG) for nine years, and in this role you decisively improved the framework conditions in research. What do you think is needed to sustainably cultivate young talent in research?

First of all, we need the will to give young scientists and researchers the necessary independence. We had and still have the habilitation procedure, which works well in some ways, but in my opinion has become almost a coercive instrument with which older professors restrict younger ones. Later on, I experienced that myself. I also have my habilitation, but my concept was this early autonomy. In other words, people who already had their doctorate for a few years, had postdocs, and were then able to work independently. I am convinced to this day that you can be hugely creative, especially at this age. Not everyone, of course, and there are older people too who are creative. Galileo wrote his famous book about the two systems at the age of 68! It was a miracle in those days to live so long. But in short: early independence. At the DFG, we developed the Emmy-Noether concept, which still exists today. This later became the Starting Grants of the European Research Council, which I also established. You need an environment where scientists can truly work in peace. That's not just early independence, but also critical mass: they must have access to tools that they can use to answer their questions. That's why I always had a mixture of young people, junior scientists and researchers, and older colleagues my age. It created a very pleasant interactive environment.

What prompted you to enter the BioRegio competition with the Munich-Martinsried

site in 1995? What were your reasons for expanding research to encompass innovation, leading you to also introduce the term "Munich innovation culture" at the time?

What lies behind the culture of innovation is that as a scientist you must also be open to applications. Not that someone must necessarily make use of what they are doing. But if projects, which you often don't even know beforehand, lead in certain directions, to projects, the researcher must be able to follow them. So, if you can start a biotech company, you must have the capacity to do it. That was the idea behind participating in this competition. To be fair, I had also learned that in America. After all, it all started back in the seventies with genetic engineering: that's when the first biotech companies were founded. I'm thinking of Genentech and Biogen, which are still around today. And the Biogen people were often the founders here in Munich back then. One colleague, Professor Hofschneider, who unfortunately has since passed away, was even part of their start-up team at that time. In this way, it was quite clear to me that we had to create a framework so that people who wanted to – nobody had to – would have this opportunity. Of course, this requires a lot of effort. And naturally it's mainly about money. Innovation culture also means venture capital, and that didn't exist at the time. But by founding this center, perhaps also by using the term "innovation culture", some of the potential investors woke up, came to me and said: Can you really found companies there?

Does science, in some way, also have a kind of obligation to society, so that through the findings of science, products should be launched for the benefit of society?

Yes, it very much does. I think that if the situation demands or requires it, then as a scientist you must also follow this direction. The BioNTech founders in Mainz are the most recent example. I know them from the time when they were working in a DFG collaborative research center and they were already working with RNA molecules, but at that time their goal was cancer research. That is still their goal today. But then the coronavirus pandemic suddenly started and, fortunately, they

were quick off the mark, and that's great I must say: they put all their resources into the development of a vaccine against the coronavirus. Technically, it's not tremendously different to developing a drug for cancer. Conceptually, however, it's much more complex and much more difficult. But they did it, which is admirable. And that was also the idea back then.

You set new standards in biochemistry and molecular biology, researched the differentiation of cells, the multiplication of genetic material, prions and associated diseases such as BSE, as well as the big world of viruses. What fascinates you so much about viruses?

As a researcher, indeed, you are interested in viruses because they are good model systems for practicing sequencing, for conducting the first genetic engineering experiments. Apart from the fact that they are also pathogens. But you can only fight them if you know what you're talking about and if you know what you're working on. The major achievement or breakthrough with the coronavirus came when someone published this sequence on January 27, 2020. Then everyone, including the BioNTech founders and many others, could draw appropriate conclusions and start working with it.

The fact that we can currently lead an almost normal life again in this country can be attributed to the effective vaccines against the SARS-CoV-2 virus. Despite genetic engineering in biological production, the novel vaccines are welcomed by the majority of the population. Genetic engineering in agriculture, on the other hand, is widely rejected by society. Recently, you called for a change of perspective in genetic policy. How could this be achieved?

To date, it has not been achieved. Medical applications have been accepted from the very beginning. Such as the first time insulin was produced by means of genetic engineering. Suddenly, the difficult conditions under which pancreases from

cattle all over the world were transported frozen to Europe or the U.S. and from which insulin was then isolated, could be eliminated. That was over in one fell swoop and everyone else was able to produce insulin. Hundreds of these proteins are now on the market. Growth factors, monoclonal antibodies etc. This is accepted because it works. In agriculture, a kind of proxy war is being fought with the help of genetic engineering. Agriculture as it is currently practiced is not sustainable. In Europe and in Germany, it's getting better and better. But these huge fields that you see in Brazil and in Ukraine, where the farms have an average size of 4,000 to 5,000 hectares, there is not a single farm in Bavaria of that size. You can no longer pluck the weeds by hand, you need plants that can either somehow cope with them or you need insecticides. The population is against insecticides and herbicides because they are chemicals, even though they have been tested hundreds of times. But in this way, the whole of agriculture is discredited and, with it, genetic engineering, which is supposedly to blame. In Europe, however, there is no genetic engineering in agriculture at all because it is prohibited. Nevertheless, agriculture is not sustainable and attempts are continually made to limit the areas of land and to achieve sustainability. By banning herbicides etc. Why I have hope now is because a new era has dawned. There is a new technology, I call it genetic engineering 2.0, namely CRISPR/Cas technology, which can be used to edit genomes. So, you no longer have to isolate and transfer whole genes, but can change individual building blocks. Two women – Emmanuelle Charpentier and Jennifer Doudna – were awarded the Nobel Prize in Chemistry two years ago for this technology. This technology has enormous potential because, unlike conventional genetic engineering, it no longer involves genes but individual building blocks.

On the occasion of Bio^M's 25th anniversary, what are your hopes for the next 25 years, for the complete biotech industry and for Bio^M?

Bio^M has of course been key to this whole story. Mr. Domdey, at that time a dedicated group leader at the Gene Center and one of the first, if not the first young scientist, set up the center envisaged in the BioRegio application, which we subsequently won, when it was clear in the summer of 1997 that I would be leaving as DFG President. Many of the things we see here, especially all the companies, are of course his babies. Achieving this was a mammoth task. Not only did you have to empower young people who wanted to start companies, but you needed money. Then you needed permission to build here. Then you needed the state government. He somehow convinced everyone that this would work. One big wish would be that this continues in the future. It's fair to say that this is the century of biology. The new CRISPR technology, which has since been further developed, has modified, or is opening up, I would almost have said, endless new possibilities. Not only for basic research, but also for company start-ups. The concept of interdisciplinarity persists. Back then, we had physicians, biologists, chemists, pharmacists, microbiologists, everyone together. That has not changed at all. On the contrary, because of the new instruments that are now available, it is becoming more and more important. But you must maintain that standard of excellence. You must still try to find young people. I'm now going to say something really mean: I don't think you find young people with committees. Not if you appoint ten people and say: this microbiologist is now the best in the world. It sounds very arrogant, but I was lucky at the time that I was allowed to do it on my own. It could have gone wrong; it could have been a disaster if the wrong people had been appointed. But you must observe the field closely and enjoy these things. I can only hope that there will be people like that in the future. Today, the Gene Center is managed very well. I can only hope that there are people who will continue to do that and especially continue so methodically, also here at Bio^M.

You can listen to the full interview from our Bio^M podcast series Biotech Talk aus Bayern in German or read it in English under: www.bio-m.org/Podcast/Interview_Winnacker





Your partner for strategic advice and operational support

End to end expert solutions to support your drug or device development project

Comprehensive experience across various areas, including:

- Advanced therapy medicinal products
- Immuno oncology
- CNS
- Gastroenterology
- Drug-device combinations

Contact us to learn more about how we can advance your project.

KLIFO.COM



KLIFO

An Integrated Drug Development Consultancy

WE NEED A NEW CORPORATE CULTURE – THIS IS THE ONLY WAY TO ATTRACT AND RETAIN THE BEST PEOPLE

As the successful founder of MorphoSys and a pioneer of the Munich Biotech Cluster, Dr. Simon Moroney was involved from the very beginning: Under his leadership, MorphoSys has developed into one of the most important companies in the biopharmaceutical industry with a broad pipeline of drug candidates. In this interview, Dr. Simon Moroney offers us an insight into his role in the success story of MorphoSys, the importance of the Munich cluster, and what he thinks a modern corporate culture should look like.

DR. SIMON MORONEY

Founder and former
CEO of MorphoSys



© Novartis AG

Bio^M: Mr. Moroney, under your leadership, the Munich-based biotech company MorphoSys has evolved into one of the leading companies in the development of therapeutic antibodies. Can you tell us your recipe for success?

Dr. Moroney: Firstly, this certainly includes the technology that we introduced and have used to develop promising drug candidates. Secondly, you can't do this work all by yourself of course. We worked with several partners, pharmaceutical companies, and other biotech companies. A crucial aspect was that we established a great team with which we worked closely and successfully. Not only to establish this technology, but also to commercialize it, was certainly one of the key factors in the success of the company.

You co-founded MorphoSys in 1992 and headed the company until 2019. You are regarded as the longest-serving CEO in the biotech industry and are now considered both a veteran and a pioneer in the industry. How do you see yourself in this story?

That's a good question. I think I've been lucky enough to work with great people. Without those colleagues, I wouldn't be here today, and we wouldn't have had the success we've had. This industry is so complex. What does it take to be successful in a company like this? You can't do something like this alone, of course. It has been a joy and a pleasure for me to work with such great people and build the company and ultimately make it successful.

In 2017, the psoriasis drug Tremfya[®], developed by the U.S. company Johnson and Johnson, was the first product based on MorphoSys's technology to receive regulatory approval. What emotions and memories does this milestone in the history of MorphoSys evoke? What was the journey toward this first approval like?

That was indeed an exciting story. Tremfya[®] is a fantastic product. Last year, sales were over USD 2 billion. That's a very, very big product. It took a long time to develop, as with all drug developments. I think we made the antibody in 2005, if I recall correctly. It took about twelve years from

first creating the antibody to final approval. That's a long way. But I was particularly happy for those who worked towards this goal: the scientists and researchers in the lab. It's common in this industry that many who work with a particular product candidate do not get to see the product reach the market. The chances of success – as we all know – are pretty low. For those who have worked on it, of course, it's been a fantastic experience. I don't know how many thousands of patients have been helped over the years with this product and will be helped in the future. The fact that we played a decisive role in the development of this product makes us proud.

The list of your partnerships reads like a Who's Who of the pharmaceutical industry: Bayer, Novartis, Janssen, Roche, Pfizer, Merck, GSK. Which partners and companions have particularly influenced you on this already long road?

These partnerships were different. We just talked about Tremfya[®], which is a Janssen product. Janssen has benefited directly from it. Our biggest partnership was with Novartis, which we started in 2004. That ran until 2017, so a total of 13 years. We collaborated on a great many projects. That Novartis relationship was particularly important to the company because of its size and the duration. The companies are all different in terms of working methods and style, etc. We worked particularly well with Roche. One product candidate from this collaboration is still in clinical development: an antibody called gantenerumab for Alzheimer's disease. We are expecting phase 3 results at the end of the year. This has always been a very good partnership. Roche is a good example of how these partnerships between big companies and small companies are best managed. But we have benefited from all the partnerships, and I think in most cases the partners have benefited as well.

With 27 years at the helm of the Bavarian biotech company MorphoSys, you personify the origins and the success story of MorphoSys and the biotechnology scene in Munich like no other. Which events do you remember fondly and which less fondly? And which developments have had a decisive influence on the direction of the company?

Yes, that was an interesting time. There were better times and worse times. Maybe we'll start with the worst ones: We went public in 1999. Everything went very well at the beginning. Then, in the early 2000s, times were very difficult – for the stock markets in general. That had a very negative impact on us. The share price went down, which in itself is not a big problem unless you need new, fresh capital. And getting fresh investments was extremely difficult for us at that time. Then, of course, you think: Can the company survive? You can't rule out the possibility of having to close the doors. Of course, that was a very difficult time. But there were also many very good times, especially when you close certain deals with the pharma partners that we've previously discussed, bringing in more security, more chances to develop products together, and you can celebrate these things together. Within the company, those were really great times. And when we re-financed the company through capital increases on the stock market, for example, that generally makes things a little easier for everybody because you think, okay, now the life expectancy of the company is longer. There have been a lot of nice moments like that. Especially the deals that we've done. Any collaboration with a pharmaceutical company, for example, brings some validation for the technology, and of course the company brings money, usually through research grants or upfront payments. Those have been particularly important for us. I mentioned our long-term collaboration with Novartis. That partnership was critical, not only for our funding, but for convincing investors that the company was on the right track. These collaborations and partnerships were probably crucial to our success.

For 25 years, the Munich Biotech Cluster has provided a home to scientists as well as emerging and established entrepreneurs. What makes this cluster and this environment special for you and how do you regard its future? How will it continue?

I am very optimistic, I have to say. The cluster really has an optimal concentration of know-how. You basically have so many companies with amazing ideas, fantastic technologies and product ideas. You have

a certain concentration of academic institutions. Having so much expertise in a small region is highly beneficial. It's easier for employees to change companies. I see that as a positive. Diversity helps. Having so much expertise in a small area makes the region strong. Without question. And that's why I believe we can look to the future with optimism that this cluster will continue to be successful.

You also advise numerous biotech companies on a freelance basis, primarily on financing issues and corporate development. What is your advice to young biotech entrepreneurs?

Indeed, many aspects are critical to the success of small companies. I mean – as I said at the beginning – it's important that the technology is established, works, does what it should do. We briefly talked about corporate culture. I'm convinced that corporate culture is also critical to the success of a company. Especially for companies that are founded by scientists or have a strong scientific base, it's very important to look into the future and ask yourself: what might my product look like when it's ready for the market? How can I commercialize this product or technology? And that may not be until five or seven or ten years from now. You have to look into that future and think carefully about how you're going to position the technology or the product. It's not always that easy for scientists. This is a commercial reality that needs to be planned and considered thoroughly. You just can't focus enough time on that aspect, because at the end of the day it has to work out and it has to work out well. That's very clear. But it's never too early to focus on those commercial aspects: How will this technology be used or how can I sell the technology? Ultimately, the question is: What does the customer need and how can I convince this

customer of my technology? How much profit can I make with my technology or product? These are all very important aspects on which you should spend sufficient time early on in order to position yourself. On the one hand, you need people within the company who are strong on the scientific side, but you also need others who are strong on the marketing side. This is too often forgotten. Unfortunately, the technology will not sell itself.

Through a mandate on the Board of Directors at the pharmaceutical company Novartis, you have been working on a cultural revolution termed "Unboss the Company" since leaving MorphoSys. What is the trend now emerging, which you have already experienced at MorphoSys, or where do you see the advantages of such a trend?

Well, first, to be clear: I'm not working on it myself. I'm on the board of directors in Switzerland. It's a Novartis management initiative to change the culture of the company. That was one reason for me to agree and join the Supervisory Board, because I am absolutely convinced that this culture change is the right thing to do. This is exactly what we pursued at MorphoSys. There is a saying: "culture drives performance". At MorphoSys, we were always convinced of that. We worked hard to establish and pursue the right corporate culture. Now Novartis wants to go in that direction as well. I am personally convinced that this is the right thing to do. We are seeing the first signs of success at Novartis. It will take a while for a company with 100,000 employees. But I am absolutely convinced that they are on the right track and that the companies of the future will have to offer such a culture if they want to attract and retain the best people. And that's why this is the right way to go.

What does that now mean in practical terms? Can you give us one or two examples?

Yes, that old-fashioned culture where there's a boss who says "we do it like this" and there's no discussion, it just has to be done that way. I believe that's a thing of the past. If we want to attract and engage smart people, we must give them the freedom to contribute their ideas and listen to their suggestions. That's the only way to get the best input for a particular project. Young people, especially, expect that. They don't expect to come into a company and just do what they are told. They want to contribute their own ideas, and the company benefits from that.

Have you also considered that it is possible to make a mistake? Keyword: Make your mistake. Can you explain that again? What happens when things don't work out?

If you expect people to bring in new ideas, fresh ideas, then you must give them a certain amount of freedom to pursue those ideas. That can lead to mistakes now and then. If you're not willing to accept those mistakes, it's extremely demotivating. That's why "mistakes are accepted" was part of the credo at MorphoSys. The most important thing, of course, is to learn from mistakes. If you forbid mistakes, then you will not make progress, in my opinion. Then the ideas that can lead to progress and breakthroughs will be lacking.

You can listen to the full interview from our Bio^M podcast series Biotech Talk aus Bayern in German or read it in English under: www.bio-m.org/Podcast/Interview_Moroney





**People living with cancer
don't just inspire us.
They drive us.**

At MorphoSys, we are motivated every day by our mission: *More life for people with cancer.* Learn more at [MorphoSys.com](https://www.morphosys.com).

morphosys

IS ANTIBIOTIC RESISTANCE THE NEXT INSIDIOUS PANDEMIC?

Antibiotic resistance is on the rise worldwide and is one of the greatest global health challenges today, not only in terms of medical progress but also for the economy. What action must be taken immediately and which novel drugs against multidrug-resistant bacteria can stop this insidious pandemic?

DR. HANNELORE MEYER

Group leader at the Institute
of Medical Microbiology,
Immunology and Hygiene at the
Technical University of Munich



© Technical University of Munich

Bio^M: According to a recent study, at least 1.27 million people worldwide died from drug-resistant bacterial infections in 2019. The United Nations has warned that by 2050 multidrug-resistant bacteria could be responsible for killing 10 million people a year. That would exceed the number of deaths from cancer at present. How and why do bacteria develop resistance to antibiotics?

Dr. Meyer: We need to go very, very far back in time: These microorganisms existed long before humans. Each microorganism tries to shape its environment in such a way that it has the best possible conditions. It therefore develops substances to keep other microorganisms out of this environment and thus secure resources for itself. To fight for these resources, the other microorganisms respond by building up resistance. The mechanisms by which microorganisms generally defend themselves against antibiotics can be divided into four major groups: firstly, microorganisms can prevent their cells from absorbing antibiotics. Keyword porins: aqueous channels through which certain antibiotics can be absorbed. If a bacterium has fewer channels or if the channels are altered so that they no longer allow this antibiotic to pass through, it is protected from uptake. Conversely, we also have efflux pumps that do the opposite: these send or pump out anything that has infiltrated a microorganism that might be unwanted. Both mechanisms, uptake and expulsion, regulate the concentration of these antibiotics – potentially to the point where they can no longer function. Other mechanisms exist that are specific to certain antibiotics. The target structure being attacked by the antibiotic could be altered such that it can no longer work. There are also mechanisms that chemically destroy antibiotics in bacteria, also ensuring that they no longer work.

Why is antibiotic resistance such a big problem, and how do you judge its significance compared to the coronavirus pandemic?

The coronavirus pandemic is caused by a pathogen that can change. We are aware of the difficulties. But with resistance, we face a variety of pathogens that are re-

sistant to different antibiotics and cause different infectious diseases. The whole system is much more complex. But more importantly, antibiotics are the basis and the foundation of modern medicine. If we can no longer protect and safeguard patients for treatments with antibiotics, then this clearly compromises our ability to treat other diseases, which of course is the major concern.

Why are multi-resistant bacteria becoming such a global problem and are we acting accordingly? Are we acting globally in this respect?

We have seen with COVID-19 how quickly infectious diseases spread worldwide. It may not be quite as fast, but in principle, the same is true for antibiotic resistance. Furthermore, antibiotics are the “fire extinguishers” of modern medicine. In many clinical interventions, we need to safeguard the patients against bacterial infections. If antibiotic resistance speeds, some treatments will bear a much bigger risk for the patients. We might lose achievements of modern medicine. Globally, we have a much bigger problem: we have huge problems in parts of the world that are not as economically robust and where there is no access whatsoever to appropriate antibiotics. This is a global issue, and Europe is no exception. Here too, we do not have access to all antibiotics. We know that we need to act globally, but solutions are very difficult to find.

What’s the biggest issue? When you say globally, are there regions that are not keeping up?

Yes, it’s always the parts of the world that are already in a rather difficult economic position. It’s in Africa and the Indian sub-continent where we are seeing serious problems with resistance. We see resistance problems in South America, but also in China and Russia. In other words, wherever people are already facing challenges they no longer have ways to get access. We must be clear about one thing: To date, more people have died from a lack of antibiotics than from resistant infections.

What global consequences do you expect?

In addition to the global consequence of people naturally suffering health damage or even dying, we are also faced with the impact on the global economy. Considerations and calculations by the World Bank indicate that an economic loss of up to 5.6 percent can be expected depending on the extent to which resistance has developed and the areas of the world with the corresponding economic power we are looking at. That exceeds the global economic contraction that we experienced in 2008. This will have an impact on people and their quality of life and prove difficult, of course.

Many large pharmaceutical companies have discontinued their antibiotic research programs. Shouldn’t the development of new antibiotics be worthwhile for companies when so many people are falling ill with untreatable infections every year?

Indeed, it should, but antibiotics are a very difficult class of drugs. On the one hand they are traditionally inexpensive, but on the other hand the treatment period is very short. Consequently, the patient – if the antibiotic works – recovers completely. Thirdly, we have the problem of resistance. All three points naturally make it unattractive for the pharmaceutical industry to invest in the development of antibiotics. The investment periods are long: 14 years with costs of up to EUR 1.8 billion. In the end, you don’t get much in return.

The public always likes quick solutions. We have now seen that with COVID-19. Is the development of new antibiotics even feasible over a short period?

Well, quick solutions are very, very difficult because we are dealing with two organisms at the same time: the bacterium that we want to fight and the human being who at the end is supposed to tolerate the treatment. That is more difficult or a different challenge with antibiotics than with viral diseases. But yes, I agree: the pharmaceutical industry should get involved again, and there are early signs that this is the case. There is the AMR Action Fund, which was launched in 2019. The pharmaceutical industry has contributed EUR 1 billion to the development of antibiotics along with its expertise. I am therefore confident that this is going in the right direction.

Would different or novel regulations and reimbursement models be needed to make antibiotic research more attractive to biotechnology and pharmaceutical companies?

Absolutely. We have seen that it is precisely small and medium-sized companies that drive such developments. Once they have successfully launched an antibiotic, it usually only takes a few months before these pharmaceutical companies or small businesses become insolvent because they simply can't make the sales. The problem is that the new antibiotics are reserve antibiotics. We should use them very, very, very sparingly, ideally not at all, and keep them in reserve as a safeguard. A product on which EUR 1.4 to 1.8 billion is spent on development, but ultimately is not used, is of course not economically viable. That's why we need new reimbursement options. This is a topic that is being widely discussed. We need to move away from volume-based reimbursement, i.e., the more I use, the more I earn and the more profit I make, to reflect the value of antibiotics for society and for patients, regardless of how often the antibiotic is used.

With your Frabiotics spin-off project, you are researching small molecules that should enable the treatment of infectious diseases. Can you explain your approach? What makes it special?

We are working on combating so-called WHO1 pathogens. These are the ones for which we urgently need to develop new treatments, because they are particularly difficult to treat. Furthermore, these pathogens have one special feature: they are carbapenem-resistant, which means they are resistant to the most important class of antibiotics we have and the treat-

ment options are therefore extremely limited. Carbapenem resistance is mediated by enzymes that act like scissors. They simply cut open the beta-lactam ring – the core structure of those antibiotics – and subsequently the antibiotic is no longer functional. Frabiotics is developing a stone to match these scissors, so to speak, that will block them. The unique feature of this stone is that it can block two types of scissors, as these enzymes come in two different forms at the same time: nail scissors and hedge clippers. In addition, the molecule has another property: independent antibiotic activity. This dual mode of action, namely protecting the beta-lactams on the one hand and acting as an autonomous antibiotic in its own right on the other, obviously offers huge advantages when it comes to the future development of resistance. As far as we know, this is unique.

You won the m⁴ Award with your Frabiotics team in 2019, which is endowed with a total of EUR 2.5 million. This competition is aimed at academic research groups from Bavaria with spin-off potential. It is coordinated by Bio^M and funded by the Bavarian Ministry of Economic Affairs. How important are such programs and other forms of research funding in your field?

These programs are of utmost importance. The m⁴ Award really helps us to move the project forward and gives us a lot of visibility. The BMBF, the Ministry of Research and the German Center for Infection Research also have funding programs. Without these programs, we could not exist at all, and the development program would already have ended.

What are the most important short- and long-term measures you are calling for to

counteract the increasing development of multidrug-resistant bacteria? What role can preventive measures play in this?

We have a whole portfolio, a potpourri of preventive measures that we all need: It starts with hygiene, from access to clean water and sanitary facilities to hospital hygiene. It's about ensuring that the production of new antibiotics is set up in a way that wastewater containing antibiotic substances is no longer released into the environment where it encourages the development of resistance. There must be a change in veterinary medicine: Three-quarters of the world's antibiotic production is still used for animal breeding, and in agriculture. Here, too, we must rethink and prevent the emergence of resistant bacteria. In other words, take preventive action. Prevention in human medicine with appropriate diagnostics and appropriate antibiotic stewardship programs is another aspect, making the use of antibiotics in human medicine a targeted and truly effective concept. We need a global approach. This is also a means of prevention, so that we do not target resistances in one corner of the world which then lead to problems in another. Lastly, we also need to expand basic research in this area. An initial approach has been made with the Bayresq.net program, for example, which is also strongly supported and accompanied by Bio^M. We must start designing new concepts now and, on this basis, we can develop new therapies in the future. To be clear: The game between antibiotics or antibiotic substances and the corresponding development of resistance, which I described earlier, continues.

You can listen to the full interview from our Bio^M podcast series Biotech Talk aus Bayern in German or read it in English under: www.bio-m.org/Podcast/Interview_Meyer



**Mountain View,
California**
Clinical
Manufacturing,
Development

**4 PC Allendale,
New Jersey**
Clinical
Manufacturing

**75 CD Allendale,
New Jersey**
Clinical and
Commercial
Manufacturing,
Development

**Ottobrunn,
Germany**
Clinical and
Commercial
Manufacturing

**Munich,
Germany**
Development

**Yokohama,
Japan**
Clinical and
Commercial
Manufacturing,
Development



Creating future cell therapy miracles together

- Leading contract development and manufacturing organization (CDMO) for cell and gene therapies
- Experts in manufacturing clinical and commercial cell products
- More than 20 years' experience in all types of cells
- One of the first CDMOs to manufacture a commercial cell therapy
- More than 30 clean rooms across our expanding global sites

RECOGNITION FOR BAVARIAN RESEARCH AGAINST COVID-19

Bavaria's highest award for three Munich scientists

COVID-19 continues to dominate many parts of our lives. However, research into the virus has been instrumental in providing us with safe and effective vaccines, reliable diagnostics and valuable therapeutics, such that we have returned to a certain degree of normality in many respects. For their efforts in the fight against the COVID-19 pandemic, Prof. Ulrike Protzer of Technical University of Munich and Prof. Oliver T. Keppler and Prof. Michael Hoelscher of Ludwig-Maximilians-Universität München were awarded the Bavarian Order of Merit by Bavarian Minister-President Dr. Markus Söder.

In honorable and grateful recognition of their outstanding services to the Free State of Bavaria and the Bavarian people, these three life scientists received the Free State's highest honor.

Virologist **Prof. Ulrike Protzer** from Technical University of Munich (TUM) has dedicated herself tirelessly to SARS-CoV-2 research and elucidation over the past two years. In his speech at the award ceremony held at the Antiquarium of the Munich Residence, Bavarian Minister-President **Dr. Markus Söder** named her as one of 50 "courage makers". Since 2007, Prof. Ulrike Protzer has been Chair of Virology at TUM and Director of the Institute of Virology at TUM and Helmholtz Munich. "I am very proud to have received this high honor! I see it as recognition for my team and their tireless efforts in COVID-19 diagnostics and combating the pandemic, and I am very, very grateful to have such highly motivated staff", said Prof. Protzer following the award ceremony.

Prof. Oliver T. Keppler, virologist and director at the Max von Pettenkofer Institute for Hygiene and Medical Microbiology (LMU), has helped fight against the spread of the disease

since the beginning of the coronavirus pandemic as a fellow campaigner, including as an advisor to the Bavarian state government, Söder said in his laudation. "To support the Free State and the people of Bavaria in the coronavirus pandemic and to be awarded the Bavarian Order of Merit for this by the Bavarian Minister-President is a great honor. I am not only grateful and delighted, but also regard it as an incentive and feel a sense of responsibility to continue on this path", Prof. Keppler stated on accepting the award.

Prof. Michael Hoelscher, a tropical medicine specialist and Director of the Department of Infectious Diseases and Tropical Medicine at the University Hospital of Munich (LMU), was awarded for his dedication to improving health care in Africa during the coronavirus pandemic. In addition, he has shared his expertise as a member of the Bavarian State Government's Council of Experts since the beginning of the coronavirus pandemic and has made an important contribution to combating the pandemic.

His institute was the first in Germany to diagnose a patient with the SARS-CoV-2 virus in 2020.

The Bavarian Minister-President views the award as a signal in difficult times, when motivation and hope are needed. He said that all those who received the Order of Merit stood for a modern, sustainable, charitable, and highly scientific Bavarian state.

The **Bavarian Order of Merit** in the form of a Maltese Cross is the Free State's highest honor and is awarded each year to selected individuals from the fields of sports, science, and culture. A total of only two thousand living recipients may hold this award at any one time.



Prof. Michael Hoelscher

Prof. Ulrike Protzer

Prof. Oliver T. Keppler (left) with Bavarian Minister President Dr. Markus Söder

© Bayerische Staatskanzlei

YOUR CRO: FLEXIBLE EXPERTS AND RELIABLE SOLUTIONS

- ▶ Full-service European CRO
- ▶ Highest quality standards
- ▶ 190+ in-house experts



FGK
CLINICAL RESEARCH

fgk-cro.com

YOUR PREMIUM EUROPEAN REPRESENTATIVE

- ▶ EU legal representative for non-EU sponsors
- ▶ Sponsor representation in Switzerland and UK
- ▶ Represents non-EU companies in the EU for:
MAAs, ODDs and SME status



FGK
REPRESENTATIVE SERVICE

fgk-rs.com

YOUR SAFETY – OUR MISSION

- ▶ Full range of pharmacovigilance services
- ▶ Provision of QPPV and PMSF management
- ▶ Literature search, signal detection, PSUR, PBRER



FGK
PHARMACOVIGILANCE

fgk-pv.com

Owned and managed by:

Dipl.-Stat. Martin Krauss
+49 89 893 119-25
martin.krauss@fgk-cro.com

Dr. med. Edgar J. Fenzl
+49 89 893 119-22
edgar.fenzl@fgk-cro.com

Delivering reliability

FGK GROUP

Heimeranstrasse 35 · 80339 Munich · Germany

I EXPECT THE BEGINNING OF A GOLDEN AGE OF BIOTECHNOLOGY

Vital vaccines, highly effective chemotherapeutics, and drugs for the treatment of genetic diseases must be tested thoroughly for their effects, shelf life, and suitability for transportation and storage. NanoTemper Technologies manufactures biophysical laboratory instruments using a globally patented optical measurement method to determine the properties of tiny molecules. Dr. Philipp Baaske, CEO and co-founder of the company, explains how this works and how NanoTemper came to be Innovator of the Year for the third time.

DR. PHILIPP BAASKE
CEO and co-founder of
NanoTemper Technologies



Bio^M: Dr. Baaske, NanoTemper Technologies offers biophysical laboratory equipment for basic research and drug development. Can you explain the technology you have developed and the special features of your portfolio in a little more detail?

Dr. Baaske: Everyone knows the drug aspirin. Imagine aspirin: it's considered a small molecule and has the complexity of a bicycle. Then there are antibodies, which are somewhat more complex. Everybody is now familiar with them from the rapid antibody tests for SARS-CoV-2. If you compare an antibody with aspirin, as a bicycle, then the antibody is a private jet in terms of complexity. Then there are these new vaccines, the mRNA vaccines, which have the complexity of a rocket, meaning they are insanely complex. At the same time, they are quite sensitive, and I now have to somehow understand whether they work and whether they are stable. The problem is that I can't touch them. When I touch them, they break. I may only look at them, i.e. at most shoot a photon at them. That doesn't break them, and that's why we use optical measurement technology.

And that's exactly what we do: We look at these molecules, obtain very complex signals, evaluate them, and then conclude: this is a good vaccine, it works where it's supposed to, and it can withstand a temperature of 60°C. This is exactly what we can read out with a wide variety of measurement methods – we have a whole portfolio of measurement methods. The substances are not usually dangerous. But porcelain is quite robust compared to a vaccine, especially when it's in development. It is important that a vaccine has a targeted effect. Then I must modify and enhance it accordingly. However, this can make it less stable and cause it to break at lower temperatures. But with our measurement methods, we can measure both and straddle this fine line. Then we can further develop the vaccine in the desired direction, and at the same time it remains stable enough to be delivered to Africa.

You founded your company in 2008 with fellow student Dr. Stefan Duhr as a spin-off from Ludwig-Maximilians-Universität in Munich. What was your vision for the company back then, and has it come to fulfillment?

Well, we had no idea back then. We took part in business plan competitions, so we had to write a business plan. And we were good at copying. Of course, you write the business plan to win the business plan competition. It needn't have anything to do with reality. We certainly had no idea about business. We just realized we had some cool technology at our disposal and a chance to make something out of it. We simply took the opportunity, and I think that's what entrepreneurs are all about – after all, the term “entrepreneur” already implies that someone is doing something. An opportunity came up and we just went with our gut: This is what we're going to do. We slept on it for one night, and still thought it was a good idea the next morning. Then we just did it.

Coming from university, entrepreneurship was something new for you of course.

I'm not so sure about that. I realized when studying for my doctorate at university that I'm not a scientist. I've probably always been an entrepreneur; my grandfather was a farmer. I learned a lot about what self-employment means. I thought it was good not to have a boss, to have the freedom to always do what you want. Not to complain either. I mean, if the weather is bad, you have to live with it, you can't complain. And I thought that was cool, just doing my own thing.

Your customers now include global players in the pharmaceutical industry, innovative biotech companies and renowned research institutions. You've written this success story without major investor involvement. You have to wonder: How does that work?

We founded the company in the middle of the financial crisis in 2008. We tried to attract financial investors and obtain venture capital, which of course is risk capital. We were too risky for them, perhaps because we couldn't explain what we were doing either. Our only chance was to get money from the customer. That's why we traveled a lot, talked to a lot of people, tried a lot of things, tried to sell something about 30 times, which never worked, but the 31st person finally made a purchase. It was very much like ... how would you

say, “trial and error”. We tried a lot, never gave up, always believed in ourselves, and then got money from the customer. With the money we made from the product, we could then do what we wanted. That was a very comfortable situation. At the same time money is a good source of information: Everyone in science appreciates new technologies until you want money for them. And when you ask for money, you first get some information in return: No, I won't buy it. I think the product is cool, but without this feature, I won't buy it. So, you develop exactly that feature and finally get money. Then you consider whether more customers have the same demands and finally you understand the market. But this need to earn money, this immediate going out and selling, was, I believe, an important step: away from science towards being an entrepreneur.

What have been the biggest challenges for you since founding the company?

Initially we did a lot of things together or alone. Then the challenges were to have confidence in others, to be able to hand things over and then grow from two employees to 210. That required a lot of personal and professional development. We had to constantly adapt. At the start it was just the two of us, then we had ten people in one room, then 40, then 100 people with offices in San Francisco and Beijing. And suddenly you have to alter the way you communicate. You no longer know everybody so well. There are friction losses, information is lost, and you must keep changing your management style without losing yourself. It's important to remain authentic, but to keep adapting. At the same time, it's exciting.

I just wandered along the corridors when I arrived. The company occupies two floors. Everyone immediately asks if they can help. Such an environment needs to be fostered to create a certain group dynamic. Do you do anything special to create the right working atmosphere?

Stefan Duhr is my co-founder and co-managing director and that is exactly how we are. We are helpful, we both like people, we are authentic, and we radiate that. There is, after all, the apt expression: “To lead by example”. That is exactly what we exemplify

as founders and managing directors. It radiates. And if we are authentic, this example is taken up and adopted by our employees. It's not always peace, joy, and happiness. A lot of innovation also comes from friction. But this warmth and above all respect for people is very important to us. We live it.

In 2021, NanoTemper was named Innovator of the Year in its size class for the third time. How do you thrive that as an innovative company? We have already briefly mentioned some things.

It is very important that employees feel at ease, that they know they are trusted. Innovation is always something new. When I try something new, there are no mistakes, I'm just learning. And I simply have to trust myself to try something new, even if 90% of it is likely to go wrong. I need a leap of faith, someone who believes I can do it – even if a lot of things can go wrong. We create space for this, so that people can live out their own projects and their own creativity is encouraged. This inquisitiveness, the urge to try new things, to look closely and to learn is very important to us.

How do you keep your finger on the pulse when developing your devices? How do you respond to the needs of your customers? Is there much room for maneuver?

You have a lot of leeway, and it is important to visit and listen to the customer and question what they want and what they need. The two things are not necessarily the same. What they want may be different to what they really need, and you should have a lot of patience. A lot of patience is needed for rapid innovations, which may be contradictory, but it's about really listening a lot, sometimes for years, collecting market feedback, questioning it again and again, and comparing it with your own ideas.

Since last year, you have been working with PharmAI, a Dresden-based start-up that specializes in virtual screening software.

What role will AI, or artificial intelligence, play in the future of drug discovery and what other trends are you seeing?

Well, AI is a tool. You have to accept that it's not a panacea for everything. It's a good tool. There was kind of a singular moment recently, it's referred to as a singularity, through the Alpha Fold of Google DeepMind, where they were able to predict structures of proteins using AI-based software. We have also developed a tool with PharmAI where you can use this to predict certain things that make everyday laboratory work easier: for example, where to place a label on a protein without interfering it. We'll go a long way once we start treating AI as a tool. It will now make many things more quantifiable, more predictable with standards that are then also scalable. Biotech will become mature, productive, and very ethical. It will be possible to program life, which will also have to be looked at early on from an ethical viewpoint. I expect that a golden age of biotechnology is dawning, because many things will become more quantifiable and predictable. And we will very often find, probably in the next 20 years, that things previously considered incurable will suddenly become curable because we understand them much better.

What are your plans for the next 5 to 10 years, if we take this period? You've set yourself the goal of becoming the world market leader in biophysical measurement technology for drug discovery by 2030. Big goals ...

Yes, it will probably happen even faster because we've reached the sweet spots right now. We are already in possession of the optical measurement technologies which larger companies are now also trying to buy up. But that's an economic target we have set. The impact we have is much more important. Many scientists use our methods, and we have already achieved the following with our method: in cancer

research, there is a molecule called K-Ras that is responsible for 20% of all cancer cases. In the U.S.A. alone, there are 100,000 new cases per year that have been "undruggable", unresponsive to drugs. Our measurement method has now made it possible to target this K-Ras molecule, which is referred to as the beating heart of cancer. What also motivates us is the huge impact we have with our measurement methods, which are used by thousands of scientists. We believe 20,000 scientists are now using our instruments. My mother had breast cancer and was also saved by a biotech drug, Herceptin. We help to ensure that a drug like this can even be developed or, in some cases, can reach the market three months earlier, saving thousands of lives. And that's a huge impact. That's what motivates us, when we see that we are making a positive contribution and we can measure it in terms of sales. We know that if we have this much revenue, we sell this many devices, and if we have this many devices on the market, then we have a corresponding impact. We manage our employees with great trust and give them a lot of freedom. When other companies see that we are successful with our management style, we assume that we will be copied. And as a result, we have a huge impact on society in the way we run the company.

You can listen to the full interview from our Bio^M podcast series Biotech Talk aus Bayern in German or read it in English under: www.bio-m.org/Podcast/Interview_Baaske



Die drei Gründerzentren in Würzburg



Life Science



Robotik/
Automatisierung




Digitale
Geschäftsmodelle

Hier entstehen aus Ideen erfolgreiche Unternehmen

www.gruenderzentren-wuerzburg.de



20 Jahre Erfahrung in Innovation



FOSTERING SPIN-OFFS IN BAVARIA

m⁴ Award winners on track for success

2021 was once again dedicated to start-ups. Both the m⁴ Award and the BioEntrepreneurship Summit 2021 provided a stage for young founders, start-ups, and spin-offs in the fields of life science, biotech, and health tech. With its m⁴ Award, initiated by Bio^M in 2011, the Free State of Bavaria promotes the creation of academic spin-offs that decisively advance the development of future medicines. The prize is awarded every two years. In the previous five rounds of the competition, a total of 23 research projects received funding and ten spin-offs have since been established. The recent prizes, grants and financing received by the m⁴ Awardees demonstrate that the pre-seed competition is a game changer for successful start-up companies, with many former winners enjoying further success.

Antibody-drug conjugates (ADCs) against cancer: EUR 60 million Series B funding for Tubulis

Only recently, winner of the 2017 m⁴ Award pre-seed competition Tubulis successfully closed a Series B round of financing worth EUR 60 million. The Munich-based biotech start-up headed by CEO Dr. Dominik Schumacher and CSO Dr. Jonas Helma-Smets plans to use the funding to accelerate its pipeline of antibody-drug conjugates (ADCs) toward clinical trials and expand its platform technology offering for the treatment of cancer. The financing is led by Andera Partners, with participation from new investors Evotec and Fund+ in addition to existing investors. Tubulis is a spin-off from Ludwig-Maximilians-Universität (LMU) München and Leibniz Research

Institute for Molecular Pharmacology (FMP) Berlin and aims to develop less invasive and more efficient cancer treatments. Tubulis already secured Series A financing worth EUR 10.7 million in July 2020.

Fighting drug-resistant pathogens: INCATE funding for Invitris and Smartbax

Infectious bacterial diseases caused by multidrug-resistant germs such as multidrug-resistant *Staphylococcus aureus* (MRSA) pose one of the greatest threats to public health. More than one million people die each year from illnesses caused by drug-resistant pathogens. Hence, new approaches to combating resistant bacteria are urgently needed. INCATE (INCubator for Antibacterial Therapies in Europe) is an initiative that supports innovative



© BioM / Claude Alberth

The five winning teams of the m⁴ Award 2021 with Prof. Dr. Horst Domdey (Managing Director Bio^M; 6th from right) and Dr. Manfred Wolter (Head of Department of the Bavarian Ministry of Economic Affairs; 7th from right)

early-stage companies in the fight against drug-resistant bacterial infections. Munich start-ups Invitris and Smartbax (formerly aBACTER) have been selected to receive funding and advice within the framework of INCATE in support of their work to develop novel antibiotic therapies. Up to EUR 10,000 in funding is available to each venture.

The 2021 m⁴ Awardee **Invitris** also recently impressed investors at the renowned **business plan competition of Rice University**, securing investment prizes worth USD 90,000. In the same year, moreover, the EXIST-supported company came first in phase II of the Munich business plan competition and was listed as one of the **Top 50 start-ups** in Germany. The founders of the start-up project from the Technical University of Munich, Dr. Kilian Vogele and Dr. Patrick Großmann, have developed cell-free production technology which, for the very first time, can be used to produce multivalent, genetically optimized bacteriophages for the treatment of antibiotic-resistant infections in vitro.

Smartbax, founded in April 2021, is a spin-off of the Technical University of Munich. The project team headed by Prof. Dr. Stephan Sieber has discovered a new antibiotic that is very effective against gram-positive, multi-resistant bacterial strains and does not appear to develop resistance. The new mechanism of action differs fundamentally from that of all previously approved antibiotics. The primary goal of the start-up is to develop a new antibiotic against endocarditis, an inflammation of the inner lining of the heart that is currently very difficult to treat. The project received the m⁴ Award in 2019.

Multifunctional antibodies to fight cancer: OpSYon winner of phase III of Münchener Businessplan Wettbewerb 2021

The winner of phase III of the **BayStartUP Münchener Businessplan Wettbewerb** of 2021 was OpSYon. OpSYon is a pre-seed project that aims to improve the efficacy and tolerability of cancer therapies and is developing innovative multifunctional antibodies with reduced side effects.

These antibodies target cancer cells as well as immune checkpoints and use the entire spectrum of the immune system to specifically and permanently eliminate cancer cells. With these novel therapies, OpSYon offers patients with acute myeloid leukemia or pancreatic cancer, among others, the possibility of longer survival with a high quality of life.

Headed by Dr. Nadja Fenn, Prof. Karl-Peter Hopfner and Prof. Marion Subklewe from Ludwig-Maximilians-Universität München, OpSYon won the Bavarian m⁴ Award in 2015 and the Jury Award for Emerging Start-ups at BioVaria 2018.

Big data for personalized therapies: Women TechEU grant for Knowing01

Knowing01, a spin-off from the Institute of Computational Biology at Helmholtz Munich and m⁴ Awardee of 2015, also has reason to celebrate. Founded in early 2020 and headed by Dr. Nikola Müller, this start-up has developed big data processing software which can be used to identify biomarkers and drug targets for personalized therapies. In March 2022, they received a **Women TechEU** grant from the funding program of the European Commission which supports deep-tech start-ups led by women. Only 15 percent of innovative start-ups are in fact founded or co-founded by women and only six percent have exclusively female founding teams. Women TechEU aims to close this gender gap in innovation by providing financial support with grants of EUR 75,000 each along with coaching and mentoring through the EIC Women Leadership Programme.

Targeting beta-cell protection and regeneration for diabetes remission: ERC Grant for BetaRegeneration

Prof. Heiko Lickert from Helmholtz Munich, winner of last year's pre-seed competition m⁴ Award, has been awarded the prestigious **ERC Advanced Grant**. Lickert aims to advance new therapies against diabetes with the **Beta-Regeneration** project. He and his team are developing a monoclonal antibody against an insulin inhibitory receptor that has a protective effect on the beta cells of

the pancreas. This novel approach could facilitate the first ever causative therapy for diabetes. Diabetes mellitus is a metabolic disease that currently affects more than 8.5 million people in Germany. This widespread disease is characterized by the loss or malfunction of insulin-producing beta cells in the pancreas. There is no cure, and the disease can so far only be treated symptomatically.

Tumor therapy using oncolytic viruses: FUSIX Biotech among winners of the Rising Star Award and the first phase of Münchener Businessplan Wettbewerb

2019 m⁴ Awardee **FUSIX Biotech** came second in the **Rising Star Award** pitch competition at the BioEntrepreneurship Summit 2021. This life science start-up impressed the audience with its technology solution and was also voted one of the phase 1 winners of the **BayStartUP Münchener Businessplan Wettbewerb 2022**. FUSIX Biotech has developed novel proprietary hybrid virus technology, using oncolytic viruses for cancer therapy. Based on cell-cell fusion reactions, both the infection of healthy cells and the release of new virus particles from infected cells into the surrounding tissue are reduced, resulting in a special safety profile. With the aid of this funding, the team hopes to commence the preclinical development of its lead product. These exceptional properties have already resulted in preclinical success.

Targeted inhibition of autoimmune reactions by AutoImmunity Modifying Biologicals: AIM Biologicals wins German Innovation Award of the Bioregions

2017 m⁴ Awardee **AIM Biologicals** won the **German Innovation Award of the Bioregions** at the Deutsche Biotechnologietage 2022. As a member of the working group under Prof. Wischhusen at the University Hospital Würzburg, Dr. Valentin Bruttel has discovered a novel mechanism which facilitates the targeted and effective suppression of individual immune reactions that arise from autoimmune diseases. On this basis, AIM Biologicals developed its platform technology, which has been adapted and thoroughly tested with the help of the

m⁴ Award funding for neuroinflammatory autoimmune diseases such as multiple sclerosis (MS) and neuromyelitis optica (NMO). Bruttel and his colleagues have set themselves the goal of developing drugs which are easy to administer but nevertheless stop harmful autoimmune reactions in a highly targeted manner and with few side effects.

Development of a nanoswitch for antibodies: Logibody funded by Else Kröner Fresenius Stiftung

Recent success is testament to the innovative strength of another start-up project: Having won the m⁴ Award in 2019, **Logibody** (formerly Plectonic), supported by EXIST and GO-Bio Initial is funded by the **Else Kröner Fresenius Stiftung**. The team and its mentor, Prof. Dietz, have developed an “on/off button” for antibody immunotherapies: the LOGIc-gated anti-BODY (Logibody), an ultra-miniaturized nanoswitch for antibodies made of DNA. The nanoswitch can specifically recognize tumor cells and fight them by recruiting the body’s own immune cells. This enables the immune system to fight tumor cells specifically and “on demand”, leading to lower activity on healthy tissue and thus fewer side effects from the over-stimulated immune system.

First-in-class therapies for endocrine disorders: Procera Pharmaceuticals funded by VIP+

Fighting obesity is the aim of **Procera Pharma**, a spin-off of the Max Planck Institute of Psychiatry in Munich and m⁴ Awardee in 2011 and 2015. The venture has received further funding through the VIP+ program of the BMBF with a view to validating its research results systematically and opening up areas of application under the Fit4Fat validation project. Obesity is a serious disease with numerous sequelae that affect 175 million people. Current drug therapy options result in only modest weight loss and often have severe side effects. Dr. Felix Hausch and colleagues are investigating a new class of drugs called selective FKBP51 inhibitors which can be taken orally and act locally in muscle and fat tissue. Since they do not reach the brain, no serious side effects are expected. The project will advance a preclinical development candidate for obesity-related diabetes in the form of orally available FKBP51-selective, non-brain inhibitors.

m⁴ Award as successful catalyzer for academic spin-offs

Many of the other spin-off projects and start-ups that previously won the m⁴ Award

have impressed with their business concepts in recent years and achieved further success. Worth mentioning here is **Cherry Biolabs**, which signed a licensing agreement with MorphoSys in 2020 for their hemibody technology with which novel T-cell-engaging medicines can be developed for cancer treatment, and **RQScue**, which is dedicated to researching new active substances against degenerative diseases such as Alzheimer’s or Parkinson’s.

Together with the Medical Valley Award (launched in 2016), the m⁴ Award pre-seed grant program run by the state of Bavaria since 2011 has become a highly successful catalyzer for academic spin-offs in the life sciences sector. The m⁴ Award is a key element of Bio^M’s unique offering for founders in medical biotechnology and health technology with its inQlab virtual incubator.

“The m⁴ Award is a great success story and a unique selling proposition for Bavaria when it comes to bringing academic projects to the point where they can be founded”, said Christina Enke-Stolle, Bio^M. “It’s an incredible pleasure to support the teams and it’s fantastic to see how the projects are progressing”, Dr. Petra Burgstaller of Bio^M added. Both jointly head inQlab at Bio^M.



CHRISTINA ENKE-STOLLE

Head of inQlab Bio^M

“Successful technology transfer from the academic environment and the continued emergence of viable start-ups are critical to our ecosystem. As we all know, biotech ventures are capital-intensive, complex, and risky. Bio^M has supported start-ups from the very beginning. With its financing activities, Bio^M has provided critical seed funding (from 1997-2014) and thereby attracted substantial private investment to the emerging biotech cluster. The m⁴ Award has helped to de-risk academic projects with spin-off potential since 2011. Our inQlab virtual incubator, moreover, aims to support founders in navigating the complex environment by introducing them to the appropriate network of mentors, experts, investors and other founders, and specialized training. We hope we can extend this unique offer by providing a unique brick-and-mortar infrastructure in the near future.”



Dr. PETRA BURGSTALLER

Head of inQlab Bio^M

Bio^M inQlab

we guide you from idea to success

virtual incubator for the future of medicine



Startup Coaching

get hands-on support



Mentor Circle

inspired by experience



Pitch Doctor

how to convince investors



BioEntrepreneur Bootcamp

validate your business idea



BioEntrepreneur Lounge

join the community



BioAngels

find the right investor



m⁴ Award

create the future of medicine



BioEntrepreneurship Summit

connecting the ecosystem



DIGIMED BAYERN

Medicine of the future – promising developments

Digitization is the most innovation-driven disruptive transformation of the 21st century and has already infiltrated the global life sciences and healthcare sector. Innovations such as health and fitness apps, connected point-of-care diagnostics and wearables, real-world-data-trained algorithms and AI-powered clinical decision support are just some of the game-changing developments in this field. Besides technological improvements, access to and integration of a large amount of health data ("Big Data") and analytical technological progress enable better disease prevention, diagnosis and treatment, as well as overall healthcare management.

The Bavarian lighthouse project DigiMed Bayern aims at incorporating the holistic concept of P4 medicine (predictive, preventive, personalized, participatory) into medical practice to improve effectiveness and efficiency of healthcare. Running from late 2018 to late 2024, the project is funded by the Bavarian State Ministry of Health and Care with a total volume of almost EUR 25 million. DigiMed Bayern focuses on the field of cardiovascular diseases, the most common cause of death worldwide. To achieve health improvements, world-leading university hospitals collaborate with research institutes in the fields of epidemiology, biology, biochemistry, omics technologies and data sciences. Beyond the clinical and scientific focus, data protection and legal questions, medical ethics and sociological topics are related areas which are fundamental to the project. An ambitious and visionary goal is the creation of a compliant and secure IT cloud infrastructure to support the collaborative health-related research and development. The greater vision is to trigger real-life improvements in personalized disease identification and risk prediction, prevention, management, and treatment for patients and individuals at risk. Hence, DigiMed Bayern will also contribute knowhow, blueprints, and infrastructure to other institutions and disease areas.

HerzFit app launched – a personalized prevention coach on your smartphone

In Bavaria alone, there were approx. 50,000 deaths from cardiovascular diseases in 2020, 6,500 of which were due to a heart attack. Preventive lifestyle adaptations could reduce these numbers by up to 80%. DigiMed Bayern initiated and contributed scientifically to the development of the HerzFit app. HerzFit was engineered by the patient organizations German Heart Foundation and German Hypertension League together with the Technical University of Munich and was supported by the largest German health insurer, Techniker Krankenkasse. HerzFit is a digital companion for people who already have heart disease and people who wish to take care of their heart health by means of primary and secondary prevention. The app was launched in April 2022 and is available to anyone in the respective app stores.


HerzFit enables an assessment of the individual long-term risk of heart attack

and stroke and supports risk reduction. Relevant factors such as blood pressure, heart rate, LDL cholesterol, body weight, and long-term blood glucose can be easily integrated and monitored. Users can define their personal health goals in terms of nutrition, stress management, physical exercise or quitting smoking and pursue them with appropriate guidance. The app offers professional advice and education through a library of articles, videos, and podcasts on the subject of heart health. All the information and guidance have been carefully reviewed by independent cardiologists and other experts in the field.

Dr. med. Fabian Starnecker from the German Heart Centre Munich and the scientific lead of the HerzFit app is pleased that the application is available to everyone free of charge: "Many cardiovascular diseases can be prevented by a healthy lifestyle. The HerzFit app encourages a heart-healthy life and helps people to keep an eye on their own health. HerzFit now brings cardiovascular prevention into the everyday lives of its users for free."



© Designed by rawpixel.com / Freepik



Vroni study – saving lives starts with a drop of blood

Familial hypercholesterolemia (FH) is the most commonly occurring monogenic disorder (prevalence 1:250) in the general population, accounting for approximately 270,000 individuals in Germany. Untreated, this congenital lipid metabolism disorder increases the risk of heart attack and stroke by a factor of 5 to 20 and, tragically, will often lead to an early death even in those under 40 years of age. In Germany, FH is alarmingly underdiagnosed; less than 1% of the individuals affected are aware of it. Early diagnosis during childhood enables pre-emptive treatment and lifestyle adaptations, reducing the risk of subsequent severe atherosclerotic manifestations almost to that of unaffected individuals.

A population-wide FH screening program has been designed and introduced in Bavaria for up to 50,000 children aged 5 to 14 years within the framework of the Vroni study. Firstly, a small drop of blood is analyzed for extraordinarily high LDL cholesterol levels. In such cases, a detailed genetic analysis is conducted. Participation in the Bavaria-wide program is free of charge and can take place as part of regular health checkups or during any other visit to the pediatrician. In the future, the Vroni study shall be used as a blueprint for effective and efficient implementation of early FH diagnosis and treatment in Germany as part of routine health care.

Currently, 412 pediatricians from across Bavaria are participating in the Vroni study. The interim results published at the end of April 2022 reveal that a surprisingly high proportion of the 8,100 children tested so far, namely 76, were found to have inherited FH. Young patients can take part in a special education and treatment program aimed at reaching normal life expectancy. This is accompanied by "cascade screening" which enables the parent and other relatives carrying the mutation to be identified and treated. Statistically, up to three relatives can be identified. In addition,



DR. JENS WIEHLER

Managing Director DigiMed Bayern Bio^M

The health system of the future and personalized medicine will be data driven. For other areas like automotive the digital revolution is taken for granted and pushed by all players. Regarding the relevance of our well-being, the insight that health data of us all need to be collected and be made available to large extend astonishingly is still largely ignored by society and by many actors in the health system. Ignorance will be paid with disease, dependency, and economic weakness. In contrast, courageous progress will be rewarded with more public health with less societal burden and with economic strength.

causal research is conducted and medical follow-up offered for the much higher number of non-carrier children with high LDL cholesterol.

Prof. Dr. med. Heribert Schunkert, Medical Director of the German Heart Centre Munich and Director of the Department of Cardiovascular Diseases, commented: "We are very happy that the Vroni study has enabled us to effectively identify FH, the hereditary cholesterol metabolism disorder. In nearly 1% of the children screened in Bavaria, the screening program revealed congenital gene mutations that are associated with a high risk of heart attacks at a young age".

Study coordinator **Dr. med. Veronika Sanin** added: "Early diagnosis enables preventive treatment. Thanks to a personalized treatment and education program, the children have a normal life expectancy, and their families are also spared a lot of heartache".

More achievements – omics, biomarkers, cohorts, IT infrastructure

DigiMed Bayern has achieved further impressive milestones. Identification of Bio-Marker candidates for early diagnosis and

treatment of cardiovascular diseases has been facilitated by progressive multi-omics analyses of a high number of patient samples. Health data have been made available and a secure and performant pilot IT infrastructure has been built at the Leibniz Supercomputing Centre. Basic data protection issues have been solved and ethical aspects addressed. The existing world-leading biosample repositories were recently complemented by a new, ground-breaking pathological "post-mortem" cohort. This will give access to a large variety of atherosclerosis-relevant tissue samples within single individuals (intra-personal), where previously only cohorts of different patients could be compared with each other (inter-personal). By April 2022, DigiMed Bayern had delivered more than 30 peer-reviewed scientific publications under its funding and will continue to contribute to improving health.

Stay tuned: Visit <https://www.digimed-bayern.de/en/> for further information and follow us on twitter @DigiMedBayern for news and events!



IT TAKES TIME TO DO BUSINESS WITH JAPAN RIGHT!

Since its launch 25 years ago, Bio^M has always maintained good, albeit initially rather sporadic contacts with pharma, science, and government in Japan, keeping up to date with developments and connecting Japanese pharma and Bavarian biotech. In a strategy workshop on internationalization priorities held shortly after the successful creation of the Munich m⁴ – Personalized Drugs and Targeted Therapies cluster in 2010, Bio^M and a number of Bavarian SME representatives resolved to intensify and widen the Japan connection. Since then, it has taken many years of building up trustful relationships with Japanese health regions, experts, and decision makers for the benefit of Bavarian SMEs in R&D partnerships and to facilitate market entry & success.

In this process, it was important to not only work alone, but to join forces with other European clusters and with Bavarian, German, European and Japanese business development organizations. By sharing contacts and best practices with “competitors” in other European regions, Bio^M was able to significantly increase the critical mass and subsequently achieve visibility and recognition among key Japanese contacts. Bio^M also utilized various German and European funding opportunities to expand its Japan-focused development activities.

Today, Bio^M can foster the internationalization processes of SMEs toward Japan by offering valuable contacts, entry points and expertise. Conversely, Bio^M acts as the first point of contact in Bavaria for incoming Japanese business, connecting interested parties with potential partners. The cluster management is proud to have established a “Gateway to Japan”, which is carefully maintained and kept open for Bavarian SMEs. It has been a long but successful journey.

DIETER LINGELBACH COO SIRION Biotech

“The Japanese market remains a top priority for many Bavarian life science companies, despite the competition from emerging markets and the still very high entry barriers.”



© SIRION Biotech



© Bayern International

The Bavarian booth at BioJapan

ACHIEVEMENTS

Bio^M's Japan connection in brief:

- 2 partnership agreements (Osaka, Kawasaki)
- Initiation of the Osaka Biotech & Pharma Partnering Conference
- Eight Japan missions: 93 Bavarian SME participations
- Bavarian booth at every BioJapan with Bayern International and the BMWK
- EUR 2.7 million public funding for R&D projects with Japan
- Five public grants for Bio^M for dedicated Japan activities
- Bavarian Round-Table Japan
- Close collaboration with the Bavarian Representative Office in Tokyo
- EU-Japan cooperation platform

Bio^M FORGING THE CE4BIG ALLIANCE WITH FOUR OTHER EUROPEAN HEALTH CLUSTERS

After two challenging but successful years, the CE4BIG project – Cluster Excellence for Business, Innovation and Growth in the health sector – came to an end in February 2022. During this two-year project, European clusters Atlanpole Biotherapies (France), Bio^M (Germany), BioWin (Belgium), and Klaster Life Science Krakow (Poland) worked intensively on mutual goals and challenges and have agreed to continue with the CE4BIG alliance beyond the funding period.



Co-funded
by the COSME programme
of the European Union

The project was aimed at strengthening the skills and knowledge of cluster management staff and optimizing cluster services for SMEs in the personalized medicine sector. Although the CE4BIG project ran almost entirely throughout the COVID-19 pandemic, it has nonetheless contributed to stimulating innovation, mainly through virtual exchanges and SME trainings. An important part of the project was the opportunity for the four clusters to acquire valuable “train the trainer” knowledge; all four were awarded an ESCA Cluster Excellence label, with Bio^M receiving the Gold Label.



Impact for SMEs and other cluster members

A series of activities was organized for cluster members throughout the CE4BIG project:

- Training courses for SMEs
- Bioproduction networking week
- Info sessions on European funding opportunities for SMEs
- Life Science Open Space Forum
- Session on “Green Transition in Life Sciences”

The CE4BIG cluster alliance will continue its work in response to European challenges in the field of personalized medicine.

DR. STEPHANIE WEHNELT

Head of International Affairs Bio^M, and Board Member CEBR

By going global, Bio^M aims to help expanding the business potential for the Bavarian health sector. Over the years, Bio^M has developed a strong European and global network with reliable international partners. We are glad that we can offer those contacts to Bavarian companies looking for R&D collaborations or market entry support.



LIFE SCIENCE CENTERS IN BAVARIA

Regional networks

Bavaria is home to a dynamic, innovative, and highly successful biotech scene that never fails to impress, with hubs in Munich, Regensburg, Würzburg, Straubing, and the Nuremberg metropolitan region. Biotech companies – start-ups and established enterprises alike – benefit from the region's optimal conditions: proximity to academic research institutions, service providers and technology parks. In addition, they can rely on the support of the respective cluster organizations regarding any biotech-related topic. The cluster organizations support the biotech community with their extensive network of companies, universities, research institutions, university hospitals, chambers and associations, investors, funding agencies, consultants, and other stakeholders in the respective clusters and beyond.

Würzburg

The Innovation and Start-up Center close to the Julius-Maximilians-University offers lab space and has developed a comprehensive program for promoting start-up activities in the region. Cluster organization: Innovation- and Start-up Center (IGZ) Würzburg
Incubator: IGZ Würzburg
(>5,000 sqm)
www.igz.wuerzburg.de



Regensburg

The Innovation Center and Start-up Center on the campus of the University of Regensburg offers state-of-the-art laboratories as well as comprehensive technology services. Cluster organization: BioPark Regensburg for BioRegion Regensburg / Healthcare Regensburg managed by BioPark
Incubator: BioPark Regensburg (>18,000 sqm)
www.bioregio-regensburg.de



Munich


The cluster organization Bio^M is the central point of contact for the biotechnology sector in Munich and Bavaria and is located in Martinsried, the heart of the Munich Biotech Cluster. The cluster has a strong focus on health, i.e. personalized medicine. Bio^M offers a wide range of services and events and has developed the comprehensive incubation program "inQlab" for company founders in the field of biotechnology.
www.bio-m.org



Industrial Biotechnology in Bavaria

Managed by Industrielle Biotechnologie Bayern Netzwerk GmbH. Established in 2008, IBB Netzwerk GmbH catalyzes the implementation of innovative biotechnological processes and industrial procedures. The main task is to connect partners from large industry, small and medium-sized enterprises, and academia, to implement joint projects in Industrial Biotechnology and sustainable economy.
www.ibbnetzwerk-gmbh.com






Erlangen and Nuremberg

The European Metropolitan Region Nuremberg is an internationally leading location for medical technology. As one-stop-shop Medical Valley offers a broad variety of services to accelerate time-to-market for healthcare innovations.

Cluster organization: Medical Valley

Incubator: Medical Valley Centers in Erlangen (>5,000 sqm) and Forchheim (>2,300 sqm)

www.medical-valley-emn.de



Straubing

The BioCampus in the port of Straubing focuses on creating value from biobased resources, BioMass logistics and start-up management. In close vicinity to the TUM Campus Straubing for sustainability and biotechnology, it offers lab space, offices, start-up and business support and industrial plots.

Cluster Organization: BioCampus Straubing GmbH

Incubator: TGZ Straubing (4,000 sqm)

www.hafen-straubing.de



IZB Martinsried and Freising

The Innovation and Start-up Center for Biotechnology (IZB) in Planegg-Martinsried (focus on medical biotechnology) and Freising-Weihenstephan (focus on life sciences) has developed into one of the leading biotechnology centers in the world and offers young biotech start-ups 26,000 sqm of modern building infrastructure for biotechnology.

www.izb-online.de



DEVELOPMENT IN REGENSBURG

Guest contribution from Dr. Thomas Diefenthal

Current BioPark Annual Report 2021

The companies in the cluster from the fields of biotechnology, pharmaceuticals and medical engineering, diagnostics, analytics and the healthcare industry were able to significantly expand their business in Eastern Bavaria in the second year of Corona and have increased their staff in many cases. This is shown by the current survey in the BioRegion Regensburg, which is conducted annually by BioPark Regensburg GmbH. The total number of companies in the cluster rose slightly compared to the previous year to 63 companies (+2).



The total number of employees increased significantly from 4,093 to 4,504. Currently, 6 pharmaceutical companies with 1,530 employees, 30 medtech companies (medical engineering, diagnostics/analytics) with 2,124 employees and 27 biotech companies with 850 employees are active in the Regensburg Bioregion cluster.

The technology and start-up center currently accommodates 35 leaseholders with almost 700 employees in its three buildings on a gross area of 18,000 sqm. These include start-up companies, university and non-university institutions, companies from Germany and abroad, as well as service providers and our own daycare center.

Healthcare Regensburg – managed by BioPark

Today, a total of 21,600 employees with social security were working in the health sector in the Regensburg region. That is a good 33.8% more than in the 2011 census. At 55%, the largest proportion is employed in hospitals. 80% of the employees work in the urban area and 20% in the rural district. There are currently 831 companies in the

health sector in the Regensburg area, 60% of them in the city and 40% in the district. These generated sales of EUR 2.7 billion in the last year, which is almost twice as much as in 2011 with a rate of increase of 92.9% and corresponds to an annual growth rate of 7.6%.

The RCI becomes a Leibniz Institute in Regensburg

The Regensburg Center for Interventional Immunology (RCI) was founded in 2010 as a central institution of the University of Regensburg to bundle all university research areas working on the development of new immunotherapies. Until the completion of the new research building (the D5) on the campus of the University Hospital in 2019, the BioPark Regensburg supported the establishment of the RCI by providing them with office and lab space. At the beginning of this year, the RCI was included in the federal-state funding of the Leibniz Association.

The LIT (Leibniz Institute for Immunotherapy) focuses on translational immunology in the fields of cancer immunotherapy, chronic inflammation and autoimmunity. Its goal is to develop effective cellular immunotherapies in these areas. To this purpose, further leading experts from the most renowned research institutions worldwide are to be engaged at the LIT. Immunologists, biochemists, computer scientists, physicists and physicians are developing methods for genetically modifying human immune cells. This can take cancer treatment into new realms. For example, if a cancer patient with an advanced tumor no longer responds to conventional

therapies, genetically tuned immune cells of the body will be induced to release an intelligent cocktail of active substances. The immune system of the diseased person is induced to destroy the tumor itself.

Regensburg clusters bundle AI expertise

In Regensburg – a high-tech and science location where artificial intelligence shows itself in all its facets – BioPark Regensburg GmbH has been working with its Life Science and Healthcare Cluster Regensburg BioRegion since 2020 with the Mobility & Logistics clusters, the IT Security Cluster e. V. and the Sensor Technology / Strategic Partnership Sensor Technology e. V. in the joint AI initiative AIR (Artificial Intelligence Regensburg). Now the four networks have also impressed at the federal level: For their approach of a cross-cluster and cross-domain service portfolio “goAIR – Artificial Intelligence Regensburg” they will receive funding from the “goCluster” program.


The Regensburg initiative AIR is a clear commitment from the regional networks for “their” region to jointly deliver a future-oriented, regional development concept that actively involves and mobilizes their respective stakeholders. The aim is to better network the stakeholders in the clusters and thus enable an optimized transfer of knowledge and technology. Industry affiliations play a subordinate role, especially in cross-sectional technologies such as artificial intelligence.

www.biopark-regensburg.de

DR. THOMAS DIEFENTHAL

is Managing Director of BioPark Regensburg GmbH and Managing Director of the German Association of Innovation, Technology and Business Incubation Centres (BVIZ) in Berlin.





THE SUCCESSFUL INNOVATION CENTRE

MADE IN REGENSBURG



Health Industry of Regensburg

- 2.7 billion Euro turnover
- 21.600 employees

Cluster BioRegio Regensburg

- 61 companies
- 4.093 employees

BioPark Regensburg

- 18.000 sqm area
- 35 companies, 718 employees
- 67 start-ups since 1999
- flexible leasehold concept & single offices
- direct motorway connection
- located on the University Campus
- own day-care facility
- conference rooms and theatre

A company of the City of Regensburg



Am BioPark 13 | D-93053 Regensburg | Phone: +49 941 92046-0 | Fax: +49 941 92046-24 | Email: info@biopark-regensburg.de | www.biopark-regensburg.de

GROWTH FACTOR & JOB MOTOR



RESEARCH

2 Universities | Cell therapy
Immunology | Oncology



DEVELOPMENT

50 Companies | Biotech
Medtech | Health IT



HEALTHCARE

Over 20,000 employees
2.7 billion Euro turnover



MAIN FOCUS

Digitalization & AI | Innovation in Nursing
Hygiene and Infection Prevention

The Top Region for **excellence** in science
and **innovative** companies:



Profit from the **Healthcare Network** with over
50 companies, five hospitals and two universities.



CUTTING-EDGE RESEARCH

Munich's IZB attracts great interest from investors

In collaboration with pharmaceutical companies, start-ups bring medical innovations to market.

The German Biotechnology Innovation and Start-up Centre (IZB), one of the leading biotechnology centres in Europe with over 50 resident biotech start-ups, gives a positive summary of the developments at the IZB in the first half of 2022. "We are incredibly proud of the progress the start-ups at the IZB have made this year. The innovative science and cutting-edge technologies being developed here continue to attract great interest from life science investors, who have supported the start-ups with around EUR 170 million in follow-on financing in this half-year alone", said Dr. Peter Hanns Zobel, Managing Director of the Biotechnology Innovation and Start-up Centre. "In addition, it is great to see how current and former IZB start-ups succeed in entering long-term collaborations with large biotech and pharma players and complementing their leadership teams with recognized industry experts. I am also particularly pleased that our renowned IZB Biotech PressLounge returned as a hybrid event after a two-year Corona hiatus and attracted more interest than ever".

A successful half-year for follow-on financings of IZB start-ups

PreOmics GmbH, a developer of sample processing technologies for mass-spectrometry-based protein analysis, has started the year on the right foot receiving EUR 13.5 million in a Series B

financing round from Bruker Corporation (Nasdaq: BRKR) in January. Bruker's financial and scientific involvement will enable the start-up to accelerate the research, development and commercialization of proteomics technologies.

The U.S. joint venture of **Origenis GmbH** and investor Kleiner Perkins, **Neuron23 Inc.**, closed a successful USD 100 million (approx. EUR 95 million) Series C financing led by SoftBank Vision Fund 2 in April. Existing Series A and B investors also participated in the new funding round, which brings the company's total funding to USD 213.5 million. Neuron23 focuses on developing precision medicines for genetically defined neurological and immunological diseases and recently nominated a clinical candidate for Parkinson's disease.

New start-ups in the IZB

In May, **Tubulis**, a biotech start-up that generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight, closed a successful Series B financing round of EUR 60 million led by Andera Partners. Apart from all existing investors, also two new investors, Evotec and Fund+, participated in the financing round. The new capital will be used to advance Tubulis' proprietary pipeline of antibody drug conjugates (ADCs) towards clinical evaluation and introduce programs addressing a range of solid tumor indications. In June, the start-up moved into the IZB.

Research at the IZB is conducted in a wide variety of fields, not only in medical but also in industrial biotechnology. **Origin. Bio**, a synthetic biology company which uses biosciences to sustainably produce raw material alternatives on an industrial scale with the goal of making petrochemicals completely superfluous in the long term, found a home at the IZB in February this year. The company's CEO, Jens Klein, however, is not new to the campus, having previously worked as managing director of AMSilk GmbH for many years.

Early this year, **SCG Cell Therapy Pte. Ltd.**, a Singapore-based biotechnology company focusing on the development of novel immunotherapies for patients with infections and infection-associated cancer, decided to open a new R&D site in Germany, and has selected the IZB as the suitable location to expand the company's portfolio of innovative immunotherapy products and platforms. SCG Cell already has operating sites in Singapore and China.

DR. PETER HANNS ZOBEL


Dr. Peter Hanns Zobel has been Managing Director of the IZB since 1996 and has built the 26,000 m² Biotechnology Innovation and Start-up Center into one of the major biotech centers in Europe.



From concept to IND to market

Global leadership in data, science, multimodality and access

With Evotec you are on the data-driven R&D Autobahn to Cures to accelerate access to more personalized, preventative and predictive approaches to medicine.



R&D efficiency

Fully integrated AI/ML-driven drug discovery & development

Precision medicine

Industrial scale Omics and iPSC

Just – Evotec Biologics

AI/ML powered disruptive biologics discovery, development, and CMO/CDMO services

Multimodality drug design

Small molecules | Biologics
iPSC-based cell therapy
Gene therapy toolbox

Evotec operates globally with more than 4,200 highly qualified people working across 15 sites in US, UK and EU.

www.evotec.com | info@evotec.com





Pinsent Masons

Leading legal minds for Life Sciences

Our Life Sciences team of over 100 industry specialists is one of the largest and most successful in Europe. We are investing heavily in the sector internationally to support clients.

We work with senior management and in-house legal teams to navigate complex regulatory environments, develop effective risk management strategies, spot and convert opportunities. Our team have technical backgrounds and experience drawn from industry or medical research and every one of them is passionate about improving patients' lives.

Contact us to find out how we can help enable success for your business.

Marc L. Holtorf

Sector lead Life Sciences Germany

M: +49 170 922 28 65

T: +49 89 203043 574

E: marc.holtorf@pinsentmasons.com

www.pinsentmasons.com



COMPANY PROFILES

www.bio-m.org/company-database





Kreillerstrasse 210
D-81825 München
Phone: +49 (0) 163 874 79 75
E-Mail: kontakt@21dx.de
Internet: www.21dx.de

21Dx GmbH

LIFE SCIENCE / TECHNOLOGY TRANSFER

Keywords: Infectious Diseases, Molecular Diagnostics, Vaccines

21Dx GmbH is a pioneer helping to fight the pandemic with high-quality test and vaccination services in Germany. Entrepreneurship and experience enable a combination of a fast and custom-fit implementation of all available technologies and end-to-end quality managed processes. We continue to develop and provide future pandemic solutions, but also offer further services in the healthcare sector, such as medical call centers and low threshold, highly localised medical services.



Am BioPark 11, BioPark II
D-93053 Regensburg
Phone: +49 (0) 941 20000890
E-Mail: info@2bind.de
Internet: www.2bind.de

2bind GmbH

BIOTECH DNA & PROTEIN ANALYTICS

Keywords: Small Molecules, Molecular Diagnostics, Peptide/Protein, Bioanalytics, Drug Development, R&D Service

2bind is a provider for biophysical services in early drug development (hit ID, hit validation and characterization) and antibody Characterization based on the core technologies MST, Dianthus, nanoDSF, BLI and ITC. Our Biotech and Pharma customers benefit from a strong expertise in biophysical methods (certified by NanoTemper for MST, Dianthus and nanoDSF), from customized milestone-based projects with clear timelines and reliable cost structures. Be smart – work with the experts!



Fraunhoferstraße 22
D-82152 Martinsried
Phone: +49 (0) 89 700763-0
E-Mail: public@4sc.com
Internet: www.4sc.com

4SC AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Rare Disease, Orphan Drug, Drug Development, Small Molecules, Oncology

4SC is a clinical-stage biopharmaceutical company developing small-molecule drugs that target key indications in cancer with high unmet medical need.

4SC's pipeline is protected by a comprehensive portfolio of patents and currently comprises one drug candidate in clinical development: resminostat.

4SC had 46 employees as of 31 December 2021 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A3E5C4).



Semmelweisstraße 5
D-82152 Planegg-Steinkirchen
Phone: +49 (0) 89 535395
E-Mail: max.scherer@abf-lab.com
Internet: www.abf-lab.com

ABF GmbH

CRO

Keywords: Metabolomics, Analytical Chemistry, Biomarker Discovery & Development

ABF is an accredited (ISO 17025, GLP) bioanalytical contract research laboratory with almost three decades of experience in method development, validation and application in the field of biomarkers and biomonitoring. The lab has particular experience in the analysis of compounds within clinical and toxicological studies by application of LC-MS/MS and GC-MS(/MS). Since end of 2001, ABF provides its services to corresponding industry, academic and governmental institutions.

abf diagnostics GmbH

PHARMA SUPPLIER & TRADE

abf diagnostics develops, manufactures and markets products and solutions for the collection, storage and onsite analysis of biological traces and samples. Our strategic focus lies on innovations in pre-analytics and decentralized testing. Our second business area comprises contact-less digital methods for the detection, identification and documentation of biological or chemical traces.

The logo for abf diagnostics GmbH features the lowercase letters 'abf' in white on a black background, followed by 'diagnostics GmbH' in white on a grey background.

Gewerbepark 14
D-85402 Kranzberg
Phone: +49 (0) 8166 9986 130
E-Mail: info@abfdiagnostics.com
Internet: www.abfdiagnostics.com

Actarmo Medical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Respiratory Diseases, Devices, Drug Delivery, Drug Development, Laboratory

Actarmo is a technology focused Contract Research Organisation supporting small to mid size pharmaceutical, biopharmaceutical and device companies in development of respiratory products. With our highly experienced team we offer GMP laboratories as well as consultancy activities.



Robert-Koch-Allee 29
D-82131 Gauting
Phone: + 49 (0) 89 614233 0
Internet: www.actarmo.com

adivo GmbH

PHARMA ANIMAL HEALTH

Keywords: Pain, Oncology, Inflammation, Antibody, Drug Development

adivo is a German biotech company generating species-specific therapeutic antibodies for companion animals. The adivo team aims to initially address high medical needs in dogs including chronic inflammation and cancer, with the potential of expanding activities into the development of therapeutics for other species in the future. Using its fully canine-based antibody library, adivo, either alone or with partners, intends to generate therapeutics for dogs that are well tolerated and efficacious.



Am Klopferspitz 19
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 - 588 08 84 71
E-Mail: info@adivo.vet
Internet: www.adivo.vet

advanceCOR GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Personalized Medicine, Cardiovascular Diseases, Peptide/Protein, Drug Development, Inflammation

advanceCOR is a biotech company focusing on personalized medicine in cardiovascular diseases. Revacept, a biological drug (lesion specific inhibitor of atherothrombosis) has completed a phase II trial in patients with stroke and cerebral vascular syndromes and a phase II clinical trial for the treatment of coronary artery disease.

Further preclinical candidates are under development.

advanceCOR is financed by MIG AG, KfW, Bayernkapital, HTGF, Occident and Bio^M.



Fraunhoferstr. 9a
D-82152 Martinsried
Phone: +49 (0) 89 2000 204-10
E-Mail: info@advancecor.com
Internet: www.advancecor.com



advanced biolab service
Gesellschaft für Laborgeräte, Beratung und Support mbH

advanced biolab service Gesellschaft für Laborgeräte, Beratung und Support mbH

DEVICES

Stäblistraße 10
D-81477 München
Phone: +49 (0) 89 45470050
E-Mail: info@advancedbiolabservice.com
Internet: www.advancedbiolabservice.com

advanced biolab service GmbH based in Munich provides maintenance, repair and troubleshooting service for capillary electrophoresis sequencers, Real Time and standard PCR instruments ABI 377, ABI 310, ABI 3100(-Avant), ABI 3130(xl), ABI 3500(xl), ABI 3730(xl), ABI 7300, ABI 7500(Fast), ABI 2700, ABI 2720 and GeneAmp 9700. Remanufactured instruments, service contracts or individual repairs, software and computer upgrades, user training and reagents offered by a small and highly professional team.



ADVITOS GmbH

MEDTECH

Keywords: Multi organ failure, Respiratory Diseases, Hepatology, Devices

Agnes-Pockels-Bogen 1
D-80992 München
Phone: +49 (0) 89 4111842-0
E-Mail: info@advitos.com
Internet: www.advitos.com

ADVITOS has developed the CE-marked & globally patented ADVOS technology (ADVanced Organ Support) the only therapy worldwide offering multi-organ support integrated in one single device, supporting all 3 main detoxification organs simultaneously: liver, lung and kidney. ADVITOS was founded near Munich in 2005 by renowned nephrology & multi-organ support expert Dr. Bernhard Kreymann who was instrumental in establishing the previous gold standard of organ support by single-pass albumin dialysis.



Aenova Holding GmbH

BIOTECH & PHARMA PRODUCTION, CMO

Keywords: Laboratory, Regulatory Affairs, R&D Service

Berger Straße 8 - 10
D-82319 Starnberg
Phone: +49 (0) 8151 9987-001
E-Mail: info@aenova.de
Internet: www.aenova-group.com

The Aenova Group is one of the leading companies in the global pharmaceutical and healthcare industry. The group's portfolio of services covers the entire value chain for the development and production of all the main dosage forms and product groups in the field of medicines and dietary supplements. Aenova operates 15 manufacturing facilities located within Europe and the United States. More than 4300 employees contribute to the group's success.



Agrobiogen GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Bioanalytics, Laboratory

Larezhhausen 3
D-86567 Hilgertshausen
Phone: +49 (0) 8250 9279040
E-Mail: info@agrobiogen.de
Internet: www.agrobiogen.de

Agrobiogen focuses on and is experienced in the application of molecular-genetic techniques in livestock animals (especially molecular-genetic diagnostics). Detection of pathogens like BVDV, as well as parentage control of animals, SNP genotyping and analysis of DNA markers are offered as a service for breeders, veterinarians and companies.

Agrolytix GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Agrolytix is your competent partner around the themes of microencapsulation and micronization. The company specializes in the areas of agrochemicals and cosmetics. We are happy to assist in the development and production of your new products or offer you our technologies as services.



Cauerstr. 4
D-91058 Erlangen
Phone: +49 (0) 9131 85-29452
E-Mail: info@agrolytix.com
Internet: www.agrolytix.com

Alexion Pharma Germany GmbH

PHARMA & CHEMICAL INDUSTRY

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines. Alexion Pharma Germany GmbH is based in Munich, Germany



Landsberger Straße 300
D-80687 München
Phone: +49 (0) 89 45 70 91 300
E-Mail: alexion.germany@alexion.com
Internet: www.alexion.de

ALGORA Gesellschaft für Medizinstatistik und Vertriebssysteme mbH

CRO

Keywords: [Data Management and Biostatistics](#), [Medical Writing](#), [Clinical Trial Management and Monitoring](#), [Infectious Diseases](#), [Oncology](#), [Autoimmune Diseases](#)

Algora offers a broad range of services for phase II-IV clinical trials as well as for observational studies in Germany, with key competencies in study start-up, clinical monitoring, data management, and statistical analysis. Experienced in oncology and infectious diseases since the first days of the company in 1989, we later gained additional expertise in immunology and entered the field of nutritional studies while we continued to cultivate strong relations with the medical community.



Münchner Str. 11
D-85540 Haar
Phone: +49 (0) 89 613727-0
E-Mail: cro@algora.de
Internet: www.algora.de

Altmann Analytik GmbH & Co. KG

PHARMA SUPPLIER AND TRADE

Keywords: [Laboratory](#), [Fine Chemicals/Reagents](#), [Devices](#), [Analytical Chemistry](#)

Specialized distributor for chromatography & lab supply. We provide consumables for HPLC & GC, Spectroscopy (lamps & flow cells) and Sample Prep (syringe filters, vials and caps) as well as chemicals and products for dairy and food industry. On www.analytix-shop.com you can find more than 200,000 lab supply products from high-quality manufacturers, such as Agilent, Chiral Technologies, Grace, Hamilton, Macherey-Nagel, Merck, Millipore, PerkinElmer, Thermo Fisher, Waters, Whatman and YMC.



Rupert-Mayer-Str. 46
D-81379 München
Phone: +49 (0) 89 724805-90
E-Mail: info@altmann-analytik.de
Internet: www.analytix-shop.com



AMGEN GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Nephrology, Bone/Joint Diseases, Oncology

Riesstraße 24
D-80992 München
Phone: +49 (0) 89 149096-0
E-Mail: corinna.jacob@amgen.com
Internet: www.amgen.de

Amgen is one of the worlds leading biotechnology companies with more than 22,000 employees in nearly 100 countries and a 40-year history. Worldwide, millions of patients with serious or rare diseases benefit from our therapies every year. Our drugs are used in nephrology, cardiology, hematology, oncology, bone health and chronic inflammatory diseases. In addition to original products, our portfolio also includes biosimilars. We have a diverse pipeline. Amgen GmbH in Munich was founded in 1989. Today, almost 650 employees work here with a focus on clinical research, regulatory affairs and the distribution of pharmaceuticals.



Research GmbH

AMGEN Research (Munich) GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Immune Therapy, Drug Development, Antibody, Oncology

Staffelseestr. 2
D-81477 München
Phone: +49 (0) 89 895277-0
E-Mail: susanne.sporer@amgen.com
Internet: www.amgen.de

Amgen Research (Munich) GmbH (formerly Micromet GmbH) located in Munich, Germany has been part of Amgen since March 2012 and is Amgen`s largest R&D site outside of the U.S. The site has about 200 employees and is specialized in the development of the "Bispecific T cell Engager" (BiTE®) antibody constructs for innovative cancer therapies. Amgen is one of the world's leading biotechnology companies with more than 22,000 employees in nearly 100 countries and a 40-year history.



AmplexDiagnostics GmbH Gesellschaft für molekularbiologische Diagnostik

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Infectious Diseases, In-Vitro-Diagnostics, Molecular Diagnostics, Clinical Diagnostics, PCR

Werkstr. 2
D-83555 Gars-Bahnhof
Phone: +49 (0) 8073 91693-50
E-Mail: info@amplexdiagnostics.de
Internet: www.eazyplex.com

Founded 2002, AmplexDiagnostics is one of the first suppliers for CE IVD diagnostics based on a real-time isothermal amplification technique in a portable device (GENIE II) using lyophilized test reagents for a maximum on user-friendliness and a minimum of hands-on time. With the new eazyplex® system you identify pathogenic bacteria within 15 min, screen swabs for multi-resistant bacteria within 20 min or realise Meningitis diagnostics directly from CSF in 30 min.

AMS Advanced Medical Services

CRO

Keywords: Data Management and Biostatistics, Medical Writing, Clinical Trial Management and Monitoring, R&D Service, Regulatory Affairs, Data Management, Pharmacovigilance

AMS specialises in Global Drug Development, are market leaders in Health Economics and Public Health Benefit Assessments of pharmaceuticals, as well as HTAs and Relative Effectiveness Assessments for medical devices. AMS can provide market access programs in Europe and field force services in German speaking countries. The comprehensive suite of AMS services also include ePRO solutions, strategic consultancy and staff development training.



Rosa-Bavarese-Str. 5
D-80639 München
Phone: +49 (0) 89 2000074-100
E-Mail: Medical.Science@ams-europe.com
Internet: www.ams-europe.com

AMSilk GmbH

BIOTECH NEW MATERIALS AND COMPOUNDS

Keywords: New Materials, Industrial Biotechnology

AMSilk GmbH is the world's first industrial supplier of synthetic silk biopolymers and has its headquarters in Planegg near Munich, Germany. Sustainably produced using a patented biotechnological process, AMSilk high-performance biopolymers combine the advantages of natural products with the possibility of large scale, industrial production processes. AMSilk's high-performance biopolymers are distributed in the form of Biosteel® fibers or as a coating solution for medical devices.



Am Klopferspitz 19
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 579 5393-0
E-Mail: info@amsilk.com
Internet: www.amsilk.com

Analytisches Forschungsinstitut für Non-Target Screening GmbH

LIFE SCIENCE / CHEMICAL INDUSTRY

Keywords: Bioanalytics, R&D Service, Laboratory, Analytical Chemistry, Metabolomics, Natural Compounds, Small Molecules

AFIN-TS was founded in 2018 as spin-off from TUM and provides research as well as important services and consulting around MS based non-target screening (NTS). Drug production processes as well as drug production origins/sources can be monitored by NTS. Thus, NTS can be used to characterize unknown/unexpected organic compounds in these or to track changes in the chemical composition (e.g. impurities, fake compounds, etc.) along treatment processes. R&D for (plant) metabolomics offered in own lab.



Am Mittleren Moos 48
D-86167 Augsburg
Phone: +49 (0) 151 50516119
E-Mail: info@afin-ts.de
Internet: www.afin-ts.de



anteris medical GmbH

CRO CONSULTANTS

Keywords: Regulatory Affairs, R&D Service, In-Vitro-Diagnostics, Clinical Diagnostics, Molecular Diagnostics, Devices, Drug Delivery

Münchner Straße 47e
D-83607 Holzkirchen
Phone: +49 (0) 8024 4686 652
E-Mail: info@anteris-medical.com
Internet: www.anteris-medical.com

anteris medical supports Pharma and Biotech companies with the development, quality control and approval of their products. Our expertise in the fields of requirements management, quality control and risks management, usability engineering, Alliance Management as well as approval accompanies the products through the entire product life cycle. anteris medical brings together the experience of its founders and employees with medical products, combination products and in vitro diagnostics under one roof.



Assay.Works GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Tissue Engineering/Cell Culture, Automation, Small Molecules, Laboratory, Pharmacology, R&D Service, Drug Development

Am BioPark 11
D-93053 Regensburg
Phone: +49 (0) 941 2000 1240
Fax: +49 (0) 941 2000 1241
E-Mail: contact@assay.works
Internet: www.assay.works

Our mission is to accelerate our partner's research programs by developing and executing predictive and scalable assays to quantify the bioactivity of novel chemical and biological entities. We combine scientific rigor with our domain expertise in laboratory automation, informatics, and industry best practices to turn challenging assays into quantitative, reproducible results.



Astellas Pharma GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Inflammation, Infectious Diseases, Immune Therapy, Autoimmune Diseases, Allergy, Antibiotics, Drug Development

Georg-Brauchle-Ring 64-66
D-80992 München
Phone: +49 (0) 89 4544-1057
E-Mail: info@de.astellas.com
Internet: www.astellas.de

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to changing tomorrow by improving the health of people around the world. We focus on oncology, anti-infectives, urology and transplantation as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies and modalities. The German headquarters are based in Munich. Located here are sales, marketing and medical.



ASPHALION, S.L., Zweigniederlassung München

CRO

Keywords: Regulatory Affairs, Pharmacovigilance, Data Management and Biostatistics, Clinical Trial Management and Monitoring, Medical Writing

Leopoldstrasse 244
D-80807 München
Phone: +49 (0) 89 208 039 280
E-Mail: munich@asphalion.com
Internet: www.asphalion.com

ASPHALION is a Scientific and Regulatory Affairs consultancy firm with offices in Barcelona, Madrid, Munich and London. Founded in 2000, ASPHALION now consists of a team of over 100 professionals offering services to Pharma and Biotech companies in Drug Development, Regulatory Strategy, Medical and CMC Writing, Regulatory Submissions, eSubmission, Pharmacovigilance and Training. ASPHALION operates in a global environment with regulatory submission expertise mostly in EU and North America.

Aurigon GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Pharmacology, Toxicology, Pharmacokinetics, ELISA/EIA, Bioanalytics, Drug Development, R&D Service

AURIGON is an independent CRO offering a full range of in vivo and in vitro non-clinical services. These services include, but are not limited to: PK/PD, ADME, bioanalytics, toxicology and safety pharmacology in all species used in toxicity testing. We're big enough to provide a full service, but small enough to fully adapt to your needs. AURIGON operates offices in Munich and state-of-the-art GLP- and GMP-compliant facilities at its ATRC Aurigon Toxicological Research Center near Budapest.



Planegger Str. 9a
D-81241 München
Phone: +49 (0) 89 780 720 010
E-Mail: info@aurigon.de
Internet: www.aurigon.de

Avergen Pharmaceutical GmbH (APG)

BIOTECH THERAPEUTICS & DIAGNOSTICS

Avergen Pharmaceutical GmbH (APG) creates long-term value through internal and collaborative innovative drug discovery programs based on novel drug targets. APG is using a platform to identify and develop protein-protein interaction (PPI) inhibitors. APG is dedicated on its core competences in neurodegenerative disease and oncology research. The location of the company in Munich enables the access to experienced experts in R&D, as well as business development and commercialization.



Am Klopferspitz 19
D-82152 Martinsried
Internet: www.avergen.com

AMW GmbH, Arzneimittelwerk Warngau

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Delivery

AMW GmbH is an innovative, and steadily growing pharmaceutical company situated nearby Munich, the capital of the Free State of Bavaria in Germany. The base of our technology is to provide a prolonged therapeutic effect with the benefit of having lesser side effects and lower consumption of the active pharmaceutical ingredients. One example from our portfolio is a biodegradable implant, that will be applied subcutaneously by an applicator with an automatic needle-retraction mechanism.



Birkerfeld 11
D-83627 Warngau
Phone: +49 (0) 8024 470999 0
Internet: www.a-m-w.eu

Axolabs GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: RNAi & Antisense, Antisense/Nucleotides, Pharmacology, Bioinformatics, Bioanalytics, Aptamer Technology, Pharmacokinetics

Axolabs is the leading research and development organization for oligonucleotide therapeutics and nucleic acid medicines. Based on the foundations of the former Roche Center of Excellence for RNA Therapeutics, we leverage our world-leading know-how and 20 years of experience to provide high-end preclinical solutions and consultancy tailored to your specific needs.



Fritz-Hornschuch-Str. 9
D-95326 Kulmbach
Phone: +49 (0) 9221 82762-0
E-Mail: info@axolabs.com
Internet: www.axolabs.com



An der Kohlplatte 23
D-89420 Höchstädt a.d.Donau
Internet: www.bappharma.com

BAP Pharma

PHARMA & CHEMICAL INDUSTRY

BAP Pharma are specialists in the clinical trial supply of comparator drugs, with a global reach. We have extensive experience both in Europe and worldwide. With over 50 years in the industry we are well-placed to understand your clinical trial supply needs. With the newly founded site in Höchstädt, Bavaria, BAP Pharma is even closer to serve customers of the pharma and biotechnology communities.



Floriansbogen 2-4
D-82061 Neuried
Phone: +49 (0) 89 9699 3401
E-Mail: info@baseclick.eu
Internet: www.baseclick.eu

baseclick GmbH

BIOTECH DEVICES & REAGENTS

Keywords: PCR, Nanobiotechnology, Chip/Array Technology

Baseclick GmbH was founded in 2008 as a spin out of the LMU in Munich by Prof. Dr. Thomas Carell. Baseclick utilizes the “click chemistry”, discovered by the Nobel laureate Prof. Dr. Barry Sharpless, and developed a wide range of nucleic acid modification products, e.g. EdU proliferation kits, labeling of nucleotides and preparation kits for “Next Generation Sequencing” (NGS) and for the development of RNA-based drugs. baseclick GmbH out-licensed this technology to leading companies worldwide.



BAVARIAN NORDIC

Fraunhoferstr. 13
D-82152 Martinsried
Phone: +49 (0) 89 255446-030
E-mail: hho@bavarian-nordic.com
Internet: www.bavarian-nordic.com

Bavarian Nordic GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Infectious Diseases, Vaccines, Drug Development, Immune Therapy, Oncology

Bavarian Nordic (BN) is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox and monkeypox vaccines. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. BN was founded in 1994 and is headquartered in Denmark. The company has more than 500 employees in Europe and USA and is listed on the Copenhagen Stock Exchange.



Edisonstr. 4
D-85716 Unterschleißheim
Phone: +49 (0) 89 31701-0
E-Mail: info_de@baxter.com
Internet: www.baxter.de

Baxter Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Nephrology, Autoimmune Diseases, Oncology, Pain, Immune Therapy, Vaccines, Tissue Engineering/Cell Culture

Baxter International Inc. (NYSE: BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

Beckman Coulter Biomedical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Nanobiotechnology, Automation, PCR

Beckman Coulter develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing. Our diagnostic systems are found in hospitals and other critical care settings around the world and produce information used by physicians to diagnose disease, make treatment decisions and monitor patients. Scientists use our life science research instruments to study complex biological problems including causes of disease and potential new therapies or drugs.



Sauerbruchstr. 50
D-81377 München
Phone: +49 (0) 89 579589-0
E-Mail: info@beckmancoulter.de
Internet: www.beckmancoulter.de

Bencard Allergie GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Allergy

Bencard Allergie GmbH is the Munich based, German subsidiary of Allergy Therapeutics plc. (Worthing/UK). As a global company, we specialize in the research and development of allergy treatments since 1934. We constantly aim to improve the quality of life of people suffering from allergies. Our strong portfolio offers specific immunotherapies to treat allergies such as pollen, pets, wasps or bees. Additionally we provide prick-tests for diagnostic purposes and OTC products (e.g. immunoBON®).

Bencard Allergie

Wir denken weiter.

Leopoldstraße 175
D-80804 München
E-Mail: info@bencard.com
Internet: www.bencard.de

bene-Arzneimittel GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Pain, Drug Development

bene-Arzneimittel GmbH has been producing high quality pharmaceuticals in Munich for 65 years. As a traditional and innovative family business, people are always at the center of our actions. Our branded products are available in 30 countries with the highest standards of quality and compatibility. More than 100 employees are constantly working to develop new products, active ingredients, dosage forms and preparations for our most important goal: human health!



Herterichstraße 1
D-81479 München
Phone: +49 (0) 89 74987-0
E-Mail: contact@bene-arzneimittel.de
Internet: www.bene-arzneimittel.de

betapharm Arzneimittel GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Pain, Drug Development

Betapharm was founded in 1993 in Augsburg. betapharm delivers generic drugs and is one of the leading generic companies in Germany. In 2006 the company was bought by globally active Dr. Reddy Laboratories, Hyderabad, India. With 75 employees Betapharm generates revenues of about EUR 180m.



Kobelweg 95
D-86153 Augsburg
Phone: +49 (0) 821 74881-0
E-Mail: info@betapharm.de
Internet: www.betapharm.de



Bicoll GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Natural Compounds, Nutraceuticals, Medicinal Chemistry, Oncology, R&D Service, Agrobiotechnology, Small Molecules

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 820106-30
E-Mail: contact@bicoll-group.com
Internet: www.bicoll-group.com

Bicoll offers novel patentable and biologically relevant structures for pharmaceutical, nutraceutical, and agricultural industry. Used proprietary, efficient and multi-disciplinary technology approach to the discovery of novel potent molecules shortens the process from initial screening to animal test to 9 months. It has 20 years experience in dealing with plant natural products: extraction, isolation and synthesis. Bicoll is an expert in high tech natural product and in medicinal chemistry.



Bind-X GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: New Materials, Agrobiotechnology, R&D Service, Industrial Biotechnology

Am Klopferspitz 19
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 2620344-0
E-Mail: info@bind-x.com
Internet: www.bind-x.com

Bind-X, formerly Dust BioSolutions, is an industrial biotechnology company with core expertise in the development, production and sale of innovative bio-based binders. Bind-X products are capable of solidifying almost any permeable material and providing additional functional properties. Foremost they always increase the sustainability of Bind-X clients in the worldwide mining, agriculture and construction industry.



BIOBANK der Blutspender Blutspendedienst des BRK

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Autoimmune Diseases, Cardiovascular Diseases, Diabetics, Metabolic Diseases, Oncology

Herzog-Heinrich-Str. 2
D-80336 München
Phone: +49 (0) 89 5399-0
E-Mail:
biobank@blutspendedienst.com
Internet: www.biobank.de

With its »Blood Donor BIOBANK«, the Bavarian Red Cross Blood Donor Service offers a unique resource for biomarker research. With a collection of more than 4 Mio plasma samples and a large pool of more than 400,000 active blood donors we are one of the largest blood donor based biobank. The serial, pre-diagnostic blood samples of several thousands of diseased BIOBANK participants per year are a unique resource for investigating markers associated with the onset and progression of diseases.

BioClinica GmbH

CRO

Keywords: Drug Development, Oncology, Neurology, Cardiovascular Diseases, Imaging, Metabolic Diseases, CNS

Bioclinica is the global leader in medical imaging core lab services, providing life-science companies with clinical trial support for all phases and across all major indications. Our commitment to service and scientific excellence is focused on advancing our clients' drug development process. Bioclinica's services create a unique and scalable platform and include Medical Imaging, Cardiac Safety Services, Clinical Event Adjudication Services, Software Solutions, and Drug Safety Solutions.



Landsberger Str. 290
D-80687 München
Phone: +49 (0) 89 202 444 97-0
Internet: www.bioclinica.com

Biogen GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Rheumatoid Arthritis, Autoimmune Diseases, Dermatology, Neuro-Degeneration, Neurology, Drug Development

Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases or related therapeutic areas. Founded in 1978 as one of the first biotechnology companies we offer the leading portfolio of medicines to treat multiple sclerosis, have introduced the first approved treatment for spinal muscular atrophy, are commercializing biosimilars and focusing on advancing the industry's most diversified pipeline in neuroscience. Biogen Germany is located in Munich.



Riedenburger Straße 7
D-81677 München
Phone: +49 (0) 89 99617-0
E-Mail: stefan.schneider@biogen.com
Internet: www.biogen.de

Biogen AG

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Infectious Diseases, Natural Compounds, Devices, Agrobiotechnology

Biogen develops, produces & sells innovative trapping systems against mosquitoes & flies, especially against dangerous vectors such as aedes aegypti, aedes albopictus & sand flies. These systems are already being used by leading health organizations (e.g. CDC, USA), several armed forces and other governmental bodies & public entities (incl. quarantine departments, research institutes & universities). Biogen also offers a fee-for-service business for insect repellents and attractants.



Weißenburgstr. 22
D-93055 Regensburg
Phone: +49 (0) 941 5699 6947
E-Mail: biogen@biogen.com
Internet: www.biogen.com

BioLink Informationstechnologie GmbH

BIOTECH BIOINFORMATICS

Keywords: Laboratory

The BioLink GmbH, an information-technology company, was founded in 1997 to serve as High Security Internet Provider and as Software Developer for Laboratory-Information-Management-Systems (LIMS). It was specifically the software-developing business which evolved over the last years. Based on the concept to design and develop personalized LIMS solutions, BioLink put forth a number of softwares aimed to support laboratory processing as well as certain aspects of genetic engineering.



Lochhamer Straße 9
D-82152 Martinsried
Phone: +49 (0) 89 741595-0
E-Mail: info@biolink.de
Internet: www.biolink.de



Robert-Koch-Str. 2
D-82152 Martinsried
Phone: +49 (0) 89 895574-0
E-Mail: info@biomax.com
Internet: www.biomax.com

Biomax Informatics AG

BIOTECH BIOINFORMATICS

Keywords: Bioinformatics, Industrial Biotechnology, Data Management, Personalized Medicine, Agrobiotechnology, Informatics, Data Management and Biostatistics

Biomax provides software solutions for efficient decision making and knowledge management.

All products are based on the BioXM technology platform:

- AILANI provides unique semantic integration and search capabilities that catalyze digital change and accelerate the innovation cycle.
- NICARA is a knowledge hub for brain image assessments.

In addition, Biomax offers solutions for Industrial Biotech and Systems Medicine.

Biomax was founded in 1997 and is certified according to ISO 9001 and ISO 27001.



Bruckmannring 32
D-85764 Oberschleißheim
Phone: +49 (0) 89 3157000
E-Mail: info@biomed.de
Internet: www.biomed.de

Biomed Labordiagnostik GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: In-Vitro-Diagnostics, Bioanalytics

BIOMED has been known for decades as a reliable manufacturer for lab diagnostics. Our core competences are diagnostic products, staining solutions and staining devices for routine and special laboratories for the detection and prevention of diseases. Whether immunology, infectiology, cytology, haematology, safe screening methods or the automation of staining for your different sample materials we offer solutions for many clinical and laboratory challenges.



Im Gewerbepark B49
D-93059 Regensburg
Phone: +49 (0) 941 454 41
E-Mail: info@biometric-gmbh.de
Internet: www.biometric-gmbh.de

Biometric GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Analytical Chemistry

Biometric GmbH is a laboratory for microbiological and chemical analysis dealing with the analysis of water, hygienic control and providing microbiological analyses of pharmaceutical products, medical devices, cosmetics and food.



Kerschensteinerstr. 11-15
D-92318 Neumarkt
Phone: +49 (0) 9181 231-90
E-Mail: info@bionorica.de
Internet: www.bionorica.de

Bionorica SE

PHARMA & CHEMICAL INDUSTRY

Keywords: Neurology, Pain, Respiratory Diseases, Oncology, Analytical Chemistry, Drug Development

Bionorica SE is one of the leading companies in the area of phytopharmaceuticals worldwide. The product range focuses mainly on diseases of the respiratory tract, urinary tract, gynaecological disorders. Phytoneering combines the huge potential of natural active substances (phytos) with the knowledge and methodology of modern pharmaceutical research (engineering) in order to develop efficient and safe preparations.

BioNTech SE - Munich Small Molecules

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Immune Therapy, Medicinal Chemistry, in silico Predictions, Analytics, Preclinical Research, Oncology

The department Munich Small Molecules (MSM) of BioNTech SE is focused on the identification and chemical synthesis of new molecular entities which can be used for therapeutic interventions, especially in the field of immune oncology. BNT411, the most advanced compound has entered clinical phase I in July 2020. MSM contains all important research units to support BioNTech's demands in computer-based hit finding, lead optimization, chemistry, analytics as well as toxicology and pharmacokinetics.



Am Klopferspitz 19 a
D-82152 Martinsried
Phone: +49 (0) 89 8188802-0
Internet: www.biontech.de

Biontexas Laboratories GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Nanobiotechnology, Gene Therapy, RNAi & Antisense, Liposomes, Gene Transfer, Fine Chemicals/Reagents

Biontexas Laboratories GmbH is an innovative biotech company with focus on transfection technology, covering the introduction of genetic material and proteins into eukaryotic cells by synthetically produced carrier systems. Current research focuses on the development of completely new strategies for maximising the transfection efficiency for all cell types in vivo or in vitro by utilising synthetic carrier components free from immunological effects.



Landsberger Str. 234
D-80687 München
Phone: +49 (0) 89 324799-50
E-Mail: contact@biontexas.com
Internet: www.biontexas.com

Bio-Rad Laboratories GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Chip/Array Technology, Peptide/Protein, Proteomics, Genomics, Gene Transfer, Laboratory, Antibody Production Service

Bio-Rad was founded in 1952. The headquarter is in Hercules, California. Today, Bio-Rad products are used in hospitals, universities, major research institutions, biotechnology companies, reference laboratories, pharmaceutical firms and classrooms around the world. Bio-Rad's key competencies incl. separation, purification and analysis. The company is a leader in electrophoresis, protein assays, gel image analysis, quality controls, diabetes monitoring, autoimmune testing, blood typing and BSE.



Kapellenstr. 12
D-85622 Feldkirchen
Phone: +49 (0) 89 31884-0
E-Mail: info@bio-rad.de
Internet: www.bio-rad.com

Biosepar Ges. für Medizin- und Labortechnik mbH

PHARMA ANIMAL HEALTH

BIOSEPAR is driving excellence in sample preparation for parasitologic diagnostics since 1987. With the vision to make parasitologists' life easier, BIOSEPAR has revolutionized parasitological stool diagnostics with standardized, hygienic, ready-to use kits and non-toxic, environmentally friendly reagents in both, human and veterinary medicine. The flagship product ParasiTrap[®] was followed by FixSepar[®] ECO and while increasing its global reach the company continues driving innovation.



Am Industriepark 2A
D-84453 Mühldorf
E-Mail: mail@biosepar.de
Internet: www.biosepar.de



Winkl 4
D-84378 Dietersburg
Phone: +49 (0) 8565 964961
Internet: www.biophyll.com

Biophyll GmbH

PHARMA SUPPLIER AND TRADE

Biophyll has over 25 years of experience in sourcing and manufacturing of biological products of animal, human, and plant origin. We assess the specific needs of our customers to provide tailored product solutions for pharmaceutical, diagnostic, and scientific purposes. - Access to new and rare biological products sourced worldwide - Supply of quality and traceability documentation - Regulatory support in import, export, and registration matters - Individually designed transport logistics concepts.



Konnereuther Straße 6g
D-95652 Waldsassen
Phone: +49 (0) 9632 9248325
E-Mail: josef.scheiber@biovariance.com
Internet: www.biovariance.com

bioVariance GmbH

BIOTECH BIOINFORMATICS

Keywords: Genomics, Bioinformatics, Personalized Medicine, Biomarker Discovery & Development, Informatics, Pharmacogenomics, NGS

BioVariance GmbH offers biomedical data analyses and related software development in the area of precision medicine for the healthcare, pharma and biotech sector. To accelerate the data analytics, we use special algorithms and machine learning to automate complex analytical processes in a customized software pipeline and to develop prediction models. We develop user-friendly interfaces including mobile apps to simplify data collection, processing, visualization and research.



Obere Hauptstr. 10 b
D-85386 Eching
Phone: +49 (0) 89 3799666-6
E-Mail: info@biozol.de
Internet: www.biozol.de

BIOZOL Diagnostica Vertrieb GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Antibody, Peptide/Protein, ELISA/EIA, Proteomics, Small Molecules, Clinical Diagnostics

BIOZOL Diagnostica Vertrieb GmbH markets and distributes products for immunology, cell biology, molecular biology, biochemistry and human and veterinary diagnostics, such as antibodies, recombinant proteins, ELISA/EIA, detection kits, biochemicals and further reagents for cell culture, flow cytometry, immunohistology and cytogenetics. The company represents almost 50 different worldwide known suppliers in Germany. Biozol offers additionally different types of services such as free product search.



Arnulfstr. 29
D-80636 München
Phone: +49 (0) 89 12142-0
E-Mail: info-bms-germany@bms.com
Internet: www.bms.com/de

Bristol-Myers Squibb GmbH & Co. KGaA

PHARMA & CHEMICAL INDUSTRY

Keywords: Oncology, Autoimmune Diseases, Cardiovascular Diseases, Rheumatoid Arthritis, Hematology

Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Around the world, our medicines help millions of people in their fight against diseases such as cancer, cardiovascular disease and rheumatoid arthritis.

BSL BIOSERVICE

Scientific Laboratories Munich GmbH

CRO



Keywords: Toxicology, Pharmacology

BSL BIOSERVICE is an internationally active Contract Research Organization. We are offering biological testing services for Pharmaceuticals, Chemicals and Medical Devices. A high degree of customer orientation, high quality and flexibility are core values of our corporate philosophy. A experienced team guarantees acceptance by authorities and supports customers from research until finalization. BSL is certified in accordance with GLP/GMP. We are listed by the WHO and been audited by the FDA.

Behringstr. 6 / 8
D-82152 Planegg-Martinsried
E-Mail: info@bioservice.com
Internet: www.bioservice.com

Carl Zeiss Microscopy GmbH

BIOTECH DNA/PROTEIN ANALYTICS



Keywords: Imaging, Molecular Diagnostics, Clinical Diagnostics, Microscopy, Tissue Engineering/Cell Culture, Toxicology, Genomics

ZEISS Research Microscopy Solutions is the world's only one-stop manufacturer of light, electron, X-ray and ion microscope systems and offers solutions for correlative microscopy. The portfolio comprises of products and services for life sciences, materials and industrial research, as well as education and clinical practice. The unit is headquartered in Jena. ZEISS Research Microscopy Solutions is part of the Industrial Quality & Research segment.

Seeing beyond

Kistlerhofstr. 75
D-81379 München
Phone: +49 (0) 89 909000-800
E-Mail: microscopy@zeiss.com
Internet: www.zeiss.com/microscopy

CASCAT GmbH

INDUSTRIAL BIOTECHNOLOGY / CHEMICAL INDUSTRY



CASCAT researches and develops processes for the production of chemicals based on chemical-enzymatic reactions. One focus is the use of renewable resources as a base. The own implementation of these processes as well as working with partners in this case represents the preferred choice of the company. In addition, the consultation of third parties in matters of biotechnology, biocatalysis, renewable resources, sustainability and bioeconomy is a main focus.

Europaring 4
D-94315 Straubing
Phone: +49 (0) 9421 7855 20
Internet: www.cascad.de

CatalYm GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS



Keywords: Drug Development, Oncology

CatalYm is developing innovative immunotherapies to transform cancer patients lives by effectively engaging their own immune systems to combat this malignant disease. Targeting novel mechanisms that lead to a potent and sustained activation of the immune system within the tumor microenvironment, CatalYms goal is to ridly bring its next-generation immuno-oncology products to patients in need.

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 2000 664-40
E-Mail: info@catalym.com
Internet: www.catalym.com



Joseph-Wild-Str. 20
D-81829 München
Phone: +49 (0) 89 451519-010
E-Mail: info@celgene.de
Internet: www.celgene.de

Celgene GmbH - a BMS company

PHARMA & CHEMICAL INDUSTRY

Keywords: Oncology, Drug Delivery, Hematology, Small Molecules, Drug Development

Celgene is a globally acting biopharmaceutical company, founded in New Jersey (USA) in 1986. Celgene is mainly active in developing and distributing drugs in hematology, oncology and immunotherapy. Since 2006, Celgene operates a German subsidiary in Munich-Riem. For further information visit: www.celgene.de

cellasys

Illerstrasse 14
D-87758 Kronburg
Phone: +49 (0) 8394 257929
E-Mail: info@cellasys.com
Internet: www.cellasys.com

cellasys GmbH

BIOTECH DEVICES & REAGENT

Keywords: R&D Service, Bioanalytics, Laboratory, In-Vitro-Diagnostics, Biochips, Devices, Toxicology

cellasys delivers systems for microphysiometry. Microphysiometry measures the functions and activities of life or of living matter and of the physical and chemical phenomena involved. The technology is used to monitor changes in the metabolism and the morphology of living cells in real-time. Its applications range from basic research to risk assessment. cellasys offers all services around installation & maintenance as well as contract research.



Lindemannstraße 13
D-82327 Tutzing
Phone: +49 (0) 8158 9064010
E-Mail: info-celltool@celltool.de
Internet: www.celltool.de

CellTool GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Devices

CellTool is a company that develops, manufactures and distributes Raman laser microscopes for single cell analysis in suspension, tissue and organoids, 2D and 3D. Multi-omics read out from functional genomics to functional metabolomics (DNA, proteins, lipids, sugars, small molecules).



Am Kleinfeld 11
D-85456 Wartenberg
Phone: +49 (0) 8762 7243-00
E-Mail: info@centronic-gmbh.com
Internet: www.centronic-gmbh.com

Centronic GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Analytical Chemistry, Medicinal Chemistry, In-Vitro-Diagnostics, Clinical Diagnostics

Centronic GmbH is a German manufacturer and distributor of a big range of high qualitative clinical chemistry and immunoturbidimetric reagents for the medical diagnosis of enzymes, electrolytes, substrates, lipids and specific proteins. The portfolio is completed with corresponding controls, calibrators, Latex and Salmonella reagents and cleaning solutions for many analysers. Our Quality Management System is certified according EN ISO 13485:2016 by the TÜV.

Cfm Oskar Tropitzsch GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Pharmacology, AntibodyDrugConjugate ADC, Antibiotics,
Natural Compounds, Drug Development, Drug Delivery, Fine Chemicals/Reagents

We support the chemical, pharmaceutical and biotechnological industry in the procurement and production of chemical specialties. We deliver the product with the right documentation, the right quantity and quality - for projects from RnD stage to commercial production.

Our products: ADCs, Metals and Metal Compounds, Fermentation, Medicinal Plants, Phytochemicals, Toxins, Pharmaceutical Products, Laboratory Chemicals, Contract Fermentation, Enzymatic Development Projects, Tailor Made Enzymes.



Oskar Tropitzsch

Adalbert-Zoellner-Str. 1
D-95615 Marktredwitz
Phone: +49 (0) 9231 9619-0
E-Mail: info@cfmot.de
Internet: www.cfmot.de

Charles River Laboratories, Research Models and Services, Deutschland GmbH

CRO

Keywords: Drug Delivery

At Charles River, we understand that the quality of our research models has a direct impact on what truly matters to you - your research. With our core programmes - biosecurity, international standardisation, animal welfare and model quality - you can focus on your work while being assured that you are receiving the highest quality and most reliable models for your research. From standard and disease-specific models to surgically altered animals, you can trust us to be an integral part of your research programmes - now and in the future.



Sandhofer Weg 7
D-97633 Sulzfeld
Phone: +49 (0) 9761 406 0
Fax: +49 (0) 9761 406 60
E-Mail: dbestell@de.crl.com
Internet: www.criver.com

Cherry Biolabs GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Cherry Biolabs GmbH has developed a novel antibody-based platform technology for the treatment of cancers, not amenable by current immune therapies. This is achieved by the combination of two complementary antibody fragments (hemibodies) that assemble on target and thus specifically tag tumor cells for lysis by the patients killer T cells. While distinct hemibody-combinations against certain tumor types have already been identified, the platform is continuously expanded.



Friedrich-Bergius-Ring 15
97076 Würzburg
Phone: +49 (0) 931 201 444 23
E-Mail: info@cherrybiolabs.com
Internet: www.cherrybiolabs.com



ChromoTek GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Antibody, Proteomics, Imaging, Laboratory

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 124 148 8 - 0
E-Mail: info@chromotek.com
Internet: www.chromotek.com

ChromoTek is an internationally growing life science tools company based in Martinsried, Germany's leading biotech cluster. We are part of the international Proteintech Group in Illinois, USA. As a group, we produce and distribute more than 15,000 antibodies, nanobodies, bioactive proteins and kits under the Proteintech, ChromoTek and HumanKine brands. All products meet the highest standards of validation and quality control. With more than 130,000 scientific publications, our products set new standards for research applications. Technical know-how and first-class service are our hallmarks.



Cipla Europe NV

PHARMA & CHEMICAL INDUSTRY

Inselkammerstraße 4
D-82008 Unterhaching
Phone: +49 (0) 89 6242208 10
E-Mail: europe@cipla.com
Internet: www.cipla.com

Cipla Europe NV, a 100% subsidiary of Cipla Limited, has presence in several countries in Europe through its partners and own network. Cipla is focused on offering a new pharma concept built on layers of value such as newer products, concepts, formats, information and services to help healthcare providers across Europe.

Cipla offers a range of products in Europe – Respiratory, HIV, Vaccines, OTC, API, Plain Generics and Hospital products.



Clariant Produkte (Deutschland) GmbH, Group Biotechnology

PHARMA & CHEMICAL INDUSTRY

Semmelweisstraße 1
D-82152 Planegg b. München
Phone: +49 (0) 89 710 661-0
E-Mail: biotech@clariant.com
Internet: www.clariant.com

Keywords: New Materials, Agrobiotechnology

Clariant is an internationally active specialty chemical company based in Muttenz, Switzerland. Clariant focuses on creating value by investing in future profitable and sustainable growth. The main focus of Clariant Group Biotechnology is on bio-catalysis and bio-refining. The company develops sustainable products and processes for bio-based chemicals and fuels. Clariant has developed a process which uses enzymatic hydrolysis followed by fermentation to produce cellulosic ethanol from agricultural residues.



Climeddo Health GmbH

BIOTECH BIOINFORMATICS

Schellingstr. 109a
D-80798 München
Phone: +49 (0) 89 32209394 0
E-Mail: info@climeddo.de
Internet: www.climeddo.de

Keywords: Automation, Cell Therapy, Oncology, Clinical Trial Management and Monitoring, Devices, Regulatory Affairs, Data Management

Climeddo offers a digital platform for conducting clinical trials in an innovative way. The modular and user-friendly solution for Electronic Data Capture (EDC) enables pharmaceutical and medical device companies to efficiently validate their products and medical innovations in a decentralized and patient-centric way. By digitally connecting all parties involved, (sponsors, doctors and patients) saves time and money while improving data quality.

Clinrex GmbH

CRO

Clinrex was founded in 2004 by Dr. Dagmar Chase to offer consulting services and training in the of areas GCP, Quality Management and Project Management for clinical trials. GCP/Quality Management Consulting - GCP gap analyses - Inspection readiness/ Audits - SOP development/streamlining - Interface sponsor/CRO - Investigator Initiated Trials (IITs) Training (Smart Training® or customised in-house training) - GCP for Sponsors, CROs or On-site Personnel - Project Management/Working with CROs - NIS.



Clinrex GmbH
your clinical research experts

PF 1223
D-85572 Neubiberg
Phone: +49 (0) 89 9292 87-0
E-Mail: info@clinrex.com
Internet: www.clinrex.com

COLORIMETRIX GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Colorimatrix GmbH - The lab in your pocket - We turn any smartphone into a portable laboratory using its camera to read diagnostic tests at home. No hardware needed, iOS and Android compatible, very competitive pricing, cloud analytics, trends, insights on the measurements, etc. Check out our first products: <https://pearlfertility.app> and <https://covidrapidtest.app> - happy to discuss opportunities, info@colorimatrix.com.

COLORIMETRIX

Oskar-von-Miller-Ring 20
D-80333 München
E-Mail: contact@colorimatrix.com
Internet: www.colorimatrix.com

Conreso GmbH

CRO

Keywords: Vaccines, Data Management and Biostatistics, veterinary clinical trials, Devices, Oncology, Infectious Diseases, Clinical Trial Management and Monitoring

Conreso, established in 1990, BVMA member, CIR accredited, offers consulting and operational clinical development services, including clinical, non-interventional and epidemiological studies for pharmaceuticals, vaccines, medical devices and IVDs. Your need for temporary insourcing can be met with the permanent permission to temporarily lend staff. We serve as "Legal Representative" for non-EU sponsors. We also offer courier services for escorted time and temperature sensitive shipments.

conreso

Neuhauser Str. 47
D-80331 München
Phone: +49 (0) 89 236650-0
E-Mail: info@conreso.com
Internet: www.conreso.com

Coriolis Pharma Research GmbH

CRO

Keywords: Peptide/Protein, Antisense/Nucleotides, Vaccines, Antibody, Viruses, Drug Development, R&D Service

Coriolis is a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs and vaccines, including proteins, peptides, RNA/DNA, viral vectors and ATMPs (up to BSL-2). Coriolis is highly experienced in biopharmaceutical characterization by using innovative and state of the art analytical technologies to support trouble-shooting, higher order structure characterization, particle identification, GMP release and more.

 **Coriolis Pharma**
Biopharmaceutical Research and Development Service

Fraunhoferstr. 18b
D-82152 Martinsried
Phone: +49 (0) 89 41 77 60-0
E-Mail: contact@coriolis-pharma.com
Internet: www.coriolis-pharma.com



CRELUX GmbH - a WuXi AppTec company

BIOTECH PRECLINICAL SERVICES

Am Klopferspitz 19 a
D-82152 Martinsried
Phone: +49 (0) 89 700760-0
E-Mail: crelux_office@wuxiappotec.com
Internet: www.crelux.com

Keywords: Peptide/Protein, R&D Service, Small Molecules, 3D-Structural Analysis

CRELUX, a WuXi AppTec company, is a provider of high-quality solutions for early stage drug development, supporting 1000+ partners from global pharma to biotech and academic institutions. As part of the WuXi AppTec HitS platform, CRELUX contributes a portfolio of state-of-the-art and cost-effective hit-to-lead technologies, including high quality protein production, fragment and DEL (DNA-Encoded Library) screening, biophysical validation and structural characterization (crystallography, cryo-EM).



CRI – The Clinical Research Institute GmbH

CRO

Arnulfstraße 19
D-80335 München
Phone: +49 (0) 89 9901649-0
E-Mail: info@cri-muc.eu
Internet: www.cri-muc.eu

Keywords: Clinical Trial Management and Monitoring; Data Management and Biostatistics; Logistics; Pharmacovigilance; Regulatory Affairs; Clinical Studies; Medical devices; Post-Marketing Surveillance; Post-Market Clinical Follow-up

We are a full-service Contract Research Organization for clinical studies - controlled trials and observational studies - in all medical indications. We perform clinical projects primarily within Europe with currently >500 contracted hospitals in about 25 countries.

The special competence of our 50+ team is large-scaled non-commercial trials, studies with medical devices, and supportive IT solutions like App-based follow-up of patients or data exchange with remote clinical monitoring services.



CROMSOURCE GmbH

CRO

Zeppelinstr. 71-73
D-81669 München
Phone: +49 (0) 89 45835 508
E-Mail: jorge.garcia@cromsource.com
Internet: www.cromsource.com

Keywords: Pharmacovigilance, Regulatory Affairs, Medical Writing, Devices, Drug Development, Clinical Trial Management and Monitoring, Data Management and Biostatistics

CROMSOURCE is an ISO-certified international provider of outsourced services to the pharmaceutical, biotechnology and medical device industries, specialized in clinical development and staffing solutions. A well-established full-service CRO, CROMSOURCE is unique in offering an end-to-end guarantee covering trial timelines, enrolment and contract price. This guarantees our clients that their trials are delivered on time and within the contract price with no CRO initiated change orders. CROMSOURCE supports the full spectrum of clinical development via our Pharmaceutical, Medical Device, and Staffing Solutions divisions.

Cryondo GmbH

OTHER SERVICES

Keywords: Logistics

CRYONDO offers the (back-up) storage of biological/medical samples, reagents and retained samples. The samples can be stored at temperatures from -196 °C to room temperature, secured by a 3D security concept. Cryondo is certified according to DIN EN ISO 9001 and has the permits to store for instance samples of genetically modified organisms or samples that are subject to infection protection. In addition, Cryondo offers various services, logistics and products around cryo storage.



Schlosserstr. 4
80336 München
Phone: +49 (0) 89 / 540435-72
E-Mail: info@cryondo.de
Internet: www.cryondo.de

CryoShop

OTHER SERVICES

Keywords: Logistics

SUPPLIER FOR LIQUID NITROGEN EQUIPMENT CryoShop is Munich based consulting and trading company specialising in the field of cryogenic and cold storage applications. CryoShop is offering value added cryogenic solutions. Our portfolio allows us to provide products and solutions along the cryopreservation (standardized) workflow: from preanalytical sample preparation, controlled rate (cell)freezing, temperature controlled transport, cryogenic archiving to controlled/automated thawing devices. Furthermore we are offering special cryogenic personal protective equipment.



WerkStadt Sendling / Haus 2
Flößergasse 4
D-81369 München
Phone: +49 (0) 89 63 899 012
Fax: +49 (0) 89 892 94 31
E-Mail: einfachcool@cryoshop.de
Internet: www.cryoshop.de

CSO Pharma Consulting GmbH

CRO

Keywords: Pharmacology, Data Management, Regulatory Affairs, Pharmacovigilance, Medical Writing, Laboratory

CSO Pharma provides reliable pharmacovigilance services, professional medical affairs support and successful QM/GDP consulting.

We run our own quality management system and offer our customers reliable services and processes based on international standards. You can benefit from our extensive experience from audits and inspections and our comprehensive knowledge of present legal requirements.



Bachbauernstrasse 1
D-81241 München
Phone: +49 (0) 89 20335359
E-Mail: info@cso-pharma.eu
Internet: www.cso-pharma.eu

Curadis GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

The pharmaceutical start-up company located in Erlangen/Regensburg researches and develops steroidal medicines for breast cancer and benign enlargement of the prostate gland. Curadis GmbH was founded in 2008 in Erlangen and has S-Refit AG of Regensburg as one of its investors. The company is developing a novel substance for breast cancer and a substance for prostate cancer.



Merianstraße 26
D-90409 Nürnberg
Phone: +49 (0) 700 - 1447 1447
E-Mail: info@curadis.eu
Internet: www.curadis.eu



An der Rehwiese 20
D-81375 München
Phone: +49 (0) 89 30725921
E-Mail: info@cytophorics.com
Internet: www.cytophorics.de

Cytophorics GbR

BIOTECH DEVICES & REAGENTS

Keywords: Molecular Diagnostics, Devices, Chip/Array Technology, In-Vitro-Diagnostics

The Cytophorics technology enables a variety of applications in the pharmaceutical industry, clinical diagnostics and basic research. Wherever a living cell sample is in interest of investigation, the patented sensor-equipped multi-well plate is able to capture high quality, relevant vital data in real time. The integrated fluidic system allows long-term studies for all kind of cell based assays. The main areas of interest are in personalized medicine in drug developing and in research to investigate basic cell mechanisms.



Gottlieb-Keim-Str. 60
D-95448 Bayreuth
Phone: +49 (0) 921 1511-254
E-Mail: info@cytox.de
Internet: www.cyttox.de

CYTOX, biologische Sicherheitsprüfungen

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, ELISA/EIA, Toxicology, Tissue Engineering/Cell Culture

CYTOX provides biological testing service for the medical device and pharmaceutical industry by using in vitro toxicological testing procedures according to ISO 10993 as well as FDA-compliant processes. Next to classical 2D cell culture testing systems we use organotypical 3D cell culture systems especially in the area of skin irritation testing and REACH applications.



Zielstattstr. 48
D-81379 München
Phone: +49 (0) 89 7808-0
E-Mail: service@daiichi-sankyo.eu
Internet: www.daiichi-sankyo.eu

DAIICHI SANKYO EUROPE GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Cardiovascular Diseases, Oncology, AntibodyDrugConjugate ADC

Daiichi Sankyo and its 15,000 employees in more than 20 countries are dedicated to the creation and supply of innovative pharmaceutical therapies. In addition to a strong portfolio of medicines for cardiovascular diseases, the Group's 2025 vision is to become a Global Pharma Innovator with Competitive Advantage in Oncology. Our European headquarters are in Munich, Germany and we have affiliates in 13 European countries.



Neuhauserstraße 25
D-80331 München
E-Mail: info@dm-matrix.com
Internet: www.dm-matrix.com

Data Matrix GmbH

CRO

Keywords: Data Management and Biostatistics, Medical Writing

Data MATRIX was established in 2014. With its high-quality software products and professional team Data MATRIX has already successfully completed over 200 projects. Our products automate the processes of clinical trials, and users manage and monitor its progress online. We adjust and validate our software before the project starts in order to do it in the best way. With Data MATRIX products, 6 out of 10 TOP Big Pharma companies reduced their R&D costs by 15%.

Dauids Biotechnologie GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Allergy, Immune Therapy, Antibody, Proteomics, ELISA/EIA, Tissue Engineering/Cell Culture, Antibody Production Service

High quality polyclonal and monoclonal antibody production in Germany with ecological methods from the beginning in since 1996. We offer you all services from the antigen design and production to the immunization and purification of the antibodies from sera and cell culture supernatants. The development of monoclonal antibodies with your antigen including the production and purification of your antibodies. 3D-Organoid-Cell-Cultures as in-vitro replica of immune systems for the determination of personalized activity of immune modulators and for the determination of the activity of substances on the human immune system in vitro. Extraction and chromatography of proteins, nucleic acids, conjugates and other molecules. Most methods under physiological conditions.



Roentgenstr. 3
D-93055 Regensburg
Phone: +49 (0) 941 948 228
E-Mail: info@dabio.de
Internet: www.dauids-bio.de

DelphiTest GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Laboratory, Clinical Diagnostics, Genomics, PCR, Analytical Chemistry

The company's core technology capitalizes on the revolutionary development of DNA analysis, DNA sequencing and DNA fragment analysis. Delphitest focussed on family relationship testing and has an ISO/IEC17025 accreditation. Additional services are paternity tests and genetic tests for dogs, as well as some antibody tests for humans and dogs. Delphitest provides its high level of competence in DNA techniques to scientific partners like universities, hospitals or pharmaceutical companies in Europe.



Unter den Schwibbögen 23
D-93047 Regensburg
Phone: +49 (0) 941 2986615
E-Mail: info@delphitest.de
Internet: www.delphitest.de

Denk Pharma GmbH & Co. KG

PHARMA & CHEMICAL INDUSTRY

In a global world it is difficult to know where a product is manufactured. Therefore all Denk Pharma products are: # Manufactured in Germany # Quality controlled in Germany # Registered in Germany.

Denk Pharma, Munich, Germany (www.denkpharma.de) is a globally operating pharmaceutical company with focus on development and marketing of innovative medicine for therapy of infectious and inflammatory disease and broad range generic portfolio. Denk Pharma was founded in Munich, Germany in 1948.



Prinzregentenstraße 79
D-81675 München
Phone: +49 (0) 89 2300 29-0
E-Mail: mathias.seidel@denkpharma.de
Internet: www.denkpharma.de



DEOXY GmbH

BIOTECH

Keywords: In-Vitro-Diagnostics, Clinical Diagnostics, Molecular Diagnostics, Genomics, Microscopy, Nanobiotechnology

Prinzregentenplatz 15
81675 München
Phone: +49 (0) 89 2180 5301
E-Mail: info@deoxy.bio
Internet: www.deoxy.bio

DEOXY develops nanometer-scale, DNA-based barcodes for quantitative and ultra-sensitive detection of biomolecules with applications in research and clinical diagnostics.



DiaServe Laboratories GmbH

BIOTECH DEVICES & REAGENTS

DiaServe is a primary manufacturer of human and animal blood derived raw materials for diagnostic industry. Based on this raw materials DiaServe also offers tailor-made in vitro controls/calibrators for medical laboratories.

Seeshaupter Str. 27
D-82393 Iffeldorf
Phone: +49 (0) 8856 80360
E-Mail: contact@diaserve.de
Internet: www.diaserve.de

The company was established in 1997 with a mission to identify, develop and manufacture in vitro diagnostics mainly on OEM basis for diagnostic manufacturers and clinical laboratories.



Dojindo EU GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Fine Chemicals/Reagents

Leopoldstr. 254
D-80807 München
Phone: +49 (0) 89 3540-4805
E-Mail: info@dojindo.eu.com
Internet: www.dojindo.eu.com

Dojindo produces over 500 well-known products used by research organizations in the world. Dojindo strives to expand its ability to analyze the future direction of science by maintaining continued interest in new research activities as well as improving its information-gathering network. Dojindo is ready for offering state-of-the-art products because our creative researchers are working continuously to meet tomorrow's research needs.



DoNatur GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Rheumatoid Arthritis

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 856625-55
E-Mail: info@donatur.de
Internet: www.donatur.de

DoNatur GmbH develops new therapeutics from herbal extracts with traditionally confirmed therapeutic efficiency. The comprehensive analysis of the genuine extracts, the isolation and structural characterization of the active substances and the test of their pharmacological activities constitutes the main competence of the company. Over the last years DoNatur has successfully developed a new immunomodulatory acting natural substance which has been proved highly efficacious for the therapy of rheumatic diseases.

Dr. Nibler & Partner

CRO

Keywords: Medical Writing, Pharmacology, Devices, Drug Development

We provide a complete pharmacovigilance full-service solution: 24-hours availability - Literature screening and -review - Data entry and MedDRA coding - Scientific assessment by experienced physicians - Authority reporting - SUSAR reporting - Periodic reports: ASR, DSUR, PSUR - Risk management plans - Implementation of pharmacovigilance systems - Audits and guidance through inspection.



Fürstenriederstr. 105
D-80686 München
Phone: +49 (0) 89 56823726
E-Mail: mail@dr-nibler.de
Internet: www.dr-nibler.de

Dr. Pflieger Arzneimittel GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Dermatology, Pain, Drug Development

Dr. Pflieger Arzneimittel GmbH is a medium-sized pharmaceutical company with 350 employees and a sales turnover of nearly 100 million EUR. Dr. Pflieger markets non-prescription and prescription medicines for indications in urology, gynecology, dermatology and areas of self-medication in Germany and selected territories worldwide. The financial surpluses generated by the company are passed onto the Doktor Robert Pflieger-Stiftung.



Dr.-Robert-Pflieger-Str. 12
D-96052 Bamberg
Phone: +49 (0) 951 6043-0
E-Mail: info@dr-pflieger.de
Internet: www.dr-pflieger.de

Dynamic Biosensors GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Antibody, Proteomics, Small Molecules, Peptide/Protein, Chip/Array Technology, Drug Development, Devices

Dynamic Biosensors is a provider of instruments, consumables, and services in the field of analytical systems for the characterization of biomolecules and molecular interactions.

The company commercializes the switchSENSE® technology, a groundbreaking platform technology for the analysis of biomolecules with applications in R&D and drug development. The switchSENSE® technology is protected worldwide and only available through Dynamic Biosensors.



Lochhamerstr. 15
D-82152 Martinsried
Phone: +49 (0) 89 897 4544-0
E-Mail: info@dynamic-biosensors.com
Internet: www.dynamic-biosensors.com

Ebenbuild GmbH

DIGITAL HEALTH

Keywords: Personalized Medicine, Respiratory Diseases, Pneumology, Biomarker Discovery & Development, Informatics, Imaging, R&D Service

Leveraging more than 15 years of bleeding edge research at TUM, we use these patient-specific models to predict and optimize therapy both in clinical as well as R&D settings in MedTech/Biotech/Pharma.

Our use cases span digital trials in pulmonary drug delivery, image-based biomarker tracking in clinical trials, and on-site critical care decision support.



Schinkelstraße 44
c/o Dr. Kei Müller
D-80805 München
Phone: +49 (0) 89 289 15265
E-Mail: info@ebenbuild.com
Internet: www.ebenbuild.com/index.html



Am Klopferspitz 19
D-82152 Martinsried
Internet: www.eisbach.bio

Eisbach Bio GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Eisbach Bio develops novel drugs that disrupt molecular machines essential to tumors with defined genetic vulnerabilities in the context of DNA damage and repair (DDR) pathways. Its proprietary platform creates targeted therapies that exploit disease-relevant vulnerabilities. By shutting off the machine's engine using allosteric inhibitors, their impactful medicines prevent thereorganization and evolution of cancer genomes. Founded in 2019, Eisbach is privately held and backed by international investors.



Semmelweisstraße 3
D-82152 Planegg
Phone: +49 (0) 89 3249 3670
E-Mail: info@electrochaea.com
Internet: www.electrochaea.com

Electrochaea GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Electrochaea delivers a technology to produce synthetic methane, a fuel that replaces fossil natural gas, and can be stored and transported in the existing gas grid. Electrochaea's patented process combats climate change by recycling of CO₂, producing a renewable fuel, and providing a solution for large scale energy storage. The company is planning to deploy its technology with partners to produce more than 15 billion cubic feet per year of renewable natural gas by 2025. Industrial-scale pilot plants have operated in the U.S., Switzerland, and Denmark.



Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 7093 9316
E-Mail: info@ellabiotech.com
Internet: www.ellabiotech.com

ELLA Biotech GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Antisense/Nucleotides, Genomics, RNAi & Antisense, Chip/Array Technology, PCR, In-Vitro-Diagnostics

Our expertise is the synthesis of special oligoribonucleotides for random mutagenesis, in-vitro diagnostics, epigenetic sequencing, Aptamer technology and many more following quality standards which you would appreciate and expect in your own lab. Through our validated technology platform, our experienced interdisciplinary team and our resolute attitude towards the highest quality in our products we offer tangible advantages to our customers and partners.



Am Morgenroth 6
D-97246 Eibelstadt
Phone: +49 (0) 9303 984 964
E-Mail: service@emfret.com
Internet: www.emfret.com

EMFRET Analytics GmbH & Co. KG

BIOTECH DEVICES & REAGENTS

emfret Analytics GmbH (founded 2002) is focussing on production, characterization, derivatization and supply of monoclonal antibodies in biomedical research, namely vascular biology.

EMP Genetech

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Drug Development, Biomarker Discovery & Development, R&D Service

EMP Genetech is a CDMO in the field of recombinant protein production. Recombinant proteins are expressed from mammalian cells. We develop stable high producer cell lines mainly of human (HEK293 EBNA) origin cells. Protein production is conducted by bioreactor driven high cell cultivation up to 10 L scale with serum free conditions. Gene cloning and single cell clone selection as well as downstream processing are well established methods in our lab. We work successfully since 2000.

EMP Genetech
RECOMBINANT PROTEIN EXPRESSION

Straussenlettenstrasse 7b
D-85053 Ingolstadt
Phone: +49 (0) 841 3796013
E-Mail: info@empgenetech.com
Internet: www.empgenetech.com

EpiGene GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Genomics

EpiGene GmbH is a genomics-based research and development company focusing on applications in plant protection. The core competences comprise the molecular characterization of plant-pathogen interactions and the development of high throughput systems for molecular diagnostics of involved genetic factors. In addition, research efforts include investigations of the mode of action of plant protective agents and the identification of mutations or differentially expressed genes in pathogens as potential new targets.

EPIGENE

Hohenbachernstr. 19-21
D-85354 Freising
Phone: +49 (0) 8161 4990-80
E-Mail: Friedrich.Felsenstein@EpiLogic.de
Internet: www.epigen.de

EpiQMax GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: R&D Service, Clinical Diagnostics, Molecular Diagnostics, Proteomics, Personalized Medicine

Since 2018, EpiQMax is a partner for the development of epidrugs and biomarker research in the epigenetic and proteomic field. Headquartered nearby Munich, we operate a state-of-the-art mass spectrometer to facilitate epigenetic screenings into clinical applications. Our technology platform comprises a KIT for quick sample preparation, a mass spectrometer for a unique quantitative analysis of modifications and software programs for intuitive and visual reporting of the results.

EpiQMax

Am Klopferspitz 19
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 2153 5730
E-Mail: info@epiqmax.de
Internet: www.epiqmax.com

essentim GmbH

BIOTECH DEVICES & REAGENTS

essentim sensors provide a scalable method for secure data acquisition and real-time monitoring of temperature, pressure, humidity, motion, light and many other variables. Benefit from fast implementation, transparent monitoring and digital documentation. Do you need a scalable solution for sensors, cloud-based apps and web technology? We realize your IoT projects, from hardware to software, from sensors to gateway technology and apps for smartphones and web.

essentim 
essential improvement.

Schragenhofstraße 35
D-80992 München
Phone: +49 (0)1608093076
E-Mail: info@essentim.com
Internet: www.essentim.com



Semmelweisstrasse 3
D-82152 Planegg
Phone: +49 (0) 89 8955 788-0
E-Mail: info@ethris.com
Internet: www.ethris.com

ethris GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Metabolic Diseases, Dermatology, Bone/Joint Diseases, Gene Therapy, Gene Transfer, Tissue Engineering/Cell Culture, Drug Development

Ethris has paved a new path from genes to therapeutic proteins using its proprietary, non-immunogenic messenger RNA technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, we are a global leader in delivering stabilized mRNAs directly to the respiratory system via optimized formulation and nebulization technologies. We are advancing our pipeline of immuno-modulation and mRNA-based protein replacement therapies with the ultimate goal of improving patients' lives.



Landsberger Str. 406
D-81241 München
Phone: +49 (0) 89 12 59 81-0
E-Mail: info@eticur.de
Internet: www.eticur.de

eticur) GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Cell Therapy

Based on the idea that umbilical cord blood contains multipotent adult stem cells, the cord blood is prepared and stored for potential later use. These cells might in future play an important role in therapies including regenerative medicine. eticur) grants the storage of stem cells following the highest quality-standards of the Federal Board of Physicians and the Institute for Sera and Vaccine (Paul-Ehrlich-Institute) and extensive testing by highly qualified personnel.



Behringstr. 6/8
D-82152 Martinsried
Phone: +49 (0) 89 899650-0
E-Mail: info-munich@eurofins.com
Internet: www.eurofins.de

Eurofins BioPharma Product Testing Munich GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Pharmacology, Small Molecules, Bioanalytics, Laboratory, Medicinal Chemistry, Toxicology

Eurofins BioPharma Product Testing Munich is part of the world's largest network of testing laboratories providing comprehensive laboratory services to pharmaceutical, biopharmaceutical and medical device companies. Certified according to GMP, GLP and ISO, Eurofins BioPharma Product Testing Munich supports its customers in the safety testing of drugs, medical devices, chemicals and cosmetics. The company was founded in 1995 and is today represented with around 400 employees in a laboratory and office space of around 14,000 sqm at Planegg near Munich.



Anzinger Straße 7a
D-85560 Ebersberg
Phone: +49 (0) 8092 8289-0
E-Mail: info-eu@eurofins.com
Internet: www.eurofinsgenomics.com

Eurofins Genomics Germany GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Genomics, NGS, PCR, Antisense/Nucleotides

Eurofins Genomics is an international provider of genomic products and services including DNA sequencing, next generation sequencing, genotyping, DNA synthesis products and bioinformatics services for pharma, diagnostics, food, agriculture, biotechnological and research markets.

Evanium Healthcare GmbH

PHARMA & CHEMICAL INDUSTRY

Evanium Healthcare develops consumer health solutions based on secondary plant compounds for the pharmaceutical industry as well as the food sector.

In addition to a platform technology for increasing the solubility of flavonoids, this also includes branded ingredients and fully developed product solutions, especially for the private label sector. The current focus here is primarily on supporting liver function and the nervous system.



Am Biopark 13
D-93053 Regensburg
E-Mail: kontakt@evanium.de
Internet: www.evanium.de

Evotec (München) GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Cell Therapy, Metabolomics, Biomarker Discovery & Development, Bioinformatics, Small Molecules, Proteomics, Genomics

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. With more than 4,000 employees globally, we provide highest quality stand-alone and integrated drug discovery and development solutions from target to clinic. Evotec (München) GmbH is the Company's centre of excellence for proteomics, biomarker and metabolomics services.



Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 4524465-0
E-Mail: info@evotec.com
Internet: www.evotec.com

ExB Health GmbH

IT, DIGITAL HEALTH

ExB Health is a subsidiary of the ExB Labs GmbH, a Germany based technology incubator and research company in the field of unstructured big data, natural language processing, Cognitive Computing and deep learning. Exb Health draws on the labs mature developments and adapts them for the use in lifescience and healthcare. The knowledge discovery and decision support systems help pharma and healthcare industries to lower costs, speed up the drug-development cycle and improve patient outcomes.



St.-Martin-Str. 63
D-81669 München
Phone: +49 (0) 89 55067340
E-Mail: contact@exb.de
Internet: www.exb-health.com

EXCELLA GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Medicinal Chemistry, Analytical Chemistry, Small Molecules, Oncology

Excella GmbH & Co. KG has been serving the pharmaceutical industry for more than 35 years with high quality API's and finished dosage forms. Focused towards high containment manufacturing Excella supplies products to the generic industry and big pharma but also develops processes for innovative API's and novel solid dosage forms. Services offered from our globally registered and approved site range from early product development through registration support to state-of-the-art manufacturing.



Nürnberger Str. 12
D-90537 Feucht
Phone: +49 (0) 9128 404-0
E-Mail: info@excella-pharma-source.de
Internet: www.excella-pharma-source.de



Feodor-Lynen-Strasse 21
D-81377 München
E-Mail: info@eximmium.com
Internet: www.eximmium.com

Eximmium Biotechnologies GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Eximmium is a new antibody company located in Munich and Singapore. By using an innovative platform technology, Eximmium focuses on identification of novel tumor targets and generation of first-in-class antibodies for both cancer therapy and diagnostics.



Semmelweisstrasse 5
D-82152 Planegg
Phone: +49 (0) 89 74032330
E-Mail: info@f-select.de
Internet: www.f-select.de

F-Select GmbH

PHARMA & CHEMICAL INDUSTRY

The element fluorine plays an increasingly important role in the field of high-performance materials and pharmaceuticals. The production of the necessary chemical substances remains a challenge and F-Select has the solution. F-Select offers selected fluorinating agents as well as a comprehensive know-how in the handling and production of fluorinating agents. The methods developed by F-Select provide resource-saving methods for the production of pharmacological building blocks.



Heimeranstr. 35
D-80339 München
Phone: +49 (0) 89 893 119-0
E-Mail: info@fgk-cro.com
Internet: www.fgk-cro.com

FGK Clinical Research GmbH

CRO

Keywords: CRO/CMO, Drug Development, Regulatory Affairs, Devices, Data Management and Biostatistics, Clinical Trial Management and Monitoring, Pharmacovigilance

FGK is a Europe-based CRO with offices in DE (HQ), PL, CZ and HU, offering full service for all phases of clinical trials. Our international client base includes biotech, medical device and pharma companies. With extensive experience in all major therapeutic areas and 150+ highly qualified medical, scientific and regulatory experts we can guide you through the clinical development process, from planning and approval up until the final report.



Heimeranstraße 35
D-80339 München
Phone: +49 (0) 89 893 119-0
E-Mail: info@fgk-pv.com
Internet: www.fgk-pv.com

FGK Pharmacovigilance GmbH

CRO

Keywords: CRO/CMO, Medical Writing, Clinical Trial Management and Monitoring, Drug Development, Pharmacovigilance, Data Management and Biostatistics

FGK Pharmacovigilance GmbH is a service provider offering vigilance services in support to pharmaceutical, biotech, and medical device companies' obligations in managing risk-benefit profile of their products. Services can be added to existing vigilance system of a client on a modular basis or comprise a stand-alone center of product vigilance on national, international or global level.

FLUICS GmbH

BIOTECH DEVICES & REAGENTS

Keywords: sample tracking, inventory management, QR code printing, IoT, mobile app development

FLUICS CONNECT is a mobile solution that helps innovative research labs to improve efficiency and reproducibility by keeping their sample inventory up to date. With our mobile app and an internet-ready printer connected to an online database we offer a convenient solution to print and track smear proof, QR-coded cryo labels. Watch our 1 min video to see how it works: go.fluics.com/teaser.



Fürstenstraße 15
D-80333 München
Phone: +49 89 71690877
E-Mail: connect@fluics.com
Internet: www.fluics.com

FoodChain ID Testing GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: ELISA/EIA, Genomics, PCR, Laboratory, Agrobiotechnology, NGS

FoodChain ID Testing GmbH provides molecular biological analysis of food and feed, plant material, and animal tissue (GMO analysis, species identification, DNA barcoding, genotyping, custom contract assay development) and immunological detection of allergens in food and feed.



Am Mittleren Moos 48
D-86167 Augsburg
Phone: +49 (0) 821 74776-30
E-Mail: info@foodchainid.de
Internet: www.foodchainid.com/de

Formycon AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Inflammation, Dermatology, Ophthalmology, Drug Development

Formycon is a leading, independent developer of high-quality biosimilars and focuses on treatments in ophthalmology, immunology and other key chronic diseases. With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible with access to vital and affordable medicines. The company currently has four biosimilars in development and is also working on the development of a COVID-19 drug FYB207.



Fraunhoferstr. 15
D-82152 Martinsried
Phone: +49 (0) 89 864667-100
E-Mail: info@formycon.com
Internet: www.formycon.com

Freeline Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Gene Therapy, Industrial Biotechnology, Drug Development

Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases. The Company has clinical programs in Hemophilia B and Fabry disease, as well as preclinical programs in Gaucher disease and Hemophilia A. Freeline is headquartered in the UK and has operations in Germany and the US.



Fraunhoferstraße 9b
D-82152 Planegg
E-Mail: infode@freeline.life
Internet: www.freeline.life



FRIZ Biochem Gesellschaft für Bioanalytik mbH

BIOTECH DEVICES & REAGENTS

Floriansbogen 2 - 4
D-82061 Neuried
Phone: +49 (0) 89 7244 09-25
E-Mail: info@frizbiochem.de
Internet: www.frizbiochem.de

Keywords: Molecular Diagnostics, PCR, Infectious Diseases, Chip/Array Technology, In-Vitro-Diagnostics, Clinical Diagnostics, Devices

We provide novel, disruptive and fastest quality molecular diagnostics with special emphasis on near-patient applications which require as little laboratory equipment and training as possible. Our two unique patented technology platforms Lab-direct-RT-PCR and Cycle® Diagnostics cover both microbiological and viral applications for clinical diagnostics as well as for R&D.

Galápagos

Luise-Ullrich-Straße 8
c/o Design Offices NOVE
D-80636 München
Phone: +49 (0) 89 26201309
E-Mail: deutschland@glpg.com
Internet: www.glpg.com/deutschland/

Galapagos Biopharma Deutschland GmbH

LIFE SCIENCE / BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Rheumatoid Arthritis, Inflammation, Small Molecules

Galapagos is a pioneering biotech with a pipeline of innovative therapies to address unmet medical needs. We built an innovative, integrated model that takes us from target discovery, through the discovery of molecules addressing targets, all the way to the development of those molecules into potential medicines, helping people worldwide with severe diseases, including inflammation and fibrosis.



DNA NANOTECHNOLOGIES

Am Schlosshof 8
D-91355 Hiltpoltstein
Phone: +49 (0) 9192 243 99 44
E-Mail: info@gattaquant.com
Internet: www.gattaquant.com

GATTAquant GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy

The worldwide first commercial DNA origami application: The key innovation behind our nanorulers is the application of an elaborate nanotechnology method, which serves as a breadboard to position dye-molecules on the nanometer scale. The used technique, where DNA is folded into predefined shapes, is called DNA origami and allows to attach dye-molecules at will.



Fraunhoferstraße 11a
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 899229-0
E-Mail: info@gba-pharma.com
Internet: www.gba-pharma.com

GBA PHARMA GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: R&D Service, Regulatory Affairs, Laboratory, Analytical Chemistry

GBA Pharma Labs run three GMP-certified and FDA-inspected sites in Germany with more than 160 highly qualified employees and over 4,500 m² of lab space. Our locations for analytical services support domestic and international customers, whether from the private industry or research institutions, with scientific and technical solutions for the development, approval process, and quality control throughout every step of the product lifecycle. Additionally we offer regulatory affairs services.

GBN Systems GmbH

BIOTECH & MEDTECH DEVICES & REAGENTS



Performing Mechatronics
Made in Bavaria

For over 20 years our challenge is to meet the outstanding demands of our clients in the fields of medical technology, biotechnology, the semi-conductor industry and automation technology. Our product range: From customized components to complete assemblies and machines from initial vision to serial end production. The Facilities are centrally located near Bavarian capital and airport of Munich. Key competencies in: Concept, development, prototyping, validation, certification, pre-series, main-serial production, quality management, fulfillment, logistics..

Fellnerstrasse 2
D-85656 Buch am Buchrain
Phone: +49 (0) 8124 5310-0
E-Mail: info@gbn-systems.com
Internet: www.gbn-systems.com

Genedata Bioinformatik GmbH

BIOTECH BIOINFORMATICS



Genedata is a bioinformatics company that specializes in developing software systems for the comprehensive analysis of genomes, transcriptomes, proteomes, metabolomes, and biochemical compounds. By working closely with key partners, the company combines its extensive product portfolio with expert scientific consulting services to offer tailor-made solutions for specific applications and multiple therapeutic areas. The company's solutions are key for moving the focus of life science research from high-throughput data acquisition to high-content data interpretation. Founded in 1997 as a spin-off from Novartis, the company is headquartered in Basel (Switzerland) with branch offices in Munich (Germany), San Francisco (USA), Boston (USA), and Tokyo (Japan).

Fürstenrieder Straße 281
D-81377 München
Phone: +49 (0) 89 4581901-0
E-Mail: peter.haberl@genedata.com
Internet: www.genedata.com

Genedia AG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Antisense/Nucleotides, Genomics, Medicinal Chemistry

Genedia AG Biotec Services and Products is a provider of DNA testing services including private DNA paternity testing, legal DNA paternity testing as well as other relationship testing services Another area is DNA genealogy and antropology, which includes ancestral origin DNA population test, Y-Chromosome Analysis, mt-DNA analysis. The forensic area includes DNA identification and banking services DNA molecular testing of diseases (Factor V and II, MTHFR, CFTR-Mutation).



Untere Grasstr. 6
D-81541 München
Phone: +49 (0) 89 543448-0
E-Mail: info@genedia.de
Internet: www.genedia.de

GeneSurge GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

GeneSurge is your access to individualized diagnostics. Even though we classify tumors according to their place of origin and appearance, each one remains somewhat different at the molecular level. And that is exactly what makes each cancer an individual disease. This fact ultimately creates a need for individual and detailed information to enable personalized treatment that is specific to the individual patient. We provide 3 tests to reach your individual profile.



Ottostr. 3
D-80333 München
Internet: www.genesurge.com



GENidee

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Molecular Diagnostics, PCR

Lise-Meitner-Str. 30
c/o IZB
D-85354 Freising/Weihenstephan
Phone: +49 (0) 8161 8068186
E-Mail: info@genidee.eu
Internet: www.genidee.eu

GENidee is a young and innovative biotech company specialized in the development, production and sales of molecular biological diagnostic kits for the rapid detection of food-borne pathogens in food. Fast and reliable real-time PCR diagnostics is guaranteed by simultaneous analytics suited to the individual customer requirements. GENidee offers DNA-based detection systems of highest quality. Using our kits directly in the production facilities enables the results of molecular food analytics to be supplied much sooner than by conventional diagnostics.



Gen-Plus GmbH & Co. KG

CRO

Keywords: Laboratory, R&D Service, Drug Development

Staffelseestraße 6
D-81477 München
Phone: +49 (0) 89 780 179 40
E-Mail: info@gen-plus.de
Internet: www.gen-plus.de

Gen-Plus GmbH & Co.KG provides solutions for challenging needs in pharmaceutical development and is a state-of-the-art CRDO. We develop tailor-made formulation and technology concepts (NCE, value-added-Generics, OTC) for solid/semisolids, non-steril liquids, patches and thin films from early idea to IMP production under GMP. Further in-house capabilities: narcotics & high potent handling (isolators), 2D&3D API printing, high-tech analytics incl. skin permeation.



Gilead Sciences GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Fraunhoferstr. 17
D-82152 Martinsried
Phone: +49 (0) 89 899890-0
E-Mail: info@gilead-sciences.de
Internet: www.gileadsciences.de

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company's website at www.gilead.com.



GILYOS GmbH

CRO

Keywords: Small Molecules, Peptide/Protein, Antibody, Nanobiotechnology, Drug Development

Friedrich-Bergius-Ring 15
D-97076 Würzburg
Phone: +49 (0) 931 907056-78
E-Mail: info@gilyos.com
Internet: www.gilyos.com

GILYOS is a contract development solution provider with more than 20 years of experience in pharmaceutical freeze drying. GILYOS` key business is consultancy and hands-on development services. Typical services include formulation development of small molecules and proteins, process optimization and analytical characterization. Further, GILYOS has a very strong expertise in scale-up and technical transfer of freeze drying cycles, including troubleshooting of established products (scale down).

gimbio mbH Gesellschaft für Informationsmanagement in der Biotechnologie

BIOTECH BIOINFORMATICS

Keywords: Automation, Data Management

Gimbio GmbH offers innovative products and solutions in bioprocess technology, especially for companies in the food, brewing or biotechnology industry. The guiding principle of the company is, in addition to the information gathering and processing, the development and application of innovative online measurement systems for biotechnical process state variables for the purpose of process design, modeling and simulation, with the ultimate goal of optimizing underlying bioprocesses.



Weihenstephaner Berg 4
D-85354 Freising/Weihenstephan
Phone: +49 (0) 8161 986 4480
E-Mail: info@gimbio.de
Internet: www.gimbio.de

GKM Gesellschaft für Therapieforschung mbH

CRO

Keywords: Regulatory Affairs, Data Management and Biostatistics, Medical Writing, Pharmacovigilance, Clinical Trial Management and Monitoring

GKM Gesellschaft für Therapieforschung is a privately owned full service Contract Research Organisation for planning and conducting clinical trials phase II-IV as well as for non-interventional studies. GKM also provides services for early benefit analyses (AMNOG), vigilance, and medical writing. Since 1981, GKM is a reliable partner for pharmaceutical, biotech and medical device companies. GKM provides flexible, cost-effective services with expert knowledge and dedication to your projects.



Lessingstr. 14
D-80336 München
Phone: +49 (0) 89 209 120-0
E-Mail: science@gkm-therapieforschung.de
Internet: www.gkm-therapieforschung.de

GlaxoSmithKline GmbH & Co. KG

PHARMA & CHEMICAL INDUSTRY

Keywords: Antibiotics, Vaccines, CNS, Dermatology, Respiratory Diseases, Urology

GSK is a science-led, globally operating healthcare company with a special purpose: to help people do more, feel better, live longer. Our goal is to be one of the worlds most innovative, best performing and trusted healthcare companies. GSK is setting milestones in healthcare prevention with a comprehensive portfolio of vaccines, respiratory and additionally in Oncology. Via our affiliate ViiV Healthcare, we are also involved in the area of HIV.



Prinzregentenplatz 9
D-81675 München
Phone: +49 (0) 89 360 440
E-Mail: service.info@gsk.com
Internet: www.de.gsk.com



GNA Biosolutions GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Clinical Diagnostics, In-Vitro-Diagnostics, Bioanalytics, Molecular Diagnostics, Devices, New Materials, Other Diagnostics

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 998 207-180
E-Mail: info@gna-bio.com
Internet: www.gna-bio.com

GNA Biosolutions GmbH was founded in 2010 as a spin-off from Ludwig-Maximilians-Universität, Munich. The company employs 40 people today. GNA develops instruments, consumables and tests for fast molecular diagnostics, based on its proprietary technology, Pulse Controlled Amplification (PCA). PCA can transform molecular diagnostics by enabling the development of testing platforms that can be used outside of the traditional laboratory setting.



GWK Präzisionstechnik GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Analytical Chemistry, Regulatory Affairs, In-Vitro-Diagnostics, Microscopy, Chip/Array Technology, Automation

Gollierstr. 70
D-80339 München
Phone: +49 (0) 89 7264960-0
E-Mail: info@gwk-munich.com
Internet: www.gwk-munich.de

GWK Precision Technology offers development and manufacturing of laboratory equipment and medical devices. Being a team of 20 specialists, we serve industry and scientific institutions since 1991. We provide special know-how in technical fields as well as the certification of equipment and production systems following ISO 13485. For the detection of Covid and Legionella we offer a differential diagnostik system using microarray-chip-technology, also see www.LegioTyper.de.



Hellsicht GmbH

BIOTECH BIOINFORMATICS

Keywords: Bioinformatics, Imaging, Data Management, Informatics

Passauerstraße 35
D-81369 München
Phone: +49 (0) 152 05390057
E-Mail: info@hellsicht.ai
Internet: www.hellsicht.ai

We build deep learning software to improve medical diagnosis by combining human expertise with machine intelligence in a unique hybrid approach.



Hema.to GmbH

BIOTECH BIOINFORMATICS

Keywords: AI/Dx

Ainmillerstraße 22
D-80801 München
Internet: www.hema.to

hema.to is a software service that reduces essential time to diagnosis, inter- and intraobserver variability, and expensive dyed antibodies for hematological laboratories. Besides a substantial reduction in misdiagnosis, we believe that we can provide patients with certainty much earlier than is the case today.

Hematrix Wound Care GmbH

MEDTECH

Keywords: Devices

Hematrix Wound Care GmbH develops, manufactures and markets products in the area of wound care. Our major initial focus is the marketing of hemostatic products to control bleeding. We are experts in the field of hemostasis and wound healing. Our vision is to build up an attractive company together with our investors in this business area.



Professor-Messerschmitt-Str. 3
D-85579 Neubiberg
Phone: +49 (0) 89 6008761-0
E-Mail: bertsch@hematrix.de
Internet: www.hematrix.de

HWI regulatory services GmbH

CRO

Keywords: Drug Development, Analytical Chemistry, Medical Writing, Pharmacology, Toxicology, Devices, Regulatory Affairs

HWI regulatory services GmbH provides regulatory services for drug substances, drug products and medical devices (strategic consultancy, procedure- and life-cycle management). For medical devices and drug-device combination products we offer clinical evaluation, biological safety assessments and technical documentation writing for certification.

The HWI group provides innovative services for pharma, biotech and medtech, particularly for API, medicinal products and medical devices.



Fraunhoferstr. 9
D-82152 Martinsried
Phone: +49 (0) 89 200 0203-50
E-Mail: s.oettl@hwi-group.de
Internet: www.hwi-group.de

HMNC Brain Health GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Medicinal Chemistry, Personalized Medicine, Laboratory, Biomarker Discovery & Development

HMNC is a biopharma company developing novel treatments for depression and anxiety: Proprietary gene-based companion tests support the decision which drugs optimize treatment effects. Our portfolio includes investigational drugs targeting stress systems in the brain. A novel formulation of ketamine holds promise to become prime option for treatment resistant depression. The myGeneCode1-test informs whether a given antidepressant passes the blood-brain barrier. The test is already on the market.



Wilhelm-Wagenfeld-Str. 20
D-80807 München
Phone: +49 (0) 89 36090200
E-Mail: info@hmnc.de
Internet: www.hmnc.de



Human Tissue and Cell Research-Services (HTCR) GmbH

BIOTECH PRECLINICAL SERVICES

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 440076442
E-Mail: info@htcr-services.com
Internet: www.htcr-services.com

Keywords: Biomarker Discovery & Development, Bioprocessing, Tissue Engineering/Cell Culture, Toxicology, In vitro Diagnostics, R&D Service, Autoimmune Diseases, Dermatology, Hepatology

HTCR Services enables basic research and drug development with specialized services and an experienced team of scientists and managers. Supported by a growing network of hospitals and clinical experts, HTCR offers a wide range of services including healthy and pathological bio-samples (e.g. fresh/cryo/FFPE tissue, plasma, serum, cell preparations) with clinical longitudinal data. This enables academic and industrial partners to advance their pre-clinical research pipeline and clinical development of innovative medicines and personalized treatment applications.



HTI Automation GmbH

BIOTECH DEVICES & REAGENTS

Am Forst 6
D-85560 Ebersberg
Phone: +49 (0) 8092 2092-0
E-Mail: info@hti-automation.com
Internet: www.hti-automation.com

Keywords: In-Vitro-Diagnostics, Laboratory, Clinical Diagnostics, Devices, Automation

For more than 20 years, we at HTI have been developing customized solutions for laboratory and production automation. Our engineering services and products contribute significantly to the success of our customers. With the X-TubeProcessor®_Series, we have created the possibility to flexibly combine established technologies and processes such as liquid handling, capping or labelling in one device. Thanks to high quality standards, innovative solutions and many years of expertise, we are now a partner for companies all over the world.



Hyglos GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Am Neuland 3
D-82347 Bernried
Phone: +49 (0) 8158 9060-0
E-Mail: info@hyglos.de
Internet: www.hyglos.de

Keywords: Proteomics, Infectious Diseases, Peptide/Protein, Clinical Diagnostics

Hyglos is BioMérieux's Endotoxin Center of Excellence based in Bernried, Germany. Our ENDONEXT(TM) range of recombinant Factor C assays and our ENDOXPERS(TM) services provide innovative solutions for endotoxin detection. We aim at revolutionizing the endotoxin detection market through the replacement of historical animal-source based methods by modern, sustainable and ecological techniques, leveraging significant advantages such as accuracy, sensitivity, lot-to-lot consistency, and easy automation.

Hyperthermics Regensburg GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Hyperthermics Regensburg is developing applications in renewable energy solutions. We use hyperthermophilic microorganisms to increase the biogas yield. Our bioactive pre-treatment plant pre-treats the substrate before it enters the biogas reactor. This process provides increased biogas production and can also replace a conventional hygienisation/pasteurization plant. In addition, we use hyperthermophilic microorganisms to produce green hydrogen from industrial organic waste streams.



Am BioPark 9
D-93053 Regensburg
Phone: +49 (0) 941 4612531
E-Mail: stefan.miller@hyperthermics.com
Internet: www.hyperthermics.com

ibidi GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Chip/Array Technology, Tissue Engineering/Cell Culture, Nanobiotechnology, Devices

The ibidi product lines include dishes, slides, and plates for the cultivation and high-resolution microscopy of cells, and also cell-based assays for investigating angiogenesis, chemotaxis, wound healing, and cells under flow. Specialized labware products and Collagen Type I, Rat Tail, providesolutions for3D spheroids and organoids. ibidi also specializes in instruments, such as stage top incubators for live cell imaging, plus a unique perfusion system for the simulation of blood vessels.



Lochhamer Schlag 11
D-82166 Gräfelfing
Phone: +49 (0) 89 520 46 17-0
E-Mail: info@ibidi.de
Internet: www.ibidi.de

ImevaX GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Infectious Diseases, Industrial Biotechnology, In-Vitro-Diagnostics, Clinical Diagnostics, Biomarker Discovery & Development

ImevaX GmbH, founded in 2013, is a Munich based life science company focussed on novel infection diagnosis. Current product in development is an innovative H. pylori rapid test that combines unprecedented sensitivity, specificity and speed. It determines the presence of two specific antibodies to H. pylori, FliD and CagA, that allow a risk-stratification into low- and high-risk groups for development of gastric cancer. ImevaX owns the global patent for the detection of antibody marker FliD.



Sendlinger Str. 60
D-80331 München
Phone: +49 (0) 89 4140 2477
E-Mail: info@imevax.com
Internet: www.imevax.com

IMGM Laboratories GmbH

BIOTECH & PHARMA PRODUCTION

Keywords: PCR, Laboratory, Genomics, Chip/Array Technology, Pharmacogenetics, Pharmacogenomics

IMGM Laboratories are a GLP and DIN EN ISO / IEC 17025 certified contract service provider for genomic services. Our four service pillars cover biomarker discovery, pharmacogenetics, metagenomics and biodistribution studies of nucleic acid compounds. In close collaboration to our clinical partner, we offer a complete pathology workflow containing the molecular characterization of cancer samples from histology to mutation detection and fusion transcript identification.



Lochhamer Str. 29a
D-82152 Martinsried
Phone: +49 (0) 89 452 4667-0
E-Mail: info@imgm.com
Internet: www.imgm.com



immatics

Machtlfinger Straße 11
D-81379 München
Phone: +49 (0) 89 540415-0
E-Mail: info@immatics.com
Internet: www.immatics.com

immatics biotechnologies GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Cell Therapy, Personalized Medicine, Immune Therapy, Oncology, Genomics, Proteomic

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors to enable a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells - unlocking new avenues for patients in their fight against cancer.



Karlstrasse 46
D-80333 München
Phone: +49 (0) 89 5432177-89
E-Mail: info@immumed.de
Internet: www.immumed.de

Immumed GmbH Gesellschaft für angewandte Immunologie

BIOTECH PRECLINICAL SERVICES

Keywords: Laboratory, Inflammation, ELISA/EIA, Clinical Diagnostics

Applied Immunology - Testing Services We offer testing services for scientific samples: - Analysis of cytokines, chemokines and hormones - Cell-characterization - Cytotoxicity. Our team is specialized in measuring multiplex-parameter analysis with Luminex-Technology in various samples like serum, cell cultures, saliva, urine. We perform many applications for flow-cytometry analysis, for example cell phenotyping or cytotoxicity assays, as well as a broad range of metabolic and aging parameters.



Lochhamer Schlag 21
82166 Gräfelfing
Phone: +49 89 2080 477 00
E-Mail: info@imux.com
Internet: www.imux.com

Immunic AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Small Molecules, Autoimmune Diseases, Inflammation, Drug Development, Immune Therapy

Immunic is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, including multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis.

Immunic, Inc. is headquartered in New York and listed on NASDAQ (ticker: IMUX). Its subsidiary, Immunic AG, is based in Gräfelfing/Munich, Germany, where the company's research and development activities are conducted.

immunoGlobe Antikörpertechnik GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Laboratory, Antibody Production Service, Antibody

immunoGlobe® GmbH, established in 1997, is a privately owned antibody manufacturer. Full service custom antibody services are supplemented by epitope mapping (single amino acid precision) and recombinant antibody technologies in cooperation with different partners. A special focus is on antibodies to posttranslational modifications (PTM), such as combinations of different (de)phosphorylation states of neighboring sites, neo-epitopes (e.g. cleavage sites), isoforms, variants, and point mutations.



Rudolf-Diesel-Str. 8a
D-97267 Himmelstadt
Phone: +49 (0) 9364 810-610
E-Mail: info@immunoglobe.com
Internet: www.immunoglobe.com

Implen GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Proteomics, Nanobiotechnology, Genomics, Chip/Array Technology, Automation, Devices

Implen is a privately held corporation that is a leading supplier for spectroscopy instruments and consumables for the non-destructive analysis of ultra low volume samples. The company focuses on biological, chemical, and pharmaceutical laboratories in industry and research.




Schatzbogen 52
D-81829 München
Phone: +49 (0) 89 7263718-0
E-Mail: info@implen.de
Internet: www.implen.de

Independent Data Lab

BIOTECH BIOINFORMATICS

Genomic data has become an essential part of almost every project in molecular biology and medicine. Unfortunately, high rate of rotation of personnel in academic environment has made it difficult to maintain collaborations for projects that often can last for years. At IDL we are committed to making sure every dataset receives the most thorough attention, and makes it's contribution to the progression of science.



Josef-Frankl-Straße 5A
D-80995 München
E-Mail: info@independentdatalab.com
Internet: www.independentdatalab.com

INCYTON GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Oncology, Drug Development, Toxicology, R&D Service, In-Vitro-Diagnostics, Imaging, Bioanalytics

INCYTON multi-sensor systems monitor different cellular key parameters simultaneously, in real time and label free. Our technology records each event, giving the user full control at every time-point without the need to be constantly present. A highly automated testing process reduces the time spent carrying out even the most complex assays. INCYTON smart technologies are combined in one housing creating a global environment control and reducing the risk of contamination and variations.



Am Klopferspitz 19a
D-82152 Planegg-Martinsried
E-Mail: info@incyton.com
Internet: www.incyton.com



Dachauer Str. 6
D-85254 Einsbach
Phone: +49 (0) 8135 8333
E-Mail: infors.de@infors-ht.com
Internet: www.infors-ht.com

Infors GmbH

BIOTECH DEVICES & REAGENTS

INFORS HT is your specialist for bioreactors, shaker incubators and bioprocess software. We offer the right solutions for the cultivation of microorganisms and cell cultures: Customer specific bioreactors and incubation shakers including qualification, parallel bioprocesses, and integration of all your bioprocesses in one software platform. Close customer relationships, high quality, innovation and flexibility are our greatest strengths.



Sonnenstraße 24-26
D-80331 München
E-Mail: contact@ingeneron.com
Internet: www.ingeneron.com

InGeneron GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Cell Therapy

InGeneron is elevating the field of regenerative medicine by translating robust science into proven patient benefit. Our purpose is to set new therapeutic standards by enabling physicians to use the patients own regenerative cells at point of care. With the initial focus on key orthopedic and wound healing indications, we will make regenerative cell therapies broadly accessible across multiple medical fields.



Balanstr. 6
D-81669 München
Phone: +49 (0) 89 48777-4
E-Mail: info@I-A-Z-zellkultur.de
Internet: www.I-A-Z-zellkultur.de

Institut für angewandte Zellkultur Dr. Toni Lindl GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Antibody Production Service, Tissue Engineering/Cell Culture

The Institut für angewandte Zellkultur Dr. Toni Lindl offers services in the area of cell culture and tissue culture, training in cell culture work, distribution of cell lines, consulting in cell culture, molecular biology, genetic engineering and development of monoclonal antibodies and in vitro processes. The core competences cover cell culture services and genetic engineering with a product range of recombinant human interleukin-2 and human monoclonal antibodies against rabies.



Friedrich-Bergius-Ring 19
D-97076 Würzburg
Phone: +49 (0) 931 3045-0
E-Mail: info@virion-serion.de
Internet: www.virion-serion.de

Institut Virion\Serion GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, ELISA/EIA, Infectious Diseases, Respiratory Diseases

Institut Virion\Serion GmbH, founded in 1978 in Germany, is one of the leading companies specializing in the manufacture of in vitro diagnostic products for infectious disease serology and major supplier of raw materials to the diagnostic industry. SERION Diagnostics provides a selection of analytical methodologies, such as SERION ELISA classic, SERION ELISA agile and SERION ELISA antigen products as well as laboratory automated systems and software solutions. SERION Immunologics offers a broad portfolio of raw materials, including antigens, antibodies and plasma products.

Intana Bioscience GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, R&D Service

Intana Bioscience GmbH is a privately owned service provider company. We contribute to our clients R&D programs by developing predictive assays and screens, by comprehensively understanding the behavior of their candidates, and by supporting drug discovery and development efforts from target validation to clinical testing. Our services cover target validation, assay development, screening, support of PK/PD studies and target occupancy measurements.



Lochhamer Str. 29 a
D-82152 Martinsried
Phone: +49 (0) 89 895 572-80
E-Mail: info@intana.de
Internet: www.intana-bioscience.de

inveox GmbH

IT, DIGITAL HEALTH

Keywords: Other Diagnostics, Data Management, Devices, Clinical Diagnostics, Laboratory, Imaging, Tissue Engineering/Cell Culture

inveox has the goal of making cancer diagnosis faster, safer, and more reliable. In today's labs, tissue samples (biopsies) are at risk of being mixed-up, contaminated or lost. But our products are designed to work as a cohesive unit to make this a thing of the past. We help patients and doctors. In addition, we create the lab of the future by bringing big data, artificial intelligence, and machine learning to labs. This provides better research data for scientists so they can eradicate cancer.



Lichtenbergstraße 8
D-85748 Garching bei München
Phone: +49 (0) 89 57847601
E-Mail: info@inveox.com
Internet: www.inveox.com

Invitrocue Europe AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Personalized Medicine, 3D-Structural Analysis, Other Diagnostics, Tissue Engineering/Cell Culture, Laboratory

Invitrocue Europe AG is an innovative leading healthcare bio-analytic company, that specialises in ex-vivo 3D cell culture models such as PDOs as well as in-vivo models by producing HiMice™ as promising tools for personalized cancer treatment. IVQ imparts to the industry valuable knowledge in creating better, faster and more affordable disease treatments.



Hildegardstr. 9
D-80539 München
Phone: +49 (0) 89 998209483
E-Mail: contact.de@invitrocue.com
Internet: www.invitrocue.com

Intercept Pharma Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases. Founded in 2002 in New York, Intercept now has operations in the United States, Europe, Canada, and Australia. Founded in 2015, Intercept Pharma Deutschland GmbH based in Munich offers medical sales and marketing support in Germany. The team has set itself the task of continuously providing high quality services to the 'liver community'.



Rosenheimer Str. 52
D-81669 München
Phone: +49 (0) 89 4111 124 11
E-Mail: info-DE@interceptpharma.com
Internet: www.interceptpharma.com/about/germany



iOmx Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, RNAi & Antisense, Immune Therapy

Fraunhoferstraße 13
D-82152 Planegg-Martinsried
Internet: www.iomx.de

iOmx Therapeutics is a biopharmaceutical company focused on developing first-in-class cancer immunotherapies addressing novel immune-checkpoints hijacked by cancer cells. Using the foundational iOTarg discovery platform, iOmx has identified several new tumor-associated immune-checkpoints and is advancing a preclinical stage pipeline of promising drug candidates that have the potential to address cancers that are resistant to current immunotherapies. For more details, please visit www.iomx.com.



Ipsen Pharma GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Einsteinstraße 174
D-81677 München
Phone: +49 (0) 89 262036100
E-Mail: contact.ipsen.germany@ipsen.com
Internet: www.ipsen.com/germany

Ipsen Pharma GmbH, subsidiary of the Ipsen Group for Germany, Austria and Switzerland, has been commercializing various drugs in the fields of oncology, neuroscience and rare diseases in Germany for more than 40 years. In 2019, the company relocated its headquarters to the competence center Munich. Ipsen would like to utilize the vibrant research landscape, with its numerous universities and clinics, to further promote the innovative spirit and the biotech mindset of within the company.



Iris Biotech GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Fine Chemicals/Reagents, Peptide/Protein, Drug Development, Drug Delivery, Medicinal Chemistry, Combinatorial Chemistry, Natural Compounds

Adalbert-Zoellner-Straße 1
D-95615 Marktredwitz
Phone: +49 (0) 9231 97121-0
E-Mail: info@iris-biotech.de
Internet: www.iris-biotech.de

Empowering Peptide Innovation – with this guiding theme in mind, Iris Biotech's mission is to support researchers by providing building blocks and reagents for

- Synthesis, Modification and Purification of Peptides (e.g. amino acids, coupling reagents, resins, solvents)
- Drug Delivery (e.g. PEGs, poly amino acids)
- Linkerology® (e.g. functionalized permanent or cleavable linkers, partial PROTACs)
- Life Sciences (e.g. Maillard reaction products, fluorescent labels)

as well as Custom Synthesis in all areas mentioned above.

IRUBIS

Schillerstraße 40b
D-80336 München
E-Mail: info@irubis.com
Internet: www.irubis.com

IRUBIS GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Drug Development, Bioanalytics, Bioprocessing, Peptide/Protein, Devices, Analytical Chemistry, Tissue Engineering/Cell Culture

IRUBIS offers an innovative analytical device for online monitoring of upstream and downstream processing in the production of biopharmaceutical drugs. Applications are in metabolite monitoring and control, as well as in downstream bioprocessing to aid in aggregation studies, contaminant detection or monitoring of target proteins and excipients.

ISAR Bioscience GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Neuro-Degeneration, Cell Therapy, Industrial Biotechnology, Biomarker Discovery & Development, Drug Development, Tissue Engineering/Cell Culture, Nutraceuticals

ISAR Bioscience GmbH is a translational research company. We overcome current limitations of stem cell research in order to advance development of novel therapeutics and industrial biotechnology products. We use human iPSC and genome editing technologies to build the next generation of disease models and cell-based models for biotechnology applications. ISAR forges strategic partnerships with industry partners and translates academic achievements and ideas into industrial solutions and products.



Semmelweisstr. 5
D-82152 Planegg
Phone: +49 (89) 3564 754-00
E-Mail: info@isarbioscience.de
Internet: www.isarbioscience.de

iThera Medical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Nanobiotechnology, Drug Development, Devices, Cardiovascular Diseases, Inflammation, Oncology

iThera Medical develops and markets a novel in-vivo biomedical imaging technology, "MSOT" = multi-spectral opto-acoustic tomography. MSOT utilizes the photo-acoustic effect to visualize and quantify anatomical, functional and molecular information of living tissue. Today, MSOT allows the early and reliable validation of new substance efficacy in drug discovery (e.g., for oncology, neurology and cardiovascular problems). For the future, MSOT also promises to become a valuable tool for clinical diagnostics.



Zielstattstr. 13
D-81379 München
Phone: +49 (0) 89 700 7449-0
E-Mail: info@ithera-medical.com
Internet: www.ithera-medical.com

ITM Isotope Technologies Munich SE

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Delivery, Drug Development, Industrial Biotechnology, Personalized Medicine, Oncology

ITM Isotopen Technologien München AG is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment. ITMs main objectives are to significantly improve treatment outcomes and quality of life for cancer patients while reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies.



Lichtenbergstr. 1
D-85748 Garching
Phone: +49 (0) 89 329 8986 600
E-Mail: info@itm-radiopharma.com
Internet: www.itm-radiopharma.com

Kalbitzer Innovations UG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: 3D-Structural Analysis, Bioinformatics, Bioanalytics, Drug Development, Oncology

Kalbitzer Innovations is a spin-off from the Institute of Biophysics and Physical Biochemistry (University of Regensburg) that provides novel experimental as well computational methods. It is focused on the application of high pressures on proteins in drug design, drug screening and protein refolding/renaturation. Kalbitzer Innovations develops software for specific application in NMR-based analytics as AUREMOL, a software package for automated protein structure determination.



Am BioPark 9
D-93055 Regensburg
Phone: +49 (0) 941 30798265
E-Mail: kalbitzer-innovations@t-online.de
Internet: www.kalbitzer-innovations.de



Landsberger Str. 284
D-80687 München
Phone: +49 (0) 89 5600 1005
E-Mail: info@kantarhealth.com
Internet: www.kantarhealth.com

Kantar GmbH

CRO

Keywords: Logistics, Pharmacovigilance, Oncology, Medical Writing, Clinical Trial Management and Monitoring, Data Management and Biostatistics, Regulatory Affairs

Kantar GmbH Clinical Research conducts phase I-IV clinical trials, retrospective and prospective non-interventional studies, patient reported outcomes and pharmaco-economic studies. Our services include: protocol and CRF design, eCRF solutions, feasibility and site selection, investigators training, handling of legal and ethical requirements, monitoring and site management, project management, data management, pharmacovigilance, quality assurance, statistical planning and analysis, medical writing.



Heimeranstr. 35
D-80339 München
Phone: +49 (0) 89 895286-0
E-Mail: info-de@klifo.com
Internet: www.klifo.com

KLIFO GmbH

CRO

Keywords: Medical Writing, Devices, Drug Development, Regulatory Affairs, Clinical Trial Management and Monitoring, Pharmacovigilance, Data Management and Biostatistics

KLIFO is an integrated North-European drug and device development consultancy with significant experience in partnering with biotech and pharmaceutical companies. We provide strategic advice and end to end operational solutions spanning all areas of clinical research, clinical trial supply, QA, CMC development, regulatory affairs, pharmacovigilance, and the development of pharmaceutical and biotech products and medical devices. We have offices in four European life science hubs.



Geyerspergerstr. 27
D-80689 München
Phone: +49 (0) 89 580 082-0
E-Mail: info@klifovet.com
Internet: www.klifovet.com

KLIFOVET GmbH

CRO

Keywords: Data Management and Biostatistics, Drug Development, Regulatory Affairs, Pharmacovigilance, Clinical Trial Management and Monitoring

KLIFOVET AG is a full service veterinary CRO and Regulatory Consultancy and provides the following services: evaluation of research projects, Regulatory Consultancy, Life Cycle Management & PhV, Preclinical and Clinical Studies, Quality Assurance, Data Management and more. Experienced in all species, we manage the development of VMPs & Feed/Feed Additives in every step. Multiple Animal Pharm Awards in 2006, 2015 and "Best Service Company" for 2019 show our long term commitment to our customers.

kmbs

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Genomics, PCR

kmbs care for organismic studies e.g. in Wildlife Biology, Phylogeny, Taxonomy, and Conservation Biology to clear up specimens' identities by means of DNA analyses (sample preparation, PCR, DNA sequencing) for purposes like identifying species, detecting animal pre-/absence, delimiting species boundaries, resolving species relations a.s.o. Off the lab, mapping species inventories or searching for organisms including electro fishing is our business.



Ferdinand-Zwack-Str. 39
D-85354 Freising
Phone: +49 (0) 8161 205957
E-Mail: info@kmbioservices.de
Internet: www.kmbioservices.de

Knowing01 GmbH

BIOTECH BIOINFORMATICS

Keywords: Data Management and Biostatistics

knowing01 is a deep tech start-up challenges the status quo of disease research. Our game-changing analytics as-a-service solution masters the complexity of the large volume and variety of biological data by separating signal from noise. Our software and services empower scientists to unlock the value of (multiOMICS) biomedical data, no data science training required. Our core technology leverages knowledge graphs, machine learning and AI to drastically shorten the data-to-insight cycle.



Am Stadtpark 66
81243 München
Phone: +49 89 74678081
E-Mail: support@knowing01.com
Internet: https://knowing01.com

Laboklin GmbH & Co KG – Unternehmensbereich Labogen

BIOTECH THERAPEUTICS & DIAGNOSTICS

Our laboratory provides a complete testing service for veterinary surgeons to meet the diagnostic needs of your practice. You can find all important information and our laboratory profiles and screens (microbiology, haematology, allergy, pathology and genetic testing). Furthermore you can download submission forms or order sample collection material. If you are registered you are able to locate your samples, the stage of investigation and much more.



Steubenstr. 4
D-97688 Bad Kissingen
Phone: +49 (0) 971 7202-0
E-Mail: mueller@laboklin.de
Internet: www.laboklin.com

Labor Friedle GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Medicinal Chemistry, Allergy

Labor Friedle GmbH is an internationally active residue analysis laboratory based in Tegernheim near Regensburg. It focuses on chemical, chemical-physical, microbiological and mycological analyses of food samples, especially fruits and vegetables. Consumer goods, cosmetics, pharmaceuticals, cleaning products and animal feed (pet food) as well as environmental medical issues from human biological matrices are also examined.



Von-Heyden-Str. 11
D-93105 Tegernheim
Phone: +49 (0) 9403 967 98-0
E-Mail: info@labor-friedle.de
Internet: www.labor-friedle.de



Mangelsfeld 4, 5, 6
D-97708 Bad Bocklet-Großenbrach
Phone: +49 (0) 9708 9100-0
E-Mail: service@labor-ls.de
Internet: www.labor-ls.de

Labor LS SE & Co. KG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Laboratory, Clinical Diagnostics, Allergy, Medicinal Chemistry, Molecular Diagnostics, Analytical Chemistry

The Labor LS is one of the leading European CROs for analytics and consulting for pharmaceuticals and medical devices. More than 1000 customers trust in the company's experience. The range of services covers microbiology, molecular-biology, biochemistry as well as physics and chemistry on raw materials and on finished products. In addition, services in industrial hygiene and clinical-microbiological diagnostic are offered.



Zeppelinstr. 1
D-85399 Hallbergmoos
Phone: +49 (0) 89 899 480 780
E-Mail: szorbas-seifried@labpmm.de
Internet:
www.invivoscribe.com/clinical-services

LabPMM GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Molecular Diagnostics

LabPMM (an Invivoscribe® company) is your partner of choice for diagnostic, research, and clinical trial services. Our network of laboratories located in the USA, Europe and Asia specialize in internationally harmonized molecular testing and collectively have CLIA and ISO15189 certifications via CAP and DAkkS. We offer an ever expanding menu of molecular assays, including NGS gene and MRD panels, FLT3 and NPM1 mutation assays, and B- and T-cell clonality and MRD assessment.



Semmelweisstr. 5
D-82152 Planegg
Phone: +49 (0) 231 97 42 70 00
E-Mail: info@lead-discovery.de
Internet: www.lead-discovery.de

Lead Discovery Center GmbH, LDC - Abteilung Antikörper

BIOTECH PRECLINICAL SERVICES

Lead Discovery Center GmbH (LDC) was founded by Max Planck Innovation in 2008 to take promising projects from academic research and develop them into pharmaceutical leads. Together with leading partners from academic research and industry, LDC is working on an extensive portfolio of projects in the field of small molecule drugs as well as therapeutic antibodies with exceptionally high medical and commercial potential.



Kopernikusstr. 9
D-81679 München
Phone: +49 (0) 89 4142 4889-0
E-Mail: info@leon-nanodrugs.com
Internet: www.leon-nanodrugs.com

leon-nanodrugs GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Drug Delivery, R&D Service, Liposomes, Small Molecules, Peptide/Protein

LEON utilises its' proprietary nano technology platform for the continuous manufacturing of SMART nanoparticles, ranging from surface stabilised polymeric nanoparticles through to lipid nanoparticles (LNP's) and liposomes.

LEON's technology enables efficient, flexible, and scalable manufacturing of nanoparticles with nucleic acid payloads and by this accelerates access to important vaccines and innovative cancer therapies. LEON works with a network of leading pharmaceutical companies to take our customers' nanoparticle projects to the next level.

LEUKOCARE AG

BIOTECH DEVICES & REAGENTS

LEUKOCARE provides proprietary formulation technologies and related development services for stabilization and protection of biologics. Our technologies are employed in collaborations with partners in the field of vaccines, therapeutic proteins, and biologic device combination products. They provide manifold benefits as improved shelf-life, terminal sterilization and significant production cost savings. LEUKOCARE provides development services based on fee for service during implementation of its technologies.

LEUKOCARE

Am Klopferspitz 19
D-82152 Martinsried/Munich
Phone: +49 (0) 89 7801665-0
E-Mail: info@leukocare.com
Internet: www.leukocare.com

lifespın GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: In-Vitro-Diagnostics, R&D Service, Analytical Chemistry, Agrobiotechnology, Laboratory, Bioanalytics, Biomarker Discovery & Development

lifespın is creating an atlas of human health to provide deeper clinical insights. Based on its metabolic profiling platform, combining NMR based liquid biopsy, a proprietary profiling software and a database with >150k profiles, lifespın captures digital snapshots of individual metabolism and enables the classification of individual samples. lifespın's solutions are accessible via lifespın service labs or as cloud-based SaaS.



Am BioPark 13
D-93053 Regensburg
Phone: +49 (0) 941 942 898 0
E-Mail: info@lifespın.de
Internet: www.lifespın.de

LINDIS Biotech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody

Lindis Biotech is a clinical stage bio-pharmaceutical company, committed to develop innovative T- cell engaging trifunctional bispecific antibodies, Triomab® to turn malignant cancers into manageable and possibly curable diseases.

Triomab® antibodies offer a unique patient-specific therapeutic vaccine effect together with its potent direct, tumor-cell-killing activity that is unrivaled by current cancer therapies. For details please visit our website: www.lindisbiotech.de



Am Klopferspitz 19 a
D-82152 Martinsried
Phone: +49 (0) 89 700 766 24
Internet: www.lindisbiotech.com

LISANDO GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Lysando AG is market-leader for antimicrobial proteins, so-called Artilysin®s. The Artilysin® platform technology fights multidrug resistant bacteria. Artilysin®s are muralytic proteins which are active on gram-positive & gram-negative target bacteria. We focus on the development of specifically designed Artilysin®s for customers across all industries, to help them overcome the rapidly increasing challenges originating from pathogenic bacteria. The technology is continually enhanced to meet the expectations of our customers as well as the addressed markets.



Am BioPark 13
D-93053 Regensburg
Phone: +49 (0) 941 28096-208
E-Mail: info@lysando.com
Internet: www.lysando.com



Truhenseeweg 8
D-82319 Starnberg
Phone: +49 (0) 8151 5590291
E-Mail: info@livimplant.de
Internet: www.livimplant.de

LivImplant GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Inflammation, Bone/Joint Diseases, Cell Therapy, Tissue Engineering/Cell Culture

LivImplant GmbH develops innovative cell based therapies for lesions and diseases of tendons, joints, cartilage and bones, focusing on stimulating the self-healing powers of the body by applying stem cells and growth factors. As a spin off from the Ludwig-Maximilians-University of Munich and a close collaboration with the Veterinary Clinic of the University of Giessen, LivImplant benefits from the latest scientific proceedings. First applications are available for curing lameness with horses and dogs.



Mühlweg 2 a
D-82054 Sauerlach
Phone: +49 (0) 8104 616-20
E-Mail: service@loewe-info.com
Internet: www.loewe-info.com

Loewe® Biochemica GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Agrobiotechnology, ELISA/EIA

LOEWE® is committed to the development and production of high quality reagents for the detection of plant diseases caused by bacteria, fungi, nematodes, and viruses. Furthermore we offer contract testing services for all kinds of crops and ornamentals (ELISA techniques, Immuno Fluorescence Antibody Assays, Blotting, and PCR).



Georg-Brauchle-Ring 89
D-80992 München
Phone: +49 (0) 89 354803-47
E-Mail: info@lre.de
Internet: www.lre.de

LRE Medical GmbH

MEDTECH

Keywords: R&D Service, Molecular Diagnostics, Other Diagnostics, Automation, Devices, In-Vitro-Diagnostics

LRE Medical is a leading provider of contract engineering and manufacturing of complex, highly integrated instrumentation for IVD, MedTech and Life Sciences. The spectrum of instruments ranges from PoC, field-testing systems through analyzers based on a variety of technologies including solutions for molecular diagnostics. LRE offers one-stop shop solutions from feasibility, product development, manufacturing, after-sales service to lifetime support. 60 years of expertise and continuity.



Am Windfeld 35
D-83714 Miesbach
Phone: +49 (0) 8025 2867-0
E-Mail: info@luyepharma.eu
Internet: www.luyepharma.eu

Luye Pharma AG

PHARMA & CHEMICAL INDUSTRY

Keywords: Pharmacology, Drug Delivery, Medicinal Chemistry

Luye Pharma AG Miesbach is one of the largest independent manufacturers of transdermal delivery systems in Europe with a product portfolio primarily focused on more sophisticated and higher margin specialty patch categories such as CNS, pain and hormone treatments. Luye Pharma AG also acts as the EU hub for Luye Pharma Groups development efforts in R&D, manufacturing, international registration, and market promotion of new formulation products to international standards.

Medical Device Services GmbH

PHARMA & CHEMICAL INDUSTRY

Medical Device Services GmbH has been qualifying the biological safety of medical devices for their producers for more than 25 years and represents the holistic partner on the path to certification and beyond. Experienced specialists identify the optimal approach while always following the latest standards. The lab is internationally reputed for its expertise, GLP-certified as well as accredited by DAkkS and ZLG



Lilienthalstrasse 4
D-82205 Gilching
Phone: +49 (0) 8105 7783 30
E-Mail: pr@mdservices.de
Internet: www.mdservices.de

Medigene AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Personalized Medicine, Cell Therapy, Vaccines, Hematology, Immune Therapy, Gene Therapy

Medigene AG is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

medigene

Lochhamer Str. 11
D-82152 Martinsried
Phone: +49 (0) 89 2000 33-0
E-Mail: medigene@medigene.com
Internet: www.medigene.com

Medizone Germany GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Clinical Trial Management and Monitoring, Logistics, R&D Service

Medizone Germany is your trusted and reliable partner regarding sourcing of comparator products for clinical trials and analytical samples for biosimilar development. We are authorized to import comparators into the EU with proper certification through our Qualified Person. With an extensive network of well-established approved suppliers, Medizone prides itself with meticulous quality standards when providing global sourcing services.



Keltenring 15
D-82041 Oberhaching
Phone: +49 (0) 89 12 11 26 36
E-Mail: info@medizone.com
Internet: www.medizone.com

Medpace Germany GmbH

CRO

Keywords: Oncology, Metabolic Diseases, Cardiovascular Diseases, Imaging, Pharmacovigilance, Drug Development, Regulatory Affairs

Medpace is a global, full-service clinical CRO providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace's mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, endocrinology, central nervous system and anti-viral.



Theresienhöhe 30
D-80339 München
Phone: +49 (0) 89 895 5718-0
E-Mail: info.de@medpace.com
Internet: www.medpace.com



MedPharmTec GmbH

CRO

Keywords: Medical Writing, Pharmacovigilance, Regulatory Affairs

Neuhauser Str. 47 / IV
D-80331 München
Phone: +49 (0) 89 354 998-0
E-Mail: office@medpharmtec.de
Internet: www.MedPharmTec.de

MedPharmTec is a service provider for pharmaceutical medicine. Our customers: pharmaceutical industry and companies in the biotechnology, medical technology and food industries. Our services: Proofreading of special and product information // Creation/maintenance of drug information // Authorization maintenance (e.g. creation of PSURs) // Consulting for pharmacovigilance and Clinical Trials/NIS // Preparation/ Submission of Ethical Applications and official registrations.



metabion GmbH

BIOTECH DEVICES & REAGENTS

Keywords: PCR, Antisense/Nucleotides, Antibody Production Service, Other Diagnostics, NGS, Genomics, Proteomics

Semmelweisstr. 3
D-82152 Martinsried
Phone: +49 (0) 89 899363-0
E-Mail: info@mymetabion.com
Internet: www.metabion.com

metabion is one of the globally leading suppliers of custom nucleic acids renowned for its focus on reliable supplies of consistently high quality products and services. Metabion offers production of a wide range of synthetic DNA and RNA oligonucleotides according to customers' needs as well as the supply of standard life science products. Successfully translating highest quality standards into daily practice is the core of metabion's business philosophy and key to its popularity at the same time.



Metabolon GmbH

LIFE SCIENCE / BIOTECH DNA/PROTEIN ANALYTICS

Keywords: R&D Service, Agrobiotechnology, Nutraceuticals, Metabolomics, Drug Development

Zeppelinstraße 3
D-85399 Hallbergmoos
Phone: +49 (0) 89 99017752
E-Mail: rpfister@metabolon.com
Internet: www.metabolon.com

Metabolomics in the heart of Europe. Where other „omics“ technologies reach their limits, Metabolon's strength begins. With results close to the phenotype, we open doors that other technologies cannot. We welcome you at any time in our International HQ in Hallbergmoos.



MetaHeps GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Toxicology, Drug Development

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 89 7007 6614
E-Mail: info@metaheps.com
Internet: www.metaheps.com

MetaHeps® is an innovative service provider specialized to identify or exclude drug-induced liver injury (DILI) in an individual patient using a blood sample. MetaHeps tackles DILI in clinical trials or postmarketing as a major cause of drug attrition: As a diagnosis of exclusion, DILI suspicion may be incorrect in up to 50% of cases. Now, the MetaHeps technology allows to clear a drug from DILI suspicion, or - in case DILI is confirmed - biomarker development using the cell- and databank.

Metronomia Clinical Research GmbH

CRO

Keywords: Data Management and Biostatistics, Medical Writing, Clinical Trial Management and Monitoring, R&D Service

Metronomia is a specialized CRO for biostatistical consulting, biostatistics, clinical data management and medical writing in Munich. Experience: > 600 projects since foundation in 1990, proven track record in all major therapeutic areas and all clinical phases / NIS. Customers: Biotech-, pharma- and medical device companies, universities, CROs. Commitment: High-quality and reliability of our data, outstanding flexibility and personal service through stable teams, competitive cost-benefit ratio.

METRONOMIA 

Paul-Gerhardt-Allee 42
D-81245 München
Phone: +49 (0) 89 829265-100
E-Mail: info@metronomia.net
Internet: www.metronomia.net

MGZ Medizinisch Genetisches Zentrum

CRO

Keywords: Personalized Medicine, Oncology, Bioinformatics, Genomics, Laboratory, Clinical Diagnostics

The MGZ, Medical Genetics Center is one of the leading laboratories for human genetics in Europe and combines interdisciplinary medical expertise with a cutting-edge, accredited (DIN EN ISO 15189) laboratory. With a team of physicians, scientists and bio-informaticians as well as a broad spectrum of methods such as short- and long-read sequencing, array, conventional cytogenetics, molecular combing, polygenic risk scores and liquid biopsy, the MGZ serves patients, physicians and pharmaceutical companies.

 **MGZ**
Medizinisch Genetisches Zentrum

Bayerstraße 3-5
D-80335 München
Phone: +49 (0) 89 30 90 886-0
E-Mail: info@mgz-muenchen.de
Internet: www.mgz-muenchen.de

Microcoat Biotechnologie GmbH

BIOTECH DEVICES & REAGENTS

Keywords: In-Vitro-Diagnostics, Bioanalytics, PCR, Laboratory, Pharmacokinetics, ELISA/EIA

Custom Development of diagnostic assays, test components and new test formats to market-ready kits. Immunological assays, molecular assays, sample and Matrix preparation protocols. Standard kit formats comprise ELISA, ELISpot, bead-based formats, lateral-flow kits. Production, modification and conjugation of antibodies and recombinant proteins, customized solid Phase coating. Biomarker Services, PK/PD, immunogenicity, sample measurement, endotoxin and pyrogen testing, Assay validation, GLP, GC(L)P, cGMP.


microcoat

Am Neuland 3
D-82347 Bernried
Phone: +49 (0) 8158 9981-0
E-Mail: info@microcoat.de
Internet: www.microcoat.de

MIKROGEN GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: PCR, Clinical Diagnostics, ELISA/EIA, Infectious Diseases, Automation, Autoimmune Diseases, Chip/Array Technology

MIKROGEN is a global provider of system solutions for medical laboratory diagnostics. We combine excellent genetic engineering know-how with scientific background and consistent customer orientation. The extensive and efficient evaluation of system solutions in collaboration with scientific experts and institutes is the basis for reliable diagnoses. MIKROGEN offers a wide range of system solutions for the indirect detection (antibodies) and direct detection (PCR) of pathogen.

MIKROGEN
D I A G N O S T I K

Floriansbogen 2 - 4
D-82061 Neuried
Phone: +49 (0) 89 54801-0
E-Mail: meyer@mikrogen.de
Internet: www.mikrogen.de



Minaris Regenerative Medicine GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Gene Therapy, Cell Therapy, R&D Service, Gene Transfer

Haidgraben 5
D-85521 Ottobrunn
Phone: +49 (0) 89 700 9608-0
E-Mail: contact@rm.minaris.de
Internet: www.rm.minaris.com

Minaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies. We offer our clients high value clinical and commercial manufacturing services, development solutions, and technologies. We are pioneers in the field with more than 20 years experience providing outstanding quality and reliability. Our facilities in the US, Europe, and Asia allow us to supply patients worldwide with life-changing therapies.



MINITÜB GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Hauptstr. 41
D-84184 Tiefenbach
Phone: +49 (0) 8709 9229-664
E-Mail: csimmet@minitube.de
Internet: www.minitube.de

Minitüb is an international established system supplier for assisted reproduction of domestic animals, notably in the areas of A.I., cryobiology and E.T. Through its participation in MWM Biomodels GmbH, a spin-off company of LMU Munich, Minitüb is also engaged in the development and characterization of transgenic large animal models for biomedical research. Current projects focus on genetically modified pigs for xenotransplantation, transgenic pig models of diabetes mellitus, muscular dystrophy and immunodeficiency.



mk2 Biotechnologies GmbH

LIFE SCIENCE / BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Industrial Biotechnology, Bioanalytics, R&D Service

Fallstrasse 9
D-81369 München
Phone: +49 (0) 160 777 0880
E-Mail: info@mk2.bio
Internet: www.mk2.bio

mk2 Biotechnologies develops, produces and investigates peptides at highest purity and quality standards using a revolutionary synthesis technology. We are able to synthesize any kind of peptide, regardless of its physical or chemical properties. We are strongly convinced, that our process has the potential to tackle parts of major social challenges as well as to provide solutions for a known and yet unknown demand for new classes of active substances.



MLL Münchner Leukämielabor GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, NGS, Laboratory, Oncology, Hematology, PCR, Genomics

Max-Lebsche-Platz 31
D-81377 München
Phone: +49 (0) 89 990 17-0
E-Mail: info@mll.com
Internet: www.mll.com

MLL Munich Leukemia Laboratory is a leading institution for leukemia diagnostics and research. An interdisciplinary structure guarantees valid, comprehensive and prompt diagnosis and includes: cytomorphology, chromosome analysis, immunophenotyping, cytogenetics, FISH, and molecular genetics. MLL performs also WGS. Several workflows are already supported by AI. This combination gives medical professionals an essential foundation to ensure ideal patient care.

Moderna Germany GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Moderna is an mRNA pioneer with a diverse clinical portfolio of vaccines and therapeutics and developed one of the earliest vaccines against COVID-19. Its mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. In April 2022, Moderna opened its German Headquarters in Munich.

moderna[®]

Rosenheimer Str. 143 c
81671 München
Internet: www.modernatx.com

Molecular Machines & Industries GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Molecular Diagnostics, Devices

MMI Microdissection, Micromanipulation and Imaging MMI is the leading provider of unique technologies for microdissection, micromanipulation, and imaging with a wide range of clinical and research applications. I.e. Capillary-based selective isolation of single cells (CellEctor), Pico-cut laser microdissection to isolate cells in tissue (CellCut), Microscopy-integrated Whole Slide Imaging (CellScan), Optical tweezers to quantify biological forces (CellManipulator).



Molecular Machines & Industries

Breslauer Strasse 2
D-85386 Eching
Phone: +49 (0) 89 319 048 40
E-Mail: info@molecular-machines.com
Internet: www.molecular-machines.com

Molecular Networks GmbH - Computerchemie

BIOTECH BIOINFORMATICS

Keywords: Molecular Modelling, Toxicology, Small Molecules

Molecular Networks and Altamira (MN-AM) offer innovative approaches and solutions for chemoinformatics, computational toxicology and safety/risk assessment of chemical compounds. The ChemTunes-ToxGPS[®] software platform provides a unique combination of expert-reviewed toxicity databases, MoA-based in silico predictions for human health endpoints and workflows to support, e.g., Read-Across and ICH M7 GTI studies. A rigorous decision theory approach delivers weight of evidence-based final outcomes.



Neumeyerstraße 28
D-90411 Nürnberg
Phone: +49 (0) 911 597 424 00
E-Mail: info@mn-am.com
Internet: www.mn-am.com

Molekula GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Antibiotics, Analytical Chemistry, New Materials, Medicinal Chemistry, Peptide/Protein, Fine Chemicals/Reagents

Molekula is a leading chemical supplier offering research chemicals and biochemicals sourced from production sites across the globe. Our clients ranging from university labs to big industrial players. With offices in the UK, USA, China, Germany and Italy, our global insight into the market keeps us firmly at the forefront of this industry. We hold over 8000 ex-stock products and also have in-house production of tailor-made gases in solutions and Grignard reagents.



Landshuter Allee 12
D-80637 München
Phone: +49 (0) 89 360 900 900
E-Mail: dinfo@molekula.com
Internet: www.molekula.com



Semmelweisstraße 7
D-82152 Planegg
Phone: +49 (0) 89 89927-0
E-Mail: info@morphosys.com
Internet: www.morphosys.com

MorphoSys AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Autoimmune Diseases, Small Molecules, Nephrology, Oncology, Antibody

MorphoSys is a global commercial-stage biopharmaceutical company with the mission to give more life for people with cancer. We use groundbreaking science and technologies to discover, develop and deliver innovative cancer medicines to patients. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts. To learn more, visit us at www.morphosys.com and follow us on Twitter and LinkedIn.



Lichtenbergstraße 8
D-85748 Garching b. München
Phone: +49 (0) 89 215 366 18
Fax: +49 (0) 89 215 366 19
E-Mail: info@msaid.de
Internet: www.msaid.de

MSAID GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Proteomics, Machine Learning, Deep Learning, Bioinformatics

MSAID is a bioinformatics spin-off from the Technical University of Munich, Germany. It was founded by an interdisciplinary team of scientists with the vision to provide better computational solutions to the field of proteomics. The company's approach is to replace current algorithms for proteomics with powerful, AI-based solutions, thereby paving the way for a smarter, deeper, and more reliable way of interrogating proteomic data.



Lindenplatz 1
D-85540 Haar
Phone: +49 (0) 800 673 673 673
E-Mail: infocenter@msd.de
Internet: www.msd.de

MSD SHARP & DOHME GMBH

PHARMA & CHEMICAL INDUSTRY

Keywords: Infectious Diseases, Oncology, Diabetics, Cardiovascular Diseases, Antibiotics, Vaccines

MSD Merck & Co., Inc., in the USA and Canada, with headquarters in Kenilworth, NJ, USA is a leading global healthcare company. MSD's core business is the discovery, development, production and distribution of prescription medicines, vaccines, biologic therapies and animal health products. In 2017, the company generated sales of approximately 40.1 billion US dollars with approximately 69,000 employees in more than 140 countries. The company has its German headquarters in Haar near Munich. Twitter: @MSD_Deutschland



Ahornweg 8
DE-93176 Beratzhausen
Phone: +49 (0) 9493 95 92 966
E-Mail: info@multi-service-monitoring.de
Internet: www.multi-service-monitoring.de

multi-service-monitoring

CRO

Keywords: Regulatory Affairs, Devices, Autoimmune Diseases, Clinical Trial Management and Monitoring, Oncology, , Drug Development

multi-service-monitoring CRO (founded in 2003) is a clinical research organisation (CRO) that is specialised in monitoring of non-commercial clinical trials and medical clinical trials with devices. All tasks are carried out in accordance with the appropriate national regulations and the international guidelines ICH/GCP and "DIN ISO 14155".

multimmune GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Imaging, Antibody, Oncology, Immune Therapy, Drug Development, Personalized Medicine, Cell Therapy

multimmune GmbH is a clinical stage company delivering innovative theranostics for tumors expressing the tumor-specific marker membrane Hsp70. Pipelines include autologous and allogeneic natural killer (NK) cells that have been activated using a proprietary process, and a pipeline of cell and molecular therapeutics based on unique proprietary monoclonal antibodies that detect membrane Hsp70, all of which are supported by a proprietary blood test for determining the status of a patient's tumor.



Kirchenstrasse 82
D-81675 München
E-Mail:
graham.pockley@multimmune.com
Internet: www.multimmune.com

MVZ Martinsried GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, NGS, Genomics, Bioinformatics, Oncology, Personalized Medicine, Laboratory

The Center for Human Genetics and Laboratory Diagnostics in Martinsried continues to broaden its expertise and competencies. The interdisciplinary collaboration between five medical specialist areas - Human genetics, Laboratory Medicine, Microbiology/Virology, Transfusion Medicine, Molecular Oncology/Pathology - enables diagnostic questions to be more efficiently, comprehensively and accurately resolved. Accredited according to DIN EN ISO/IEC 17025 and ISO 15189.



Lochhamer Str. 29
D-82152 Martinsried
Phone: +49 (0) 89 895578-0
E-Mail:
info@medizinische-genetik.de
Internet:
www.medizinische-genetik.de

MWM Biomodels GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Pharmacokinetics, Transgenic Animals, Cardiovascular Diseases, Diabetics, Respiratory Diseases

MWM Biomodels GmbH is specialized in the development and characterization of transgenic large animal models for biomedical research. Current projects are focused on genetically modified pigs for xenotransplantation as well as transgenic pig. MWM Biomodels offers support starting from the design of a project, the development of expression and targeting vectors, the generation of genetically modified large animals, their phenotypic characterization and the performance of preclinical studies.



Hauptstr. 41
D-84184 Tiefenbach
Phone: +49 (0) 8709 9229-0
E-Mail: csimmet@minitube.de
Internet: www.mwm-biomodels.com

Nanion Technologies GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Nanobiotechnology, Devices

Nanion Technologies combines exceptional instrumentation with trusted support and decades of scientific expertise, to accelerate successful drug development and scientific research. As a world leading provider of automated patch clamp systems with a wide range of throughput capabilities and formats, we have expanded our product range to in vitro systems for membrane pump/transporter, bilayer recordings, and confluency and contractile force measurements from cell monolayers.



Ganghoferstraße 70a
D-80339 München
Phone: +49 (0) 89 2190 95-0
E-Mail: info@nanion.de
Internet: www.nanion.de



Würmstraße 4
D-82319 Starnberg
Phone: +49 (0) 8151 959022-0
E-Mail: info@nanosaar.com
Internet: www.nanosaar.com

nanoSaar AG

NANOTECHNOLOGY

Keywords: Nanobiotechnology

THE POWER OF NANO! nanoSaar AG is a leading provider of tailor-made nanotechnology solutions that give a wide range of partners from the chemical industry a competitive advantage. - Very homogeneous, superior product quality - Continuous, cost-effective production process - Fast, simple scale-up for industrial chemical production - Business opportunities with license or joint venture models - You can find out more at: www.nanosaar.com



Flößergasse 4
D-81369 München
Phone: +49 (0) 89 4522 895-0
E-Mail: info@nanotemper.de
Internet: www.nanotempertech.com

NanoTemper Technologies GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Automation, Devices, Bioanalytics, Drug Development, Bioprocessing, Vaccines

NanoTemper provides biophysical instruments, kits & software. We have a strong customer focus and stand for strong commitment to quality, ease of use and high precision instrumentation. Our globally operating team of experts strongly focuses on the users benefits by ensuring maximum efficiency for the Pharmaceutical and Biotech industries as well as academic research. With our optical technologies like MST, TRIC, nanoDSF and DLS, we provide knowledge about the most challenging targets.



Neumarkter Straße 18
D-81673 München
Phone: +49 (0) 89 3585-4000
E-Mail: munich@ndareg.com
Internet: www.ndareg.com

NDA Regulatory Service GmbH

CRO

Keywords: Pharmacovigilance, Drug Development, Medical Writing, R&D Service, Regulatory Affairs

NDA is a leading regulatory consultancy, supporting drug development companies of all sizes on the shortest and most economic path to approval and patient access. Our experienced team of 150 consultants (30 in Munich) provide advice on all phases of development and therapeutic areas, including procedure and submission management, for both US and EU. Our specialist Advisory Board, consisting of very senior ex-regulators, provides independent strategic advice with an inside the agencies view.



Am Haag 6+7
D-82166 Gräfelfing
Phone: +49 (0) 89 898888-0
E-Mail: info.germany@neovii.com
Internet: www.neovii.com

NEOVII Biotech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Gene Therapy, Cell Therapy, Antibody, Immune Therapy, Hematology, Drug Development

Neovii Biotech GmbH develops, commercializes and manufactures immunologically active biopharmaceutical therapeutics, especially the medicinal product Grafalon®. Neovii is headquartered in Switzerland (Neovii Pharmaceuticals AG, Zürcherstrasse 19, 8640 Rapperswil, Switzerland (Phone: +41 55 210 05 00; Fax: +41 55 210 55 08; E-mail: info@neovii.com) and part of the Neopharm Group, Israel.

NeuroProfile GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

NeuroProfile is committed to the discovery and development of novel therapeutics for the treatment of Central Nervous System (CNS) diseases. The main objective is the identification and commercialization of novel neuronal drug targets for the most important neurodegenerative diseases Alzheimer and Parkinson and for psychiatric disorders such as schizophrenia and depression. Our targets will be the basics for drugs with new mechanisms of action and improved therapy of the diseases.



Keilsteiner Breiten 6
D-93055 Regensburg
Phone: +49 (0) 941 785 369-0
E-Mail: info@neuroprofile.com
Internet: www.neuroprofile.com

nexttec GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Laboratory, Devices, Genomics, Automation

nexttec1-Step kits for rapid purification of plasmid and genomic DNA from tissue, cell cultures, blood, bacteria and plants. The nexttec1-Step DNA purification system consists of only one buffer system for the lysis of the corresponding samples and nexttecCleanColumns, or nextteccleanPlates96. The nexttec 1-Step DNA purification is a reversal of the usual, well-known DNA purification methods. Here, proteins and other inhibiting substances are adsorbed on a special sorbent surface. The DNA does not bind, passes through the adsorbent layer and is immediately available in the eluate for the applications. This allows purification of the DNA in just 4 minutes.



Larezhausen 2
D-86567 Hilgertshausen
Phone: +49 (0) 8250-92 790 32
E-Mail: service@nexttec.biz
Internet: www.nexttec.biz

NIGU Chemie GmbH c/o AlzChem AG

PHARMA & CHEMICAL INDUSTRY

Nigu offers a full range of high-purity guanidine salts for biotechnological applications, which meet the supreme quality standards set by the biopharmaceutical industry. The product group includes several grades of guanidine hydrochloride for separation and purification of recombinant proteins and antibodies. Guanidine thiocyanate for nucleic acid based diagnostics (test kits for viral RNA/DNA) is another integral part of the portfolio.

NIGU

AlzChem Group

Dr.-Albert-Frank-Str. 32
D-83308 Trostberg
Phone: +49 (0) 8621 86-2622
E-Mail: info@alzchem.com
Internet: www.nigu.de

Novartis Pharma GmbH

PHARMA

Novartis is reimagining medicines to help improve and extend people's lives. We use innovation and digital technologies to develop therapies in areas with high unmet medical need. We invest a high share of our turnover in research and development. Our products reach around 800 million people worldwide and we strive to expand access to them. In Germany Novartis employs around 7,400 people at 12 locations and around 109,000 worldwide. www.novartis.de and www.novartis.com



Roonstr. 25
D-90429 Nürnberg
Phone: +49 (0) 911 273-0
E-Mail: angelika.gaufer@novartis.com
Internet: www.novartis.de



Nucleus Medical GmbH

LIFE SCIENCE / BIOTECH

Nucleus Medical GmbH has been founded in November 2019 by private investors. The company is focused on the development of innovative immune-modulating products in the field of transplantation medicine. Nucleus combines cutting-edge pharmaceutical technologies to ensure the intended therapeutic success of the later product. Nucleus works together with a network of service companies to ensure greatest possible flexibility and efficiency to achieve market authorization in a minimum of time.

Am Wildwechsel 7a
D-82031 Grünwald
Phone: +49 (0) 178 8087262
E-Mail: wb@nucleusmed.eu
Internet: www.nucleusmed.eu



numares AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Cardiovascular Diseases, Metabolomics, Biomarker Discovery & Development, Drug Development, Clinical Diagnostics, Nephrology, Metabolic Diseases

numares AG, based in Regensburg develops and markets innovative diagnostic tests based on NMR metabolomics. Essentially, our tests consist of metabolic constellations that are characteristic of certain diseases. To find these, we apply machine learning to clinical study cohorts measured with our AXINON® NMR system. We have a successful commercial base especially in laboratories in the USA.

Am BioPark 9
D-93053 Regensburg
Phone: +49 (0) 941 280949-00
E-Mail: jobs@numares.com
Internet: www.numares.com



Nuvisan GmbH

CRO

Keywords: Oncology, Small Molecules, Peptide/Protein, Pharmacokinetics, PCR, ELISA/EIA

The NUVISAN Group is an international service provider in the field of clinical trials, laboratory services and contract manufacturing of drugs or their intermediates for the pharmaceutical industry.

Headquartered in Neu-Ulm, NUVISAN operates several sites in Germany and France.

Wegenerstr. 13
D-89231 Neu-Ulm
Phone: +49 (0) 731 9840-0
E-Mail: bdinfo@nuvisan.com
Internet: www.nuvisan.com



Octamer GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Epigenetic mechanisms promise to open new avenues to drug discovery because they allow interfering with the most basic processes of transcriptional regulation. We research nucleosomes for decades and offer the unique opportunity to provide disease-relevant substrates to epigenetic targets both for academic research and drug discovery.

Friedemann-Bach-Str. 95
D-82166 Gräfelfing
Phone: +49 (0) 89 21538575
E-Mail: support@octamer.com
Internet: www.octamer.de



Lise-Meitner-Str. 30
D-85354 Freising
Phone: +49 (0) 8161-976289-0
E-Mail: info@omicScouts.com
Internet: www.omicscouts.com

OmicScouts GmbH

BIOTECH BIOINFORMATICS

Keywords: Pharmacogenomics, Bioinformatics, Proteomics, Drug Development, Biomarker Discovery & Development

OmicScouts is a chemical proteomics company focused on supporting drug and biomarker discovery with its unique expertise and innovative technologies. We provide and develop proteome-wide assays that work with native proteins and enable the identification of small molecule drug targets, target engagement markers, molecular mechanisms of action and drug response biomarkers. OmicScouts supports your drug and biomarker discovery projects with end-to-end solutions tailored to project specific needs.



Zugspitzstr. 5
D-85757 München-Karlsfeld
Phone: +49 (0) 151 2062 1612
E-Mail: request4more@oncolead.com
Internet: www.oncolead.com

OncoLead GmbH & Co. KG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Clinical Diagnostics, Oncology

Oncolead, is a privately owned service provider company. We offer a unique cellular screening of anticancer agents in a panel of 80-200 cancer cell lines. Routine operation and highly standardized processes guarantee our customers the results within 2-4 weeks with outstanding reproducibility for cellular screening. Customers will further benefit from a comprehensive data analysis including correlation of activity profile with mutation status and with activity profile of thousands of known anticancer agents.



Gollierstr. 70
D-80339 München
Phone: +49 (0) 89 927 78775
Internet: www.optores.com

Optores GmbH

MEDTECH

Optores GmbH provides the world's fastest solutions for optical coherence tomography (OCT). With sweep rates of several million OCT A-scans per second, Optores founders coined the term "MHz-OCT". These ultrahigh speeds are ideal for novel OCT applications, such as real-time surgical guidance, endoscopic OCT, large area surveys, visualization of blood flow, and high-throughput industrial inspection.



Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 7801676-0
E-Mail: info@origenis.de
Internet: www.origenis.de

origenis GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Combinatorial Chemistry, Medicinal Chemistry, Automation, Combinatorics, Molecular Modelling, Small Molecules

Origenis is a privately owned company based in Martinsried, Germany, and a leader in small molecule drug discovery with over 14 years of experience in the field. Origenis runs its own patented drug discovery platform MOREsystem® which combines state-of-the-art drug design, patent analysis, chemical synthesis and biological characterization performed on 20.000 square feet of integrated lab space. We are currently focusing on anti-inflammatory and CNS drugs. Origenis runs research alliances as well as active in-house programs and is offering a variety of out-licensing opportunities via its proprietary patent database Cippix® - www.cippix.com.

Oryx GmbH & Co. KG

BIOTECH THERAPEUTICS & DIAGNOSTICS

ORYX is a privately held Munich based biotech company. The company develops three highly innovative drug candidates for the treatment of a whole range of cancers, originating from leading research institutions like the German Cancer Research Center (DKFZ) and the University of Heidelberg. The ORYX clinical development portfolio consists of an oncolytic virus and two therapeutic cancer vaccines. In 2015, these candidates successfully completed clinical Phase I/IIa trials.



Marktplatz 1
D-85598 Baldham
Phone: +49 (0) 8106 21 311-0
E-Mail: info@oryx-medicine.com
Internet: www.oryx-medicine.com

Otsuka Novel Products GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Clinical Diagnostics, Antibiotics, Infectious Diseases

Otsuka Novel Products GmbH (ONPG) est. 2011, is a subsidiary of Otsuka Group Company with an international network of 195 subsidiaries, 47,000 employees in 31 countries. With our corporate philosophy Otsuka-people creating new products for better health worldwide, ONPG focuses on fighting tuberculosis through innovative research and development, equitable access to medicines, collaborations, and capacity building programs that strengthen the quality and delivery of care.



Otsuka Novel Products GmbH

Erika-Mann-Str. 21
D-80636 München
Phone: +49 (0) 89 2060205 50
E-Mail: reception@otsuka-onpg.com
Internet: www.otsuka-onpg.com

Oxford BioLabs Ltd.

BIOTECH DEVICES & REAGENTS

Oxford Biolabs is a science-routed company that develops and markets naturally-based nutraceuticals and cosmeceuticals aimed at helping people combat unwanted signs of ageing. This includes the areas of androgenetic alopecia, hair greying, skin ageing, immune support, or healthy ageing. Our goal is to create innovative products that are of high value for its users.



'Am BioPark 9
D-93053 Regensburg
Phone: +49 (0) 941 640 791 02
E-Mail: kontakt@oxfordbiolabs.com
Internet: www.oxbiolabs.com

Panacea Biotec GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Panacea Biotec is the third largest biotechnology company (as per ABLE Survey, 2011), as well as among the top 50 pharmaceutical companies (as per ORG IMS March 2010) of India. Panacea Biotec Germany GmbH is located in Munich and delivers and markets products in transplantation, immun-suppression and anti-infection.



Landshuter Allee 8-10
D-80637 München
Phone: +49 (0) 89 5455 83-50
E-Mail: info-de@panaceabiotec.com
Internet: www.panaceabiotec.de



Gewerbepark 6
D-94501 Aidenbach
Phone: +49 (0) 8543 6016-30
E-Mail: info@pan-biotech.de
Internet: www.pan-biotech.de

PAN Biotech GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Tissue Engineering/Cell Culture, Industrial Biotechnology

PAN-Biotech GmbH, founded in 1988, manufactures and distributes sera, media, serum-free systems, biologicals, reagents and further services. We deliver our goods to customers from research, clinics and the biopharmaceutical industry. PAN-Biotech is certified by the international quality management standards of DIN ISO 9001 and the strict EN ISO 13485. Production takes place in Aidenbach, Bavaria and since this year also in its modern GMP biotech facility. "Quality - Made in Germany!"



Moosstr. 3
D-82319 Starnberg
Phone: +49 (0) 89 742846-0
E-Mail: eFlow-partnering@pari.com
Internet: www.pari.com/eflow-partnering

PARI Pharma GmbH

MEDTECH

Keywords: Antibiotics, Analytical Chemistry, Laboratory, Devices, Drug Delivery, Infectious Diseases, Respiratory Diseases

PARI Pharma's focus is the development and manufacturing of optimized eFlow® Technology nebulizers in cooperation with partners from the pharmaceutical industry. eFlow Technology is a platform suitable for a wide range of drug formulations and patient populations. It enables short development times for optimized drug-specific nebulizers.

PARI has a committed team with a considerable track record. As of today, six commercial drug-specific eFlow Technology nebulizers administer inhaled drugs.



Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 51728659-0
E-Mail: info@pelobiotech.com
Internet: www.pelobiotech.com

Pelobiotech GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Laboratory, Tissue Engineering/Cell Culture, Fine Chemicals/Reagents

PELOBIOTECH is competent for cells and offers the broadest portfolio of animal & human cells and media. We bring your research from bench to bedside. You get the whole variety of solutions from tissue dissociation to cryopreservation for research and clinical applications (GMP). Tissue Dissociation Enzymes; Defined & Xeno-free Media; Human & Animal Primary & Stem Cells from healthy & diseased donors; Tagged Cells; ES/iPS Cells, Media, Reprogramming & Small Molecules; 2D/3D Cell Culture Systems.

Pharma Stulln GmbH

PHARMA & CHEMICAL INDUSTRY; CMO

Keywords: Ophthalmology, Respiratory Diseases

Experience in manufacturing of eye drops in bottles and single-doses for almost 40 years. Specialist in manufacturing: Eye drops, Nasal sprays, Respiratory solutions and Lens care products. A modern zone concept fulfills European and international standards in production of sterile fluid pharmaceuticals. Pharma Stulln has approximately fifty well established pharmaceutical customers in Germany, Europe and international countries such as Australia, China, Canada etc.

pharma **STULLN**

Werksstraße 3
D-92551 Stulln
Phone: +49 (0) 9435 3008-0
E-Mail: info@pharmastulln.de
Internet: www.pharmastulln.de

Pharmalog – Institut für klinische Forschung GmbH CRO

Pharmalog (TÜV certified and BVMA member) offers full service with an excellent reputation for all phases of clinical trials since 1983. We operate in Germany and all EU/EEU-countries and have performed more than 400 clinical trials in all medical indications for medical products/-devices/biotechnology products.



Oskar-Messter-Str. 29
D-85737 Ismaning
Phone: +49 (0) 89 544637-0
E-Mail: pharmalog@pharmalog.com
Internet: www.pharmalog.com

PhaToCon (Pharm/Tox Concept) BIOTECH PRECLINICAL SERVICES

Keywords: Antibody, Pharmacology, Regulatory Affairs, Toxicology,
Drug Development, Drug Delivery, Tissue Engineering/Cell Culture

Safety of Medical Device and Pharma for patients and manufacturers. Our competence are toxicological Assessments (in vitro / in vivo) as well as biocompatibility evaluation and related preclinical study-management. Our support is customized, adapted from international standards like GLP/GMP, ISO, and we support "hands-on", based on science, evidence, quality and pragmatism. With our network of competence and capabilities we mark the difference to your competitor on your way to success.



Am Klopferspitz 19
D-82152 Planegg-Martinsried
Phone: +49 (0) 89 444 899-41
E-Mail: info@phatocon.com
Internet: www.phatocon.com

Phytochem Referenzsubstanzen GbRmbH

BIOTECH DNA/PROTEIN ANALYTICS

Phytochem (PC) develops, produces and markets pure reference substances for the pharmaceutical industry, research, analytics and authorities and synthesizes or isolates Impurities in remedies for customers needs with best equipment and experience. PC further develops analytical methods and new products mainly focussed on natural sources for Phytopharmaceuticals, Functional Foods as well as Cosmetics. The CEO has also the status of a qualified person acc. § 65 AMG for product release in Pharma.



Krumbacherstr. 9
D-89335 Ichenhausen
Phone: +49 (0) 731 97205-45
E-Mail: phytochem@t-online.de
Internet: www.phytochem-standards.de



Zeppelinstrasse 3
D-85399 Hallbergmoos
Phone: +49 (0) 811 12 447-0
E-Mail: info@pieris.com
Internet: www.pieris.com

Pieris Pharmaceuticals GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Respiratory Diseases, Peptide/Protein, Drug Development, Immune Therapy

Pieris Pharmaceuticals is an international Nasdaq-listed (TICKER: PIRS), clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin[®] protein to treat uncontrolled asthma and a half-life-optimized Anticalin[®] protein to treat anemia.



Raiffeisenstr. 31a
D-85276 Pfaffenhofen
Phone: +49 (0) 8441 87948-30
E-Mail: info@pika-weihenstephan.de
Internet: www.pika-weihenstephan.de

PIKA Weihenstephan GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, New Materials, Analytical Chemistry, PCR

PIKA Weihenstephan GmbH, a spin-off from TU München, is specialized in microbiology and DNA analyses for the food and beverage industries including breweries. Besides consultancy and lab service, our portfolio covers development, production and sales of products for on-site testing. Major products for quality control are FastOrange[®] enrichment media and 4everyone[™] Detection kits, besides we supply fresh yeast from our HefeFarm[®]. PIKA Weihenstephan is certified according to DIN EN ISO 9001:2015.



Industriestraße 1
D-93077 Bad Abbach
Phone: +49 (0) 9405 96 999-10
E-Mail: info@polyquant.com
Internet: www.polyquant.com

PolyQuant GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Biomarker Discovery & Development, Peptide/Protein, Laboratory, Clinical Diagnostics, Proteomics, In-Vitro-Diagnostics, R&D Service

PolyQuant provides ISO 9001:2015 certified products, services and bioinformatics support for protein analysis and proteomics covering: Stable isotope-labelled reference standards for absolute protein quantification based on our proprietary QconCAT platform technology, Kits for LC and MS instrument calibration and standardization, entire assay development for proteomics workflows (quantitative/qualitative), comprehensive support for protein analytics (Medtech, Biotech, Life Sciences, Pharma).



Rankinestrasse 1
D-86899 Landsberg a. L.
Phone: +49 (0) 8191 985 688-0
E-Mail: info@postnova.com
Internet: www.postnova.com

Postnova Analytics GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices

Postnova is a manufacturer of analytical instruments based on Field-Flow Fractionation. The application range of 1 nm-100 µm and 1000 Da up to many MDa, Postnova provides an analytical tool for the separation/characterization of particles, polymers, proteins, viruses, antibodies, liposomes or exosomes in complex aqueous/organic matrices. Postnova offers the complete range of FFF techniques as Electrical/Asymmetrical FlowFFF, CentriFFF and ThermalFFF along with detection as MALS, DLS, and ICP-MS.

PPD Germany GmbH & Co. KG

CRO

Keywords: Medical Writing, Logistics, Devices, Drug Development

PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. With offices in 46 countries and more than 23,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. Visit www.ppdi.com.



Hansastr. 32
D-80686 München
Phone: +49 (0) 89 57877-0
E-Mail: genl.info@ppdi.com
Internet: www.ppdi.com

PreciPoint GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Automation, Devices

PreciPoint, located in Freising, is a manufacturer of digital microscopes and complex lab automation devices. PreciPoints core competency is combining optics, mechanics, electronics, firmware and software to modern micro imaging applications. Currently, the company is focused on Whole Slide Imaging, Digital Pathology and Virtual Microscopy. Our well-rounded engineering staff develops practical, economical and precisely manufacturable solutions for a wide array of complex problems.



Alois-Steinecker-Str. 22
D-85354 Freising
Phone: +49 (0) 8161 976979-0
E-Mail: vertrieb@precipoint.de
Internet: www.precipoint.de

PreOmics GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Molecular Diagnostics, Proteomics, Bioanalytics, Clinical Diagnostics

The PreOmics GmbH develops and commercializes tools for mass spectrometry-based proteomics. The main focus are easy and optimized sample preparation methods enabling fast, efficient and sensitive measurements at high throughput. PreOmics further develops instruments for automated fractionation and enrichment to achieve complete proteomics and to facilitate the analysis of signal-transduction pathways. PreOmics addresses customers in research, drug development and diagnostics.



Am Klopferspitz 19
D-82152 Planegg/Martinsried
Phone: +49 (0) 89 23 14 163-0
E-Mail: info@preomics.com
Internet: www.preomics.com

PreSens Precision Sensing GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Drug Development, Tissue Engineering/Cell Culture, Analytical Chemistry

PreSens is a world leader in the field of chemical-optical sensors and develops, manufactures and distributes microsensors, 2D imaging and non-invasive sensor systems for Biotech & Pharma, Food & Beverage, Scientific Applications and Medical Devices – with service all over the world. The out-of-box products and the engineering of customized sensors focus on parameters essential for life: oxygen, pH, CO₂ and biomass. PreSens is certified EN ISO 13485:2016 and ISO 9001:2015.



Am BioPark 11
D-93053 Regensburg
Phone: +49 (0) 941 94272-100
E-Mail: info@presens.de
Internet: www.presens.de



Geyerspergerstr. 27
D-80689 München
Phone: +49 (0) 89 58 00 82-0
Internet: www.prevtectmicrobia.com/en/

Prevtect microbia GmbH

PHARMA ANIMAL HEALTH

Prevtect microbia is an agri-food biotechnology company specialized in developing technologies and marketing products for improving the health of food animals in order to increase production performance and food safety. Prevtect microbia's mission is to be a world leader in the development and commercialization of products providing an alternative to antibiotics for the prevention of bacterial infections and the improvement of food animal performance. The company has offices in Montreal and Saint-Hyacinthe, Quebec (Canada). Its German based subsidiary is run in conjunction with Klifovet AG.



Fraunhoferstr. 22
D-82152 Martinsried
Phone: +49 (0) 89 452289-700
E-Mail: info@project-pharmaceutics.com
Internet: www.project-pharmaceutics.com

Project Pharmaceuticals GmbH

CRO

Keywords: Drug Development, Drug Delivery, AntibodyDrugConjugate ADC, Antibody, Peptide/Protein, Small Molecules, Viruses

Project Pharmaceuticals transfers delicate pharmaceutical molecules into pioneering drugs with a deep expertise in formulation and pharmaceutical process development for liquid or lyophilized proteins, high-concentration products, ADCs / cytotoxics and live viral vaccines. We develop a quality product and its manufacturing process on a scientific rationale pursuant to international guidelines. Teamed up with manufacturing CMOs, we smooth technology transfer from pre-clinical to large-scale supply.



Bunsenstr. 7a
D-82152 Martinsried
Phone: +49 (0) 89 700761-0
E-Mail: business@proteros.com
Internet: www.proteros.com

Proteros biostructures GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Oncology, Metabolic Diseases, Infectious Diseases, Cardiovascular Diseases, Small Molecules, Fine Chemicals/Reagents, 3D-Structural Analysis

Proteros, Martinsried/Munich, Germany is a private biotechnology company aimed at drug discovery for technically demanding drug targets. Proteros is currently working for most of the big pharma and biotech companies in Europe, US and Japan in different types of service and collaborative relationships. For more information please visit www.proteros.com.



Behringstrasse 7
D-82152 Planegg-Steinkirchen
Phone: +49 (0) 89 89996080
Internet: www.psi-cro.com

PSI CRO Deutschland GmbH

CRO

PSI CRO Deutschland GmbH is a subsidiary of PSI CRO AG (Switzerland), a globally operating service provider specialized in clinical research and development services on behalf of the pharmaceutical and biotechnology industry. With more than 100 employees in Germany and over 2500 worldwide, we plan and execute clinical trials related to the global development of new therapies in many indications like Oncology, Gastroenterology, Haematology, Infectious Diseases, MS and other rare diseases.

PUREN Pharma GmbH & Co. KG, ein Unternehmen der Aurobindo Pharma Ltd.

PHARMA & CHEMICAL INDUSTRY

Already in the 1980s, PUREN Pharma had an important position in Germany thanks to high-quality, inexpensive generics and numerous branded drugs. Over time strategic takeovers have led to diverse company names. The range grew in the area of therapy-relevant generics and branded medicines, the broadest parenteral portfolio for clinics in Germany and attractive OTC specialties. Actavis Germany has been part of the Actavis-Allergan group and belongs now to the globally operating AUROBINDO group.



Willy-Brandt-Allee 2
D-81829 München
Phone: +49 (0) 89 558909-0
E-Mail: info@puren-pharma.de
Internet: www.puren-pharma.de

quattro research GmbH

BIOTECH BIOINFORMATICS

quattro research addresses the needs of life science and chemical industry by providing state-of-the-art solutions to manage all scientific data produced in research projects. Our applications help scientists to optimise the value of their research data, e.g. the compound management solution quattro/CM or the ELN quattro/LJ. quattro research offers software development and consulting services to solve any data management challenges in life science R&D, e.g. Biologics registration.



Fraunhoferstraße 18a
D-82152 Martinsried
Phone: +49 (0) 89 4132904-0
E-Mail: info@quattro-research.com
Internet: www.quattro-research.com



VOSSIUS

Special Ideas Require Special Protection

For over 60 years, VOSSIUS & PARTNER has been providing high-end consultancy for innovative companies in all fields of patent, trademark, design and copyright law. VOSSIUS & PARTNER works in your interest: competently, reliably, precisely and creatively.

Legal areas. Patents, trademarks and brands, design rights, copyrights, know-how protection, domains, competition law, anticounterfeiting, software and IT, data protection, law on employees' inventions, licensing, food law, distribution agreements, franchise agreements, R & D agreements, media law, right of publicity, antitrust aspects in licensing, supplementary protection certificates.

Technical areas. Mechanical & electrical engineering, IT, physics, chemistry, biotechnology, pharmacology, life sciences.

Services. IP prosecution, IP litigation, IP searches, freedom to operate, contracts, annuities, arbitration, mediation, IP portfolio management, due diligence, strategic IP consulting, IP landscaping, IP valuation services.

It is not without reason that VOSSIUS & PARTNER is among Europe's most renowned law firms in the field of intellectual property.

www.vossius.eu

Taking Ideas Further
Intellectual Property and Technology Law Expertise

RAS AG

An der Irlrer Höhe 3a
D-93055 Regensburg
Phone: +49 (0) 941 60717-300
E-Mail: office@ras-ag.com
Internet: www.ras-ag.com/kontakt

RAS AG

PHARMA & CHEMICAL INDUSTRY

The RAS AG emerged from the merger of rent a scientist® GmbH and the ras materials GmbH. The task of the new corporation is to develop, produce and sell new materials and technologies. The R&D services are still available as a 'rent a scientist®' division.



Kettelerstr. 3-11
D-97222 Rimpar
Phone: +49 (0) 9365 8826-43
E-Mail: info@rapidbiomed.de
Internet: www.rapidbiomed.de

RAPID Biomedical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Oncology, CNS, Cardiovascular Diseases, Bone/Joint Diseases, Devices

RAPID Biomedical GmbH is specialised in RF coils for MRI and NMR spectroscopy. Our products include 1H MR resonators for clinical studies at all magnetic field strengths and for all organs. We also supply multi-nuclear (e.g. 1H / 31P) MR-coils for combined MRI and MRS in clinical and basic science investigations. We offer custom made MR probeheads for routine animal research and various accessory devices. Our recent work concentrates on dual tuned coils and multi array coils for parallel MRI both for human as well as for animal studies.

REMARK



Ringstr. 3
D-85764 Oberschleißheim b. München
Phone: +49 (0) 89 31577199
E-Mail: info@remark-pharma.de
Internet: www.remark-pharma.de

REMARK GmbH

Pharmaservices & Consulting

CRO

Keywords: Drug Development, Medical Writing, Clinical Trial Management and Monitoring, R&D Service

REMARK is a privately owned pharma services and consulting company founded in 1999. Quality and speed are the decisive factors in the success of a company involved in the healthcare market. To reach your goals we offer the following services: - Strategic Consulting - Project Management - Sponsor Representative - Medical Affairs Services - Quality Assurance Services - Medical Marketing For more information visit our web site at www.remark-pharma.com.



Ainmillerstr. 22
D-80801 München
Internet: www.resmechanica.com

res mechanica

BIOTECH BIOINFORMATICS

res mechanica is a Munich-based company that develops hema.to, a software service for automatic and supportive diagnosis of leukemia based on flow cytometric data using artificial intelligence. hema.to has achieved a level of reliability in the diagnosis of mature B-cell neoplasms that is comparable to the judgment of an experienced diagnostician and is demonstrably world-class.

Ritter GmbH, Medical

BIOTECH DEVICES & REAGENTS

Keywords: Genomics, PCR, Pharmacogenetics, Proteomics, Devices, Automation, ELISA/EIA

Ritter GmbH was founded 1965. The company is established in Schwabmünchen, Bavaria. On 25,000 m² Ritter develops and produces with about 300 employees sterile and non-sterile laboratory equipment, high precision dispensers, tips and plates, certified according to the current DIN EN ISO 9001 and 13485 standards. In more than 70 countries, millions of Ritter medical products are used in clinical and biotechnological applications every day. Products: Robotic Consumables, Liquid Handling, Clinical Products.



Kaufbeurer Str. 55
D-86830 Schwabmünchen
Phone: +49 (0) 8232 5003-0
E-Mail: medical@ritter-online.de
Internet: www.ritter-medical.de

Rnatics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

rnatics develops therapeutics to target disease-causing RNAs in tissue resident macrophages. This novel way of delivery enables access to organs previously not accessible to nucleic acid therapy offering tremendous therapeutic opportunities for multiple diseases. For the first indication, COVID-19, IND-enabling work is ongoing, and we aim to begin first-in-human studies by the end of this year.



Am Klopferspitz 19a
D-82152 Martinsried
E-Mail: info@rnatics.com
Internet: www.rnatics.com

Roche Diagnostics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Peptide/Protein, Antibody, PCR, ELISA/EIA, Automation, Clinical Diagnostics, Drug Development

Roche Diagnostics GmbH is part of Roche, Switzerland, a leader in research-focused healthcare with combined strength in pharma and diagnostics. At Penzberg, Roche runs one of Europe's largest biotechnology centers for research, development and production as well as a pioneer in digital health. The portfolio comprises test systems for the life science market, diagnosis, patient stratification and therapy monitoring as well as therapeutic proteins with focus on antibodies and biomarkers for oncology.



Nonnenwald 2
D-82377 Penzberg
Phone: +49 (0) 8856 60-0
E-Mail: penzberg.allgemein@roche.com
Internet: www.roche.de

R-Pharm Germany GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Automation, Logistics

For many years we have been manufacturing and packaging pharmaceuticals for patients in over 150 countries. Innovative technologies and a highly motivated and competent team guarantee highest reliability and quality standards as well as an extraordinary price-performance ratio besides patient safety and customer satisfaction including personal contact. A company history of more than 150 years - both independent and historically within the global production network of Pfizer, Inc. is our pride.



R-PHARM
Germany GmbH

Heinrich-Mack-Str. 35
D-89257 Illertissen
Phone: +49 (0) 7303 12-0
E-Mail: r-pharm-germany@r-pharm.com
Internet: www.r-pharm.de

SanoLiBio GmbH

Walpurgisstraße 4
D-81677 München
Phone: +49 (0) 89 20 333 292
E-Mail: info@sanolibio.com
Internet: www.sanolibio.com

SanoLiBio GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

SanoLiBio focuses on automated solutions in blood circulating rare cell enrichment and rare cell analysis. Cost-efficiency, accessibility, scalability, and diagnostic accuracy drive our innovations. Our technology distinguishes itself from any existing rare cell enrichment platform by our no-loss enrichment of desired cells. SanoLiBio's market priority is non-invasive prenatal testing and cancer diagnostics and ultimately, thriving to pioneer disease prevention by cell-based liquid biopsy.



Am Klopferspitz 19
DEU-82152 Martinsried
Phone: +49 (0) 89-614241230
E-Mail: info@SciRhom.com
Internet: www.SciRhom.com

SciRhom GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Rheumatoid Arthritis, Inflammation, Autoimmune Diseases, Antibody, Drug Development

SciRhom GmbH, a biopharmaceutical start-up company, develops first-in-class antibodies against iRhom2, a key modulator of several crucial pro-inflammatory signaling pathways, including TNF-alpha signaling. Based on a decade of cutting-edge bench research and the successful completion of antibody generation campaigns, SciRhom is now pursuing the preclinical and early clinical development of monoclonal antibodies against iRhom2 for the treatment of autoimmune and other serious diseases.



Am Klopferspitz 19
D-82152 Planegg/Martinsried
Phone: +49 (0) 89 21546375
E-Mail: info@secarna.com
Internet: www.secarna.com

Secarna Pharmaceuticals GmbH & Co. KG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Secarna Pharmaceuticals is the leading independent European antisense drug discovery and development company. Leveraging its proprietary LNAplus platform, Secarna develops next generation antisense oligonucleotide (ASO) therapies addressing challenging or currently undruggable targets. LNAplus™ is fully validated by over 15 in-house programs and numerous industry collaborations focusing on immuno-oncology, immunology, fibrotic-, viral-, neurodegenerative- and cardiometabolic diseases.



Lilienthalstr. 7
D-85579 Neubiberg
Phone: +49 (0) 89 2030 8016-51
E-Mail: info@securetec.net
Internet: www.securetec.net

Securetec Detektions-Systeme AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Analytical Chemistry, R&D Service, In-Vitro-Diagnostics, Infectious Diseases, Antibody, Toxicology, Small Molecules

Securetec Detektions-Systeme AG provides specific technologies for the detection of drugs and hazardous substances. We understand the worldwide demands of traffic safety, customs and enforcement authorities. Our competencies are the development and production of test solutions for a highly reliable day-to-day use for a multitude of rapid identification applications of drugs and hazardous substances. We detect to protect - Securetec is proud to play a part in making today's world a safer one.

selectiON Therapeutics GmbH,
Martinsried,
selectiON Inc., San Diego
BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Peptide/Protein, CNS, Pain, Cardiovascular Diseases

selectiON is a privately owned biopharmaceutical company focused on the development of new peptide therapeutics for the treatment of severe autoimmune diseases and rare oncology indications. The Company has established an efficient technology platform to develop highly selective peptide blockers for ion channels. The most advanced drug candidate is si-544, a best-in-class Kv1.3 blocker for treatment of effector memory T cell (TEM) driven diseases.



Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 547 2695-0
E-Mail: info@selectiontherapeutics.com
Internet: www.selectiontherapeutics.com

Sension GmbH
BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, ELISA/EIA, Autoimmune Diseases, Antibody

Sension develops immunoassays and rapid test systems for on-site analysis. The tests find broad applications in the fields of food analysis, environmental analysis, medical diagnostics, reproductive management in agriculture, and in the monitoring of samples for mold. Also technologies for label production to prevent products from counterfeiting are realized. Sension is realizing own product developments, but also performs R&D developments for partners and customers and specifically focus on the specific needs required.



Provinostr. 52, Gebäude B14
D-86153 Augsburg
Phone: +49 (0) 821 455799-0
E-Mail: info@sension.eu
Internet: www.sension.eu

SequiServe GmbH
BIOTECH DNA/PROTEIN ANALYTICS

Sequiserve offers the following custom services in molecular biology: Sanger-DNA-sequencing (plasmids, PCR-products, BACs, PACs, primer-walking, direct sequencing of bacterial pellets). Purification of PCR products and Plamid-DNA preparation for subsequent sequencing. Sequiserve - your expert in DNA-sequencing since 1994!



Joh.-Seb.-Bach-Str. 7
D-85591 Vaterstetten
Phone: +49 (0) 8106 8887
E-Mail: service@sequiserve.de
Internet: www.sequiserve.de

SERVIER Deutschland GmbH
PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Cardiovascular Diseases, Hematology, Neurology, Rheumatoid Arthritis, Oncology

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Paris-Suresnes). With a strong international presence in 149 countries and a turnover of 4.6 billion euros in 2019, Servier employs 22 000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excl. generics) in R&D. Five areas of excellence: cardiovascular, immune-inflammatory, neurodegenerative diseases, cancer, diabetes and generics.



Elsenheimerstr. 53
D-80687 München
Phone: +49 (0) 89 57095-01
E-Mail: arnd.prillipp@servier.com
Internet: www.servier.de

SIGMA-ALDRICH®

Eschenstr. 5
D-82024 Taufkirchen
Phone: +49 (0) 89 6513-0
E-Mail: deorders@sial.com
Internet: www.sigma-aldrich.com

Sigma-Aldrich Chemie GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Proteomics, Antibody, Genomics, CNS, Small Molecules, Knock Out, PCR

Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals and in industry. Sigma-Aldrich operates in 36 countries and has over 7,600 employees providing excellent service worldwide.



Gollier Str. 70 C
D-80339 München
Phone: +49 (0) 89 500941-0
E-Mail: info@silantes.com
Internet: www.silantes.com

Silantes GmbH

BIOTECH DEVICES & REAGENTS

Silantes GmbH, engages in development, manufacturing, marketing and distribution of stable isotopically labeled biomass and bio-molecules. By using a new patented technique for labelling S-isotopic bio-molecules, Silantes is able to offer improved quality and reduced costs for the customers in industrial and academic research fields at the same time. Additionally, international research projects with different scientific groups and close collaboration with NMR-specialists enable synergetic effects.



Kurpromenade 2
D-95448 Bayreuth
Phone: +49 (0) 921 730052-10
Internet: www.simfo.de

SIMFO GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

simfo GmbH is a research and development facility with advanced expertise in personalized medicine. It focuses particularly on the development of innovative analysis methods in haematological and oncological diagnostics. With maintrac®, simfo GmbH offers an analysis platform for the early detection of circulating tumor cells. In simfo, biotechnology and pharmaceutical companies will find a professional partner for conducting scientific studies and for preclinical phases of drug development.



Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 856625-55
E-Mail: info@sinatur.net
Internet: www.sinatur.net

SiNatur GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Metabolic Diseases, Diabetics

SiNatur owns the patent rights for the structure, preparation and medicinal applications Sub-Nano-Silicic Acid (SNSA). This recently discovered SNSA is the first biologically active form of silicic acid and of silicon generally. The substance is a potent inhibitor of P-type ATPases and of certain Protein-Phosphatases with IC50 in the nanomolar range. Due to the ubiquitous presence of Si in living organisms the discovery of the first biological active form of this element will have a broad scientific and practical impact. SiNatur is developing medicinal applications of SNSA first of all in the therapy of diabetes and of gastric hyperacidity.

SIRION BIOTECH GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Gene Transfer, R&D Service, Viruses, Cell Therapy, Gene Therapy, Drug Development

SIRION Biotech offers the world's most comprehensive viral vector AAV-, Lentivirus-, and Adenovirus-based technologies to expedite gene and cell therapy and vaccine R&D. LentiBOOST transduction reagent is actively used to improve hematopoietic cell transductions in clinical trials (USA, Europe). Commercial arrangements range from fee-for-service, all the way to milestone & licensing.



Am Haag 6
D-82166 Gräfelfing
Phone: +49 (0) 89 700961-999
E-Mail: info@sirion-biotech.de
Internet: www.sirion-biotech.com

siTOOLS Biotech GmbH

BIOTECH DEVICES & REAGENTS

Keywords: RNAi & Antisense

siTools Biotech is a young, innovative Biotech start-up dedicated to provide innovative and superior RNAi reagents to the scientific community. siTools Biotech is located at Munich's biotech cluster in Planegg/Martinsried. "siPools" are highly complex but accurately defined pools of siRNAs. They enable highly efficient and reliable target gene silencing without detectable off-target effects.



Lochhamer Straße 29a
D-82152 Planegg
Phone: +49 89 12501 4800
E-Mail: info@sitools.de
Internet: www.sitoolsbiotech.com

Smart4Diagnostics GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Bioinformatics

Smart4Diagnostics GmbH closes the data gap between blood collection and lab analysis and enables a new quality standard for diagnostic decision making. We change medical diagnostics from a trust-based system into an evidence-based system. Our digital human sample fingerprint is a quantum leap forward for patient safety, the quality of medical decisions and sample turnaround time in the lab. We create a trustworthy and verifiably basis for the personalized medicine of the future.



Trogerstraße 14
D-81379 München
Phone: +49 (0) 89 724 018 40
E-Mail: contact@s4dx.com
Internet: www.smart4diagnostics.com

SmartBax GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Infectious Diseases, Medicinal Chemistry, Small Molecules

smartbax develops novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms. With the first-in-class compounds, the company targets the multi-drug resistant pathogens methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant enterococci (VRE). Due to the increasing prevalence of resistance against marketed antibiotics, smartbax addresses an urgent medical need which is growing dramatically.



Leopoldstraße 37
D-80802 München
Phone: +49 (0) 151 5835 0852
E-Mail: info@smartbax.de
Internet: www.smartbax.de



Mühlthaler Str. 91c
D-81475 München
Phone: +49 (0) 89 854 665-13
E-Mail:
ulrichschubert@smartecbio.de
Internet: www.smartecbio.de

SMARTEC IngenieurBüro

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Automation, Chip/Array Technology, PCR, Tissue Engineering/ Cell Culture

Smartec IngenieurBüro is your competent partner for individual system approaches and instrument development in the biological laboratory. Smartec IngenieurBüro convinces with know-how within the ranges biotechnology, analytics, genetic engineering, micro technology as well as micro fluidic. Smartec IngenieurBüro solves tasks of instrumentation for molecular and immunological process engineering. Smartec IngenieurBüro supports you from the idea to all stages of the product.

Sourcia.

Lochhamer Strasse 31
D-82152 Martinsried
Phone: +49 (0) 151 74403195
Internet: www.sourcia.eu

Sourcia GmbH

CRO

Keywords: Pharmacovigilance, Regulatory Affairs, Drug Development, Clinical Trial Management and Monitoring, R&D Service, Devices

Sourcia is your high-experienced, flexible and independent partner in clinical development. While you are focusing on sciences, we are your partner in project management, operational set-up and execution of your Clinical Development Plan.



Landsberger Str. 23/25
D-82110 Germering
Phone: +49 (0) 89 800 650-0
E-Mail: info@cro-sss.de
Internet: www.cro-sss.eu

SSS International Clinical Research GmbH

CRO

SSS International Clinical Research is a Service Provider for the pharmaceutical, biotechnological and medical device industry since 1993, with headquarter in Germany and subsidiaries in Romania and Poland. We provide high quality, comprehensive and internationally integrated Clinical Operations Services throughout Europe. Our services have been proven for more than 25 years and through many successful projects.



Aschauer Str. 26b
D-81549 München
Phone: +49 (0) 89 5527 1520
E-Mail: info@staburo.de
Internet: www.staburo.de

Staburo GmbH – Statistical Consulting

CRO

Keywords: Oncology, Data Management and Biostatistics, Biomarker Discovery & Development, Bioinformatics, Data Management, Cardiovascular Diseases

Staburo is a Munich-based data science company, specialized in statistical consulting and programming in the field of clinical trials. We develop tailor-made client solutions, based on our 6 pillars: Clinical statistics, Translational medicine & biomarkers, PK/PD, HTA, Non-clinical statistics and statistical programming. Our customers are pharmaceutical companies, CROs and biotech companies, with whom we work on a flexible basis.

SÜD-LABORBEDARF GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Devices

SLG is a German whole seller for molecular biology research consumables, located in Gauting near Munich since 1980. Our main business is high quality consumables such as gloves, liquid handling products, DNA/RNA kits and plastic ware like racks and cryo boxes. We sell by direct mail to Germany, Austria and Switzerland and through distributors in various European Union countries under our own brands SLG, SafeGrip, SL-Tip, SL-Pette and Hi Yield.



Starnberger Str. 22
D-82131 Gauting
Phone: +49 (0) 89 850 6527
E-Mail: info@suedlabor.de
Internet: www.suedlabor.de

Swedish Orphan Biovitrum GmbH, SOBI

BIOTECH THERAPEUTICS & DIAGNOSTICS

Swedish Orphan Biovitrum is an international company specializing in rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of these patients and their families. The Swedish Orphan Biovitrum GmbH (Sobi) has been active in Germany since 2017. The company is based in Martinsried, Bavaria. Behind the success of Sobi are the nearly 40 employees in Germany whose daily motivation is to help improve the lives of patients with rare diseases.



Fraunhoferstr. 9a
D-82152 Martinsried
Phone: +49 (0) 89 550 66 760
E-Mail: mail.de@sobi.com
Internet: www.sobi.com

SYNLAB pharma institute

CRO

Keywords: Analytical Chemistry, Bioanalytics, R&D Service, Logistics,
Clinical Diagnostics, Laboratory, Biomarker Discovery & Development

SYNLAB Pharma offers a very broad range of laboratory services to the biotechnology and pharmaceutical industries as well as to manufacturers of medical devices. Our portfolio includes global clinical trial services, bioanalytical services, biomarker testing, personalized medicine concepts, logistics, sample storage, production monitoring, product release and stability studies, always working in accordance with the highest standards such as DIN/EN ISO/IEC 17025/15189, GMP, GLP, GCLP or GCP.



Bayerstr. 53, SPI-Munich, 6. Stock
D-80335 München
Phone: +49 (0) 89 741393-0
E-Mail: SPI-Munich@synlab.com
Internet: www.synlab.com

Syntacoll GmbH

PHARMA & CHEMICAL INDUSTRY

Syntacoll is a subsidiary company and the only development and production site of Innocoll Pharmaceuticals Limited, an international pharmacy group. Since 1992, Syntacoll is developing and producing innovative, collagen-based absorbable implants and wound dressings at our production site in Saal an der Donau. Our facility is GMP compliant and ISO 13485 certified. Additionally, Syntacoll holds a manufacturing license for collagen-based drugs.



Donaustr. 24
D-93342 Saal/Donau
Phone: +49 (0) 9441 6860-0
E-Mail: info@syntacoll.de
Internet: www.syntacoll.de



Albrechtstr. 14
D-80636 München
Phone: +49 (0) 89 126680-0
Internet: www.synteract.com

Synteract GmbH

CRO

Keywords: Cardiovascular Diseases, CNS, Metabolic Diseases, Nephrology, Oncology, Pain

Synteract is an innovative mid-size CRO with European HQ in Munich. We are providing international, full-service, Phase I-III clinical trials services to biopharma companies. Over its nearly 35-year history, Synteract has contributed to more than 240 product approvals. Our core development areas are: oncology, dermatology, neuro sciences, general medicine and vaccination, rare/orphan disease, and pediatrics.



Stefan-George-Ring 6
D-81929 München
Phone: +49 (0) 89 993913-0
E-Mail: reza.khosravani@syneoshealth.com
Internet: www.syneoshealth.com

Syneos Health Germany GmbH

CRO

Keywords: CRO/CMO, Clinical Trial Management and Monitoring, Medical Writing

The coming together of INC Research and inVentiv Health as one global company, called Syneos Health, has created the industry's only true end-to-end solution. This one entity combines world-renowned clinical research and commercialization capabilities with today's most advanced science, business and data technologies to make real advances possible. We help you improve performance, reduce risk and expedite delivery of healthcare innovation to patients worldwide.



Balanstr. 6
D-81669 München
Phone: + 49 (0) 89 2155 3085
E-Mail: info@systasy.de
Internet: www.systasy.de

Systasy Bioscience GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: R&D Service, Biomarker Discovery & Development, CNS, Personalized Medicine, Small Molecules, Drug Development

Systasy Bioscience GmbH is a biopharma company, founded in 2012, engineering biology to decode the human complexity for discovering new drugs targeting mental disorders. Systasy's game changing approach will disrupt the drug market by introducing a scalable and unrivaled signalomics-based and AI-powered drug discovery engine, called Barcoded Drug Discovery Engine. Systasy combines its core technologies, molecular barcoding and human disease modelling, with phenogenomic compound screening and AI crawled-big data analysis to enable personalized medicine.



Friedrich-Bergius-Ring 15
D-97076 Würzburg
Phone: +49 (0) 931 250 99 712
E-Mail: info@t-curx.com
Internet: www.t-curx.com

T-CURX GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Hematology, Personalized Medicine, Cell Therapy, Drug Development

T-CURX develops a new generation of CART cells for personalized cancer immunotherapy built on proprietary technologies that overcome challenges in safety & efficacy, manufacture & scalability of conventional CART therapy. T cells are reprogrammed using virus-free gene transfer to destroy tumor cells. CART cells are living drugs that persist life-long and aim to provide continuous protection from relapse. T-CURX's product pipeline addresses several cancer indications within hematology and oncology.

TauroPharm GmbH

PHARMA & CHEMICAL INDUSTRY

TauroPharm GmbH is a healthcare company founded in 2000 and based in Waldbüttelbrunn, Germany. We want to minimize infection risks in global healthcare and thus increase patient safety worldwide. We manufacture products that prevent infections associated with central venous catheters and port systems in a variety of applications like administration of medication in the fields of oncology and haematology as well as other implanted medical devices.



August-Bebel-Straße 51
D-97297 Waldbüttelbrunn
Phone: +49 (0) 931 40480511
E-Mail: infos@tauropharm.de
Internet: www.tauropharm.de

The NCD Company GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Toxicology

The NCD Company is an independent project company and provides all services of a non-clinical development department for biotech and pharma companies with an experienced team at highest level. By outsourcing preclinical development, you will increase flexibility, save internal resources and ensure the access to a broad spectrum of knowledge and experience. We provide Drug Development Planning and Management, Safety Testing/Toxicology, ADME/DMPK, Outsourcing, QA (GLP) and Regulatory Submission.



Propst-Hartl-Straße 8
D-82398 Polling
Phone: +49 (0) 881-12123876
E-Mail: info@ncd-company.com
Internet: www.ncd-company.com

Therawis Diagnostics GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: In-Vitro-Diagnostics, Oncology

Therawis Diagnostics GmbH was founded by an experienced team with proven track record in oncology, diagnostics, corporate development, capital markets and develops diagnostics to support and guide optimal therapy for cancer patients. Therawis Diagnostics and its partner Qjagen, Hilden, Germany, launched the thescreenPITX2 RGQ PCR Kit in 2018, a novel clinically validated biomarker test to predict outcome to anthracycline-based chemotherapy in high risk breast cancer patients.



Grillparzerstrasse 14
D-81675 München
Phone: +49 (0) 89 41 42 45 57-0
E-mail: info@therawis.com
Internet: www.therawis.com

Thermo Fisher Scientific GENEART GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Genomics, Combinatorics

Thermo Fisher Scientific supplies innovative solutions for the world's pharmaceutical and biopharmaceutical industries. With applications that span the drug development process - from drug discovery through large-scale commercial production - we provide a broad range of products and services including single-use technologies, customized fluid transfer systems, high-quality media and sera, freezing and storage equipment, and innovative consumables and reagents, purification, and analytics.



Im Gewerbepark B35
D-93059 Regensburg
Phone: +49 (0) 941 94276-0
E-Mail: geneart.info@lifetech.com
Internet: www.thermofisher.com



Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 7167 760-31
Fax: +49 (0) 89 7167 760-49
E-Mail: info@thermosome.com
Internet: www.thermosome.com

Thermosome GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Liposomes, Small Molecules, Drug Development, Drug Delivery

Thermosome is leveraging its technology platform to create products with improved therapeutic index that exploit a novel MoA called intravascular drug release. Drug-loaded nanocarriers are created which after i.v. infusion release their content locally upon the influence of mild heat achieved by various clinically established targeted heating techniques (microwave, ultrasound). As a result, up to 15-fold higher local drug concentrations can be reached to improve therapeutic outcomes.



Friedenstraße 18
D-81671 München
E-Mail: info@tilibit.com
Internet: www.tilibit.com

tilibit nanosystems GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Nanobiotechnology, New Materials, R&D Service

tilibit nanosystems is specialized in the development and production of functional DNA nanostructures. We offer the design of custom structures for research applications, as well as collaborative development projects with industry partners for novel commercial applications. Nanostructure application fields comprise fields such as drug delivery, diagnostics, sensors, and analytical devices.



Am Klopferspitz 19a
D-82152 Planegg/Martinsried
Phone: +49 (0) 89 2032 4142-20
E-Mail: info@till-id.com
Internet: www.till-id.com

TILL I.D. GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Automation, Microscopy, Imaging, 3D-Structural Analysis

TILL I.D. is a small, innovative company in between research and industry. We develop concepts and prototypes for all areas in light microscopy. Our projects focus on an innovative microscopy platform, which is entirely tailored for digitalization. Its versatility and flexibility does not stem from a number of attachable modules, but from a fundamental design to which different imaging techniques and illumination concepts have contributed right from the start.



Fraunhoferstr. 18 a
D-82152 Martinsried
Phone: +49 (0) 89 2441 45412-81
E-Mail: info@toplab.de
Internet: www.toplab.de

TopLab GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Proteomics

TOPLAB GmbH is a leading ISO 9001/GMP certified and FDA registered service provider having outstanding expertise in proteome analysis, protein identification and characterization with more than 25 years of experience. The vision of TOPLAB is to support our clients from pharma, biotech and academia with highest quality standards, modern technologies and an experienced and highly motivated team, to achieve confident results in compliance with the timelines of our customers with calculable costs.

TRIGA-S e.K. Scientific Solutions

CRO

Keywords: Laboratory, Data Management and Biostatistics, Clinical Trial Management and Monitoring, Regulatory Affairs, In-Vitro-Diagnostics, Molecular Diagnostics

TRIGA-S is a contract research institute and has stood for quality and reliability in clinical and analytical studies of in-vitro diagnostics for over 20 years. We offer manufacturers tailor-made performance studies according to EU-IVDR. In addition, we carry out contract measurements in our in-house laboratory. We are ISO 13485 certified and work according to the requirements of GCP/GCLP, GDP and GLP.



Mühlal 5
D-82392 Habach
Phone: +49 (0) 8847 695 78-0
E-Mail: info@triga-s.de
Internet: www.triga-s.de

TRION Research GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Immune Therapy, Antibody Production Service

Our services comprise Liquid Biopsy diagnostics with the analysis of virus-infected cells and the detection of disseminated tumor cells in blood, urine and other body fluids. Moreover, we offer the full range of preclinical and clinical support from trial design over immunomonitoring and tumor biology analysis to data management and logistics solutions. We work together with our partners to elucidate the modes of action of new compounds.



Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700 766-0
E-Mail: mail@trionresearch.de
Internet: www.trionresearch.com

Tubulis GmbH

OTHER SERVICES

Keywords: Oncology, AntibodyDrugConjugate ADC, Drug Delivery, Drug Development

Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.



Butenandtstraße 1
D-81377 München
E-Mail: info@tubulis.com
Internet: www.tubulis.com

vasopharm GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

vasopharm is a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences. The company is focused on the development of therapeutics which permits steering the bioavailability of biological NO, covering the entire NO/cGMP signal cascade and its functional counterpart NOX. vasopharm's drug candidate VAS203 represents a completely new class of NOS modulators targeting cerebral vessels and cerebral tissue, thus preventing life threatening rises in intracranial pressure after a traumatic brain injury.



Friedrich-Bergius-Ring 15
D-97076 Würzburg
Phone: +49 (0) 931 359099-0
E-Mail: office@vasopharm.com
Internet: www.vasopharm.com



Robert-Koch-Allee 29
D-82131 Gauting
Phone: +49 (0) 89 897969-0
E-Mail: info@vectura.com
Internet: www.vectura.com

Vectura GmbH

MEDTECH

Keywords: Inflammation, Respiratory Diseases, Infectious Diseases, Small Molecules, Peptide/Protein, Devices, Drug Delivery

Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading inhaled airways disease focused business with proprietary formulation and devices across DPI, pMDI and smart nebulisation platforms. With our extensive range of technologies, capabilities and collaborations, we believe we can become a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases. Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies.



Am BioPark 11
D-93053 Regensburg
Phone: +49 (0) 941 463 747 30
E-Mail: office@velvio.com
Internet: www.velvio.com

Velvio GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Velvio develops medicines to restore organ repair functions as treatment for Orphan Diseases in Neurodegeneration – first of all Amyotrophic Lateral Sclerosis (ALS). Further, Velvio is innovating new opportunities in Idiopathic Pulmonary Fibrosis (IPF) and treatment concepts in Immune-Oncology, Liver and Brain Tumors. From our broad compound pipeline, we are ready to go “first in man” with ALS and we are about to finish preclinical drug development in IPF.



Zeppelinstraße 3
D-85399 Hallbergmoos
Phone: +49 (0) 8111244940
E-Mail: info@vermicon.com
Internet: www.vermicon.com

vermicon AG

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Microscopy, Laboratory, Bioanalytics, Other Diagnostics

vermicon AG provides innovative technologies, specific microbiological expertise and cultivation-independent methods for the in-situ identification, quantification and visualization of microorganisms. By using FISH (Fluorescence In Situ Hybridization), Flow Cytometry, qPCR, NGS and individually adapted solutions, vermicon provides deeper and holistic understanding of the microbial ecology within the samples. With satisfied customers worldwide, vermicon is driving the evolution of modern microbiology.



Sonnenstr. 19/Geb. 2, 2nd floor
D-80331 München
Phone: +49 (0) 89 20602-9900
Fax: +49 (0) 89 20602-9907
Internet: www.vrtx.com

Vertex Pharmaceuticals (Germany) GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying cause of cystic fibrosis (CF) and has several ongoing clinical and research programs in CF. Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases, as well as a rapidly expanding pipeline of genetic and cell therapies.

vertis Biotechnologie AG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: PCR, NGS, Informatics, Genomics

VERTIS is a research-oriented company in the field of functional genomics. The strength of our service is customer-oriented flexibility which is based on our innovative technology platform which we have developed in our 20-year history. We offer innovative tools and strategies for the comprehensive qualitative and quantitative analysis of bacterial and eukaryotic transcriptomes, using state-of-the-art Next Generation Sequencing (NGS) of RNA molecules (RNA-seq).



Lise-Meitner-Str. 30
D-85354 Freising-Weihenstephan
Phone: +49 (0) 8161 18516-11
E-Mail: info@vertis-biotech.com
Internet: www.vertis-biotech.com

verum.de GmbH

CRO

Keywords: Cardiovascular Diseases, CNS, Dermatology, Diabetics, Oncology, Respiratory Diseases

verum is a regional CRO specializing in clinical trials management in Germany, Austria as well as in Central and Eastern Europe. Since 2001 verum served 158 trials in different areas: neuroscience, oncology, cardiology, etc. During last years verum is also focused on biosamples (BS) collection studies, sponsored by developers and manufactures of integrated systems for the analysis of genetic variation and biological function. We are an expert in regulatory and ethic affairs for BS collection.



Kraillinger Str. 1
D-82152 Planegg
Phone: +49 (0) 89 800777-60
E-Mail: verum@verum.de
Internet: www.verum.de



Tel.: +49 (89) 85 89 63 - 0
kontakt@wander-immobilien.de



You are looking for suitable laboratories?

We are your specialist!

www.wander-immobilien.de

Office, laboratories and production space

from 250 sqm – 10.000 sqm

**We are looking forward to send you
an attractive offer.**





Föhrenstr. 12
D-85649 Brunnthäl
Internet: www.vicron.com

vicron gmbh

BIOTECH THERAPEUTICS & DIAGNOSTICS

vicron applies its medical expertise to develop Decision Support Systems for doctors. Guideline-derived and proprietary algorithms as well as advanced data analytics are designed to facilitate data-based treatment decisions in real time. To ensure data integrity, vicron develops decentralized data management processes with on-site anonymization.



Baierbrunner Str. 29
D-81379 München
Phone: +49 (0) 89 324918 600
E-Mail: info-de@viforpharma.com
Internet: www.viforpharma.de

Vifor Pharma Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Vifor Pharma is an internationally active pharma company, which researches, develops, produces and markets its own pharmaceutical products worldwide. The Company's main area of focus is iron replacement therapy, Vifor Fresenius Medical Care Renal Pharma and infectious diseases.



Semmelweisstraße 3
D-82152 Planegg
E-Mail: info@ViGeneron.com
Internet: www.vigeneron.com

ViGeneron GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Neuro-Degeneration, Ophthalmology, Gene Therapy, Industrial Biotechnology, Orphan Drug

ViGeneron is dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical need, as well as partnering with leading biopharmaceutical players in other disease areas. The company's pipeline is built on two proprietary adeno-associated virus (AAV) technology platforms.



Behringstr. 11
D-82152 Planegg-Steinkirchen
Phone: +49 (0) 89 899336
E-Mail: viramed@viramed.de
Internet: www.viramed.de

Viramed Biotech AG

BIOTECH DEVICES & REAGENTS

Keywords: ELISA/EIA, Clinical Diagnostics, In-Vitro-Diagnostics, Infectious Diseases, Chip/Array Technology

Viramed Biotech AG develops and produces IVD-Products for serological screening and confirmation of infectious and autoimmune diseases. With its in-house ViraChip® technology, the company focuses on multiplex antibody tests in a microarray format for innovative, efficient and reliable diagnostics. The products comprise test kits for Borrelia, Treponema, Yersinia, Helicobacter, Bordetella, SARS-CoV-2, EBV, CMV, HEV, Parvovirus B19, ZIKV, DENV, CHIKV, ANA and autoimmune liver diseases.

vivoPharm Europe Ltd

CRO

Keywords: Bioanalytics, Pharmacokinetics, Oncology, Drug Development, Pharmacology, Toxicology, Vaccines

vivoPharm is a successful and fast-growing precision research organization (CRO) that provides integrated preclinical services worldwide. Using our experience and knowledge, we assist in the planning and performance of tailored studies, from discovery stage through to clinical development and beyond. We're a unique IO precision service organization, active in preclinical and clinical services. All work is carried in AAALAC accredited and GLP compliant facilities in Australia and the US.



Grillparzerstr. 25
D-81675 München
Phone: + 49 (0) 89 122 287 6-90
E-Mail: info@vivopharm.eu
Internet: www.vivoPharm.com

Wacker Chemie AG

PHARMA & CHEMICAL INDUSTRY

Keywords: Fine Chemicals/Reagents, Antibody Production Service, Peptide/Protein, CRO/CMO, Nutraceuticals

WACKER is a globally active chemical company headquartered in Munich, Germany. With a wide range of state-of-the-art specialty products, WACKER is a leader in numerous industrial sectors. Within its bio division, WACKER uses advanced biotech processes to offer innovative and tailored solutions and biotech products for the pharma and the food & nutrition industry. Its products include pharmaceutical proteins, cyclodextrins and fermentation-grade cysteine.



Hanns-Seidel-Platz 4
D-81737 München
Phone: +49 (0) 89 6279-0
E-Mail: info@wacker.com
Internet: www.wacker.com

Winicker Norimed GmbH Medizinische Forschung

CRO

Keywords: Data Management and Biostatistics, Medical Writing, Clinical Trial Management and Monitoring, Pharmacovigilance, Regulatory Affairs

Winicker Norimed GmbH is an independent contract research organization. We manage projects from the planning through the field phase to the analysis and the clinical study report or publication. We deliver quality services according to applicable laws and international guidelines based on either our own or our clients SOPs. Winicker Norimed manages phase II-IV clinical trials with pharmaceuticals, studies with medical devices as well as non-interventional and epidemiological studies.



Deutschherrnstr. 15-19
D-90429 Nürnberg
Phone: +49 (0) 911 92680-0
E-Mail: wn@winicker-norimed.com
Internet: www.winicker-norimed.com



Lise-Meitner-Str. 30
D-85354 Freising
Phone: +49 (0) 8161 53730-90
E-Mail: info@xl-protein.com
Internet: www.xl-protein.com

XL-protein GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: AntibodyDrugConjugate ADC, Drug Development, Drug Delivery, Pharmacokinetics, Peptide/Protein, Oncology, Endocrinology, Inflammation, Rheumatoid Arthritis

XL-protein is a German biotech company commercializing its ground-breaking PASylation® technology, which enables the design of biopharmaceuticals with extended plasma half-life as well as prolonged residence time in the eye. Based on a strong proprietary technology position, XL-protein focuses at the preclinical as well as clinical development of PASylated proteins in diverse disease areas. XL-protein is engaged in numerous partnerships with international pharmaceutical and biotech companies at various levels.



Nymphenburger Str. 1
D-80335 München
Phone: +49 (0) 89 9931 7446
E-Mail: info@xvir.com
Internet: www.xvir.com

XVir® Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

XVir Therapeutics GmbH is focusing on the clinical development of oncolytic adenoviruses for the treatment of various solid tumors, and in particular of drug-resistant or radiation-resistant tumors. XVir Therapeutics has completed preclinical development of its most advanced product candidate XVir and is preparing a Phase I clinical study in the indication glioblastoma. XVir's therapeutic approach is covered by proprietary patents and patent applications, respectively.



Münchnerstrasse 8
D-85354 Freising
Phone: +49 (0) 8161 99210
E-Mail: manfred.seifert@zeta.com
Internet: www.zeta.com

Zeta GmbH

BIOTECH & PHARMA PRODUCTION

Keywords: Bioinformatics, Data Management and Biostatistics, Devices, Bioprocessing, Industrial Biotechnology, Automation

The ZETA Group, with 800 highly qualified employees and 13 subsidiaries worldwide, specializes in planning, automation, digitization and maintenance of customized biopharmaceutical facilities for aseptic process solutions. ZETA acts as a one-stop shop, combining plant engineering with HVAC and cleanroom design.



Junkersstraße 9
D-89231 Neu-Ulm
Phone: +49 (0) 7304 9283270
E-Mail: info@zimmer.de
Internet: www.zimmer.de

Zimmer BioTech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Zimmer BioTech, a Neu-Ulm, Germany-based start-up is advancing Alevin deep a drug based on 5-Aminolevulinic acid (ALA), used for treatment of actinic keratoses in photodynamic therapy (PDT). New developments show a huge upside potential as the drug could be used to treat Acne. Investors include Zimmer MedizinSysteme GmbH, the medical device producer, and High-Tech Gründerfonds. The company will use the funds to continue to develop a new therapy to combat skin cancer and Acne.


HERZINFARKT MIT 35?

„OHNE
MICH!“

**MACH DEN
VRONI-CHECK!**
DIREKT BEIM KINDER- & JUGENDARZT



Träume Leben. Gesund bleiben.



MYVRONI.DE

IMPRINT

Editorial Staff:

Gabriele Klingner, Dr. Christina Grimm, Dr. Max Pöhlmann, Christiane Proll, Dr. Andreas Berghammer, Dr. Stephanie Wehnelt, Dr. Ruoyu Sun, Dr. Jens Wiehler, Christina Enke-Stolle, Dr. Petra Burgstaller

Company Profiles:

Dr. Christina Grimm, Nikolaus Repgen

Advertisement:

Dr. Andreas Berghammer

Podcast interviews were produced on behalf of Bio^M by Edmund Soutschek

Data analysis was compiled together with BIO-Deutschland e.V. We thank the Bavarian companies and the regional organizations of the Bavarian Biotechnology Cluster for supporting this survey.

CONTACT

Prof. Dr. Horst Domdey, CEO Bio^M

Managing Director and Spokesman of the Bavarian Biotechnology Cluster

The Bavarian and the Munich Biotechnology Clusters are managed by:



Bio^M Biotech Cluster Development GmbH

Am Klopferspitz 19 a
D-82152 Martinsried
Phone: +49 (0)89 - 89 96 79-0
Fax: +49 (0)89 - 89 96 79-79
E-Mail: info@bio-m.org
www.bio-m.org



The layout, graphics and other contents of this brochure of the Bavarian Biotechnology Cluster are protected by copyright law.

Layout-Design:

GRAFIK-SL Stephanie Lüdeling, 83646 Wackersberg
www.grafik-sl.de

Pictures copyright as indicated

Pictures interviews: Shutterstock

Supported by the Bavarian Ministry of Economic Affairs, Regional Development and Energy <https://www.stmwi.bayern.de>

About this Study:

Data collection

For the Bavarian Biotech Report, a biotechnology company has been defined as a company which develops and/or manufactures products on the basis of state-of-the-art molecular biological methods.

The biotechnology companies were classified according to the location of their headquarters as 'international' or 'native Bavarian'.

Data were collected in cooperation with BIO Deutschland e.V., and by own surveys between March and June 2022.

Possible deviations from previously published figures are the result of additional data gathered in this survey that also may refer to previous years. The period under review for this report is 2021.

There are more than 300 company profiles listed in the appendix of this brochure. Not every company listed is also considered in this survey, for example some companies with very specific services. Furthermore, some Bavarian biotech and pharma companies are included in the survey but have not activated their listing in the appendix. More than 500 Bavarian companies in medical engineering are not included in this survey (by numbers or with profiles).

Processing of data and estimation procedures

For the assignment of the companies to branch areas and business fields, the answers of the companies, the classifications in the databases of Bio^M and BIO Deutschland e.V., the classification by the Chamber of Industry and Commerce as well as internet research were used. To determine the number of employees, the mean of the selected size ranges was used for companies for which no precise figures or additional information were given. In addition, the values were supplemented by annual financial statements and internet research as well as reported figures from the previous year. For the extrapolation of the total number of employees per group, the mean values of the respective branch areas (biotechnology, pharmaceuticals, CRO, others) were then calculated and multiplied by the total number of companies in the areas. The assignment and the estimates given were made with the greatest possible care; however, no liability is assumed for the completeness and correctness of the information.

Published in July, 2022



Bavarian Ministry of
Economic Affairs,
Regional Development
and Energy



invest
in
bavaria

Welcome to Bavaria.

A leading hub for Health,
MedTech and Life Science.



Bavaria is known to have a big heart. That's surely one of the reasons why world class research at universities and R&D institutions, venture capital as well as important multinational players work together to create a thriving cross-industry innovation ecosystem for Health, MedTech & Life Sciences. Discover the opportunities for your business at www.invest-in-bavaria.com



IZB



Innovations- und
Gründerzentrum
Biotechnologie

Fördergesellschaft IZB mbH
Am Klopferspitz 19
82152 Planegg/Martinsried

Tel. + 49 (0)89.55 279 48-0
Fax + 49 (0)89.55 279 48-29
info@izb-online.de
www.izb-online.de



SIE HABEN DIE IDEE – WIR HABEN DEN STANDORT

- Standort mit 26.000 m², S1-Labore
- Immobilienmanagement und Haustechnik vor Ort
- Faculty Club und Konferenzräume für bis zu 100 Personen
- Kindergarten/-krippe (Bio Kids), Chemieschule Elhardt
- Hotel CAMPUS AT HOME
- Restaurant SEVEN AND MORE, THE BOWL Food Lounge
- Auf dem Campus Martinsried: u. a. über 50 Start-ups im IZB, zwei Max-Planck-Institute, neun Fakultäten der LMU, Klinikum der Universität München

HIER ENTSTEHT ZUKUNFT